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ABSTRACT 
       Obesity has become a global epidemic, and obesity prevalence rose from 4.8% to 9.8% in men 
and from 7.9% to 13.8% in women between 1980 and 2008. Preventing obesity and related chronic 
diseases, especially type 2 diabetes (T2D) and cardiovascular disease (CVD), is of crucial public 
health significance. Identification of dietary factors that are beneficial to health is of high priority. 
This dissertation focused on two kinds of foods, coffee and soy food, and their associations with 
obesity-related health outcomes.  
       In Chapter 1, the dose-response relationship of long-term coffee consumption with CVD risk 
remained inconclusive. In the current study, I examined the association between coffee consumption 
and risk of CVD by meta-analyzing results from 36 prospective cohort studies with 1,279,804 study 
participants and 36,352 CVD cases. Our results showed that coffee consumption was non-linearly 
associated with risk of CVD: moderate coffee consumption was associated with lower risk of CVD, 
with the lowest CVD risk at 3 to 5 cups per day, and heavy coffee consumption was not associated 
with risk of CVD. However, whether the non-linear association was due to a true biological effect or 
confounding of smoking is not known. Therefore, in Chapter 2, with 208,501 participants and 31,956 
deaths in three large cohort studies, I prospectively examined the associations of coffee consumption 
with total mortality and cause-specific mortality among the overall population as well as never 
smokers.  
          In Chapters 3 and 4, I examined the association of soy food with risk of type 2 diabetes. Two 
different approaches were used to assess soy food intake. First, soy food assessed by food frequency 
questionnaire (FFQ) was used as main exposure, and the association of soy food consumption with 
3 
 
 
 
risk of type 2 diabetes was examined prospectively in three Harvard cohorts. Second, urinary 
isoflavones excretion was used as main exposure, and the association of urinary isoflavones 
concentration with risk of type 2 diabetes was assessed using a nested case-control design. 
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ABSTRACT 
Background Considerable controversy exists regarding the association between coffee 
consumption and cardiovascular disease (CVD) risk. A meta-analysis was performed to assess 
the dose-response relationship of long-term coffee consumption with CVD risk.  
Methods and Results Pubmed and EMBASE were searched for prospective cohort studies of 
the relationship between coffee consumption and CVD risk, which included coronary heart 
disease, stroke, heart failure, and CVD mortality. Thirty-six studies were included with 
1,279,804 participants and 36,352 CVD cases. A non-linear relationship of coffee consumption 
with CVD risk was identified (P for heterogeneity = 0.09, P for trend < 0.001, P for non-linearity 
< 0.001). Compared with the lowest category of coffee consumption (median: 0 cups/d), the 
relative risk of CVD was 0.95 (95% CI, 0.87 to 1.03) for the highest (median: 5 cups/d) category, 
0.85 (0.80 to 0.90) for the second highest (median: 3.5 cups/d), and 0.89 (0.84 to 0.94) for the 
third highest category (median: 1.5 cups/d). Looking at separate outcomes, coffee consumption 
was non-linearly associated with both CHD (P for heterogeneity = 0.001, P for trend < 0.001, P 
for non-linearity < 0.001) and stroke risks (P for heterogeneity = 0.07, P for trend < 0.001, P for 
non-linearity< 0.001) (P for trend differences > 0.05).   
Conclusions A non-linear association between coffee consumption with CVD risk was observed 
in this meta-analysis. Moderate coffee consumption was inversely significantly associated with 
CVD risk, with the lowest CVD risk at 3 to 5 cups/d, and heavy coffee consumption was not 
associated with elevated CVD risk.  
Key Words: coffee, cardiovascular disease, meta-analysis 
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INTRODUCTION 
Coffee is one of the most widely consumed beverages around the world; thus, investigating 
whether or not coffee consumption is associated with chronic disease risk has important public 
health implications. The relationship between coffee consumption and risk of coronary heart 
disease was first studied in the 1960s, given that the prevalence of coffee drinking and CHD 
were both high in western countries. 
1
 Short-term metabolic studies found that caffeine ingestion 
acutely induces cardiac arrhythmias, and increases plasma renin activity, catecholamine 
concentrations, and blood pressure. 
2, 3
 In the 1980s, cross-sectional studies found a positive 
association between coffee consumption and serum total cholesterol concentrations, which might 
be related to the coffee brewing method (i.e. boiled or unfiltered coffee). 
4
 A later randomized 
trial showed that boiled coffee consumption increased the serum cholesterol. 
5
 From the 1980s to 
the 2000s, many case-control studies, which are prone to recall and selection bias, showed a 
positive association between coffee consumption and CHD risk. 
6-8
 In contrast, meta-analyses of 
prospective cohort studies tended to find no association, although results varied substantially 
across studies. 
9, 10
  
        Since 2000, the association between coffee consumption and other cardiovascular disease 
(CVD) outcomes such as stroke, heart failure, and total CVD mortality has also been more 
frequently studied. 
11-13
 Meta-analyses have been published to summarize the association 
between coffee and risk of CHD, 
14
 stroke, 
15
 and heart failure. 
16
  These meta-analyses did not 
support an association between coffee consumption and a higher CVD risk, but the shape of the 
association remains uncertain.  Moreover, a number of additional studies have been published 
since the publication of these meta-analyses, 
11, 13, 17-19
 and one recent meta-analysis paper 
showed that heavy coffee consumption was not associated with risk of CVD mortality. 
20
 To 
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examine the dose response association of coffee consumption with cardiovascular disease risk, 
we conducted a systematic review and meta-analysis of coffee consumption and incidence of 
total CVD outcomes, including incidence of CHD, stroke, and heart failure, and CVD mortality.  
 
Methods 
We followed the Meta-Analysis of Observational Studies in Epidemiology 
21
 protocol 
throughout the design, implementation, analysis, and reporting of our meta-analysis. 
Search strategy and selection criteria 
We searched the PubMed and EMBASE databases for prospective studies that had evaluated the 
association between coffee consumption and risk of CVD between January 1966 and March 
2013. The computer-based searches included the key words “coffee”, “cardiovascular disease”,  
“coronary heart disease”, “stroke”, “mortality”, “heart failure”, “myocardial infarction”, 
“ischemic heart disease”, “sudden cardiac arrest”, and “acute coronary syndrome”. Reference 
lists of retrieved articles were manually scanned for all relevant additional studies and review 
articles. We restricted the search to studies on humans that were written in English. 
Study Selection 
Studies were included in this meta-analysis if they met the following criteria: 1) prospective 
cohort studies, including case-cohort studies and nested case-control studies with a prospective 
design; 2) the exposure was coffee consumption, including total coffee, caffeinated coffee, or 
decaffeinated coffee; 3) the outcome was risk of CVD, including incidence of CHD, stroke, and 
heart failure, and CVD mortality. Studies were excluded if 1) the study had a retrospective 
design; 2) the estimates were presented without standard errors or other information that allowed 
17 
 
 
 
calculation of standard errors; 3) the outcome was atrial fibrillation, atherosclerosis, hypertension, 
aortic stiffness, or venous thrombus; 4) no confounders were adjusted for.  
Data extraction and quality assessment 
One author (M. D.) assessed study eligibility and extracted the data, the other author (A. S.) 
independently double-checked the available data. The following data were extracted from each 
study: first author’s name, year of publication, geographical location, follow-up time, sex, age, 
number of CVD events, number of participants/person-years of follow up, categories of coffee 
consumption, mean/median coffee consumption in each category, CVD assessment method, 
covariates adjusted for in the multivariable analysis, and relative risks and the associated 
measure of variance for all categories of coffee consumption. For cohorts with published data on 
several CVD outcomes, we chose incidence instead of mortality or heart failure results. For 
studies with data on both CHD and stroke as the outcome, we included both in the meta-analysis. 
The correlation of CHD and stroke was accounted for in the main analysis (see below).  In a 
sensitivity analysis, we analyzed one of the two outcomes. The Newcastle-Ottawa quality 
assessment scale (NOS) 
22
was used to evaluate the quality of the included studies. M. D. and S. 
B. developed the evaluation criteria (supplemental table 1). The score ranges from 0 to 9 points 
with a higher score indicating higher study quality.  
To perform a dose-response meta-analysis, we assigned the median coffee consumption 
in each category of consumption to the corresponding relative risk for each study. We used 
means for this purpose if medians were not reported. If neither the mean nor the median 
consumption per category was reported, the midpoint of the upper and lower boundaries in each 
category was used to estimate median consumption. If the upper boundary for the highest 
category was not provided, the assigned median value was 25% higher than the lower boundary 
18 
 
 
 
of that category. If the lower boundary for the lowest category was not provided, the assigned 
median value was half of the upper boundary of that category.  
Data Synthesis and Analysis 
To analyze the trend of coffee consumption and risk of CVD, we used both semi-parametric and 
parametric methods. For the semi-parametric method, four coffee consumption groups were 
generated, namely lowest, third highest, second highest, and highest. For each study that was 
included, the lowest and the highest coffee consumption categories corresponded to the lowest 
and highest groups, respectively. For studies with four exposure categories, the second and third 
categories corresponded to the second and third highest groups, respectively. For studies with 
three exposure categories, the middle category corresponded to either the second or the third 
highest group in the meta-analysis, depending on the similarity of the median coffee 
consumption to either the second or the third highest group of the meta-analysis. If the study had 
more than four exposure categories, two consumption groups, other than the lowest and highest, 
were chosen based on their similarity of the amount of coffee consumption in that category to the 
second and third highest groups of the meta-analysis. For each group, we computed correlation 
coefficients (ρ) between CHD and stroke outcomes in the same cohort. We imputed ρ =1 initially 
to obtain the most conservative effect estimates.  A random-effects model was used first and was 
changed to a fixed-effects model if no between study heterogeneity was found for the random-
effects model (tau-squared < 1). 
23
 Sensitivity analysis was conducted by imputing different ρ (0 
< ρ ≤ 1) to evaluate the robustness of the effect estimates.  We used the STATA command 
ROBUMETA to obtain the effect estimates.  
For the parametric method, a dose-response meta-analysis was performed. 
24
 The number 
of cases and participants in each coffee consumption category was extracted to estimate the 
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covariance of the relative risk in each study. Together with the observed adjusted variance of the 
relative risk, we estimated the variance/covariance matrix of the data. The weight of each study 
was calculated as the inverse of the variance/covariance matrix. We used generalized least 
squares models (GLST) with the maximum likelihood method to estimate the coefficients for 
each study. We fit a fixed-effects generalized linear model first, and changed to a random-effects 
generalized linear model if the p value for the goodness of fit/heterogeneity of the previous 
model was < 0.05. Additionally, we tested for potential non-linearity in the association between 
coffee consumption and CVD risk using a fixed/random-effects restricted cubic spline model 
with 3 knots. In sensitivity analysis, we used two-stage fixed/random-effects dose response 
models to combine studies that reported results for categorized coffee consumption and studies 
with reported results for continuous coffee consumption. Specifically, the RR of CVD per unit 
increase of coffee consumption for each study was first estimated separately by GLST, and then 
the RRs from all of the studies were pooled together by a fixed/random-effects model. We used 
the STATA command GLST for model fitting, and the command LINCOME to obtain effect 
estimates for the fitted model.  
We performed stratified analyses by baseline hypertension or MI of the study population, 
smoking status, publication year, NOS study quality score, dietary assessment method, 
evaluation of stroke or CHD as the outcome, country, sex, and type of coffee (caffeinated coffee 
or decaffeinated coffee). The interaction between categorized coffee consumption and the 
stratifying variable with the risk of CVD was tested by a likelihood ratio test comparing the 
models derived using GLST method with and without the interaction terms. We assessed the 
potential for publication bias using Egger’s regression symmetry test. 25 All analyses were 
conducted using STATA Version 11.2 (STATA Corp, College Station, Texas).  
20 
 
 
 
 
Results 
Characteristics of studies 
Our initial search identified 2587 potentially relevant citations. After screening titles and 
abstracts, we identified 53 studies for further evaluation. Of the 53 initially included studies, we 
excluded 14 studies due to duplicate publication, one study with point estimate without standard 
error, and one nested case control study with a retrospective design. Thirty-six studies remained 
in the meta-analysis (Figure 1). The included studies comprised approximately 1,283,685 study 
participants and 47,779 CVD cases, including 28,347 CHD cases, 12,030 stroke cases and 7,402 
other CVD cases. Characteristics of these 36 studies are shown in Table 1. One study had a 
nested case-control study design, one had a case-cohort study design, and the rest of the studies 
were cohort studies. Duration of follow-up for incident CVD ranged from 6 to 44 years, with a 
median follow-up of 10 years. Twenty-one studies were conducted in Europe, 12 in the US, and 
3 in Japan. Three studies assessed coffee consumption repeatedly during the course of the 
follow-up, and the rest of the studies assessed coffee consumption at baseline. Thirteen studies 
assessed coffee consumption without using a specific dietary assessment method, and the rest of 
the studies assessed coffee consumption by diet recalls, diet records or food frequency 
questionnaires (FFQ). One study modeled coffee consumption as a continuous variable, and the 
remaining studies modeled coffee consumption categorically. Nine studies assessed the 
association of caffeinated coffee consumption with CVD risk, and four studies assessed the 
association of decaffeinated coffee consumption with CVD risk. The outcome in 17 studies was 
risk of stroke, while the outcome in 22 studies was risk of CHD. The scores of the NOS quality 
assessment ranged from 3 to 8, and 31 studies had scores of 5 or higher. The corresponding 
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results of each criteria of the NOS quality assessment for our meta-analysis are shown in 
Supplemental Table 1. The study modeling coffee as a continuous exposure was excluded in the 
following analysis due to the difficulty of combining the risk estimate with those of other studies 
and was only included in the sensitivity analysis. 
26
 All of the remaining 35 studies were 
included in the main analysis, and 29 studies were included in the dose-response analysis 
between coffee consumption and risk of CVD. 
 
Coffee consumption and risk of CVD 
The relative risks for CVD with different coffee consumption categories relative to the lowest 
category are shown in Figure 2. Of the 35 studies, 6 cohorts presented the outcome of stroke and 
CHD simultaneously. Compared with the lowest category of coffee consumption (median and 
mean: 0 cups/d), the pooled RR for incident CVD was 0.89 (95% CI, 0.84 to 0.94) for the third 
highest (median: 1.5 cups/d; mean: 1.48 cups/d), 0.85 (95% CI, 0.80 to 0.90) for the second 
highest (median: 3.5 cups/d; mean: 3 cups/d) and 0.95 (95% CI, 0.87 to 1.03) for the highest 
(median: 5 cups/d; mean: 5.5 cups/d) category of coffee consumption (Figure 2). Low between-
study variances of CVD risk were found for each category of coffee consumption (tau-squared = 
0.00 for the random-effects models), and the imputed correlation coefficient between the risks of 
stroke and CHD within the same cohort (0 < ρ ≤ 1) did not have an effect on the relative risk of 
CVD for each category of coffee consumption.   
Stratified analyses 
Stratified analyses were conducted according to baseline hypertension or MI of the study 
population, smoking status, publication year, NOS study quality score, dietary assessment 
method (24-h diet recall/diet record/FFQ versus other methods), stroke versus CHD as the 
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outcome, country, sex, and type of coffee (caffeinated coffee or decaffeinated coffee). No 
interactions between categorized coffee consumption and stratification variables in relation to 
CVD risk were observed (all P for interactions >0.05) (Figure 3). Only 4 studies provided the 
stratified results by age. 
27-30
 The summarized results showed that, comparing the highest with 
the lowest intakes, the RR of CVD was 0.96 (95% CI, 0.65 to 1.42) for age < 65 years, and the 
RR was 0.91 (95% CI, 0.59 to 1.40) for age ≥ 65 years. 
     For the risk of CHD, compared with the lowest category of coffee consumption, the RRs of 
CHD were 0.89 (95% CI, 0.85 to 0.94; P for heterogeneity = 0.83; I
2
 = 0.0%) for the third 
highest category, 0.90 (95% CI, 0.84 to 0.97; P for heterogeneity = 0.02; I
2
 = 40.3%) for the 
second highest category, and 0.93 (95% CI, 0.84 to 1.02; P for heterogeneity < 0.001; I
2
 = 52.8%) 
for the highest category of coffee consumption. The corresponding RRs of stroke were 0.89 (95% 
CI, 0.84 to 0.94; P for heterogeneity = 0.58; I
2
 = 0.0%) for the third category, 0.80 (95% CI, 0.75 
to 0.86; P for heterogeneity = 0.37; I
2
 = 6.5%) for the second category, and 0.95 (95% CI, 0.84 to 
1.07; P for heterogeneity = 0.001; I
2
 = 54.5%) for the highest category. 
 
Dose-response analysis of coffee consumption with risk of CVD 
In our dose-response analysis, we observed a non-linear association between coffee consumption 
and risk of CVD (P for non-linearity < 0.001) with a significant trend (P for trend <0.001) and 
limited heterogeneity in study results (P for heterogeneity = 0.09) (Figure 4a). Compared to those 
with no coffee consumption, the RR estimated directly from the cubic spline model was 0.95 (95% 
CI, 0.93 to 0.97) for 1 cup/d, 0.92 (95% CI, 0.88 to 0.95) for 2 cups/d, 0.89 (95% CI, 0.85 to 0.93) 
for 3 cups/d, 0.88 (95% CI, 0.83 to 0.93) for 4 cups/d, 0.89 (95% CI, 0.83 to 0.95) for 5 cups/d, 
0.91 (95% CI, 0.84 to 0.99) for 6 cups/d, and 0.93 (95% CI, 0.85 to 1.03) for 7 cups/d.  
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        Non-linear (p values for non-linearity <0.001) associations between coffee consumption and 
disease risk with significant trends (p values for trend <0.001) were found for both CHD and 
stroke (Figures 4b and 4c). There was stronger evidence for heterogeneity in study results for the 
association of coffee consumption with CHD risk (P heterogeneity=0.001) than for the 
association with stroke risk (P heterogeneity=0.07). 
       We further explored the reason for the heterogeneity between coffee consumption and CHD 
risk by stratifying the studies by publication year (≤ 2000 or > 2000). We found that in studies 
published in year 2000 or earlier, coffee consumption was not significantly associated with CHD 
risk (n=13, P for heterogeneity = 0.20), whereas in later studies, coffee consumption was non-
linearly associated with CHD risk (n= 18, P for heterogeneity = 0.08). We didn’t perform a 
similar analysis for stroke because very few studies on stroke were published prior to 2000. 
Sensitivity analysis  
We tested the robustness of our results in sensitivity analyses. Because the RRs of stroke and 
CHD from the same cohort were correlated and a total of 6 studies included both CHD and 
stroke results, we conducted a sensitivity analysis by including only one outcome at a time. Our 
results remained largely unchanged and non-linear curves were found with including either CHD 
or stroke as the outcome (Supplemental Figure 1a and 1b). 
      One study with coffee consumption modeled as a continuous variable was excluded from the 
main analysis; 
26
 we added the RR from this study to the dose-response analysis by a two stage 
method and the results did not substantially change.  
       To test whether the association between coffee consumption and risk of CVD was different 
for unadjusted and multivariable adjusted models, we performed a dose-response meta-analysis 
of the only age-adjusted data including 34 comparisons (Supplemental Figure 2). Multivariate 
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adjustment strengthened the inverse association between moderate consumption and CVD risk, 
most likely due to adjustment for smoking. 
 
Publication bias 
The Egger test did not suggest publication bias for associations for any category of coffee 
consumption and risk of CVD (Supplemental Figure 3 and Table 2). 
 
DISCUSSION 
The findings from this systematic review and meta-analysis, based on approximately 1,283,685 
study participants and 47,779 CVD cases, including about 28,347 CHD cases, 12,030 stroke 
cases and 7,402 other CVD cases, demonstrate a non-linear association between coffee 
consumption and risk of CVD. Moderate coffee consumption (3-5 cups/day) was associated with 
lower CVD risk, and heavy coffee consumption (≥6 cups/day) was neither associated with a 
higher nor a lower risk of CVD.  
In contrast to our results, a previous meta-analysis summarizing 21 prospective cohort 
studies 
31
 found no association between moderate coffee consumption and CHD risk in the 
overall population. One possible reason is that the previous meta-analysis included 7 studies 
without adjustment for confounders, which might have biased the relative risks upwards because 
of confounding by factors such as smoking.  
          A recent cohort study by Liu et al 
32
  found that 4 cups per day of coffee consumption was 
associated with increased mortality, but the association was only significant for participants 
under 55 years old. The results from this study contradict those from this meta-analysis and the 
majority of studies in the literature.  Possible reasons for this discrepancy include a relatively 
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small size, lack of updated dietary assessment, and subgroup analysis.  In our meta-analysis, 
stratified analysis by age revealed no significant differences in the association across age groups.                  
          The debate about the relation between coffee consumption and CVD risk mainly stemmed 
from inconsistent results according to different study designs. Case-control studies, which are 
prone to recall bias and selection bias, tended to show a positive association, whereas cohort 
studies generally showed a null association. 
10
 Still, findings from prospective cohort studies on 
coffee consumption and CVD risk have remained inconsistent. Differences among studies in 
sample sizes, the characteristics of the study populations, the assessment methods for coffee 
consumption, and statistical adjustments may have contributed to divergent results. Since the true 
association between coffee consumption and CVD risk is likely to be modest and nonlinear, the 
differences in coffee assessments and covariate adjustments may result in changes the magnitude 
and even the direction of the associations and thus lead to different conclusions.  
      The U-shaped association between coffee consumption and CVD risk observed in this meta-
analysis need to be considered from both methodological and biological points of view. First, 
individuals with hypertension or other conditions related to CVD risk might have changed their 
coffee consumption before baseline. Thus, baseline disease, especially hypertension, as a 
confounder could result in reverse causation. However, we observed no significant difference in 
the association between coffee consumption and CVD risk between cohorts with hypertensive 
and MI patients and the general population cohorts. Second, smoking is likely to be an important 
confounder for the association between coffee consumption and CVD risk, and could bias the 
relative risks upwards. Heavy coffee consumption was associated with higher risk of CVD in 
age-adjusted analyses, but this is likely due to confounding by smoking. After adjustment for 
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smoking and other covariates, heavy coffee consumption was not significantly associated with 
CVD and the inverse association between moderate consumption and CVD became stronger.  
         The non-linear U-shaped association between coffee consumption and CVD risk might also 
be true based on plausible biological mechanisms. Coffee is a complex chemical mixture with 
hundreds of compounds including the phenolic compound chlorogenic acid, caffeine, minerals 
such as potassium and magnesium, niacin and its precursor trigonelline, and lignans.  Coffee 
consumption has been associated with higher insulin sensitivity, a lower risk of type 2 diabetes, 
and lower concentrations of inflammatory markers such as C-reactive protein and E-selectin. 
33, 
34
 However, short-term metabolic studies have shown that caffeine can acutely increase blood 
pressure by antagonizing the adenosine A1 and A2A receptor, 
35-37
 and could also acutely 
adversely affect arterial stiffness and endothelium dependent vasodilation. 
38, 39
 Long-term heavy 
coffee consumption has been associated with a slightly elevated risk of hypertension, 
40
 and a 
higher level of plasma homocysteine. 
41, 42
 In addition, cafestol in unfiltered coffee increases 
serum total cholesterol concentrations. 
43
  The non-linear U-shaped association between coffee 
consumption and risk of CVD might be due to a combination of beneficial and detrimental 
effects: for moderate coffee consumption, beneficial effects may be greater than adverse effects; 
whereas for heavy consumption, detrimental effect may counterbalance beneficial effects. 
Results from case crossover studies suggest that coffee consumption transiently increases risk of 
nonfatal myocardial infarction, ischemic stroke onset, and sudden cardiac death. 
44-46
 However, 
we could not differentiate acute effects from long-term effects of habitual coffee consumption in 
this study. 
 No significant association between decaffeinated coffee consumption with CVD risk was 
observed in this meta-analysis. There were several potential explanations. First, the consumption 
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of decaffeinated coffee was much lower than caffeinated coffee, diminishing the power to detect 
any association. Second, the null association might be due to a reverse causation problem in that 
individuals with hypertension or other CVD-related conditions might switch from regular coffee 
to decaffeinated coffee. This reverse causation may mitigate an inverse association between 
decaffeinated coffee consumption and CVD risk.      
         We did not observe a significant association between coffee consumption and CHD risk for 
earlier publications (2000 or earlier). There are two potential reasons for this finding. First, 
coffee brewing methods have changed over time and nowadays the filter method has become 
more popular, effectively replacing unfiltered forms of coffee such as boiled coffee that was 
more widely consumed by participants in earlier studies. It has been shown that drinking boiled 
coffee increases serum cholesterol, an important risk factor for CVD 
5
. Second, in earlier studies, 
the sample size was typically small; the measurement of baseline characteristics was typically 
crude; statistical control of confounders such as diet was inadequate; and the average NOS study 
quality score was lower. Our stratified analysis showed that coffee consumption was not 
associated with CVD risk in subgroups with a lower NOS score.  
A study by Cornelis et al. 
47
 showed that CYP1A2 genotype was an effect modifier 
between coffee consumption and risk of myocardial infarction: coffee consumption was related 
to higher risk of myocardial infarction for the slow caffeine metabolizer, and was not related to 
myocardial infarction for the fast caffeine metabolizer. However, this analysis was based on a 
case-control study conducted in Costa Rico and the results have not been replicated in 
prospective cohort studies yet.  
Recently, a genome-wide association study (GWAS) found a highly significant 
association between a variant on CYP1A2 and coffee intake 
48
. However, this variant explains 
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only a very small population variance.  Since the vast majority of our participants were 
Caucasians, the allele frequency was expected to be consistent across various cohorts. Ideally, 
the meta-analyses should be done according to different genotypes of CYP1A2. However, none 
of the included cohorts assessed the genotypes and thus we were unable to conduct such a 
stratified analysis.  
      Our meta-analysis has several strengthens. First, our meta-analysis included 35 cohort studies 
and 1,283,685 participants, which provided sufficient power to detect modest associations. 
Second, because of the prospective design of all included studies, differential misclassification of 
coffee consumption due to recall bias was minimized and the likelihood of selection bias is 
reduced. Third, we used both semi-parametric and parametric methods, and both analyses 
indicated a U-shaped relationship between coffee consumption and CVD risk.  Finally, we 
conducted stratified analyses according to disease endpoints, geographic locations of the studies, 
type of coffee, and baseline characteristics of the study populations. The subgroup results are 
highly consistent and robust.    
      Our study also has several limitations. Given the observational nature of the studies, the 
possibility of residual confounding cannot be excluded. However, since higher coffee 
consumption was generally associated with a less healthy lifestyle such as a higher prevalence of 
cigarette smoking, less physical activity, and a less healthy diet, the observed association 
between moderate coffee consumption and a lower CVD risk is unlikely to be explained by these 
confounders. In addition, residual confounding by smoking may have biased the association for 
heavy coffee consumption upward, which may explain our finding that adjustment for smoking 
and other covariates actually strengthened the inverse association. Nonetheless, because of the 
observational nature of the included studies, a causal relationship cannot be established with 
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these data alone. In addition, coffee brewing methods were not assessed in the included studies. 
However, given coffee consumption habits in the studied populations most consumed coffee is 
likely to have been filtered coffee. As a result, our results may not apply to unfiltered coffee (e.g. 
French press, Scandinavian boiled, or Turkish/Greek coffee). 
     In conclusion, our meta-analysis suggests a non-linear relationship between coffee 
consumption and CVD risk. Moderate coffee consumption was associated with lower CVD risk, 
with the lowest CVD risk at 3 to 5 cups/d of coffee consumption, and heavy coffee consumption 
was not associated with CVD risk. This non-linear association with coffee consumption was 
observed for both the risk of CHD and stroke.   
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Table1. Basic characteristics of included studies 
Author/ 
Year/ 
Country/ 
Special 
annotation 
Sex Follow
-up 
years 
Age at 
start of 
follow-
up 
(y) 
No. of 
cases/Tot
al No. of 
participa
nts 
Exposure(cup/d) 
Relative risk 
(95% CI) 
Outcome Exposure/ou
tcome 
assessment 
Confounders adjusted for 
Wilhelmsen 
et al  
1977 
Europe 
Men 12 50 60/834 Per cup increase of coffee 
consumption:  
1.11 (0.83-1.51) 
CHD Not specific 
diet 
questionnaire 
(baseline)/ 
Hospital 
record 
Smoking, cholesterol, SBP, 
dyspnea, registration by 
temperance board 
Legrady et al 
1987 
US 
men 19 40-56 220 
CHD,57 
stroke/ 
1910 
Stroke mortality stroke 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
Death 
certificates 
age, diastolic blood 
pressure, serum 
cholesterol, and smoking 
status 
0-1cup/d 1.00 (1.00-1.00) 
>1cup/d 1.64 (0.80-3.38) 
Martin et al  
1988 
US 
Hypertensive 
population 
both  4 30-69 336/ 
10,064 
Stroke mortality CVD 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
Death 
certificates 
age, sex, race, type of care, 
marital status, month of 
interview, body weight, 
initial diastolic blood 
pressure, fasting plasma 
blood glucose and serum 
cholesterol, 
0 cup/d  1.00 (1.00-1.00) 
0.1mg-2 cups/d  0.73 (0.37-
1.46) 
2-4 cups/d 0.61 (0.26-1.44) 
>4 cups/d 1.30 (0.56-3.04) 
CHD mortality 
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0 cup/d  1.00 (1.00-1.00) initial end organ damage, 
and location of the study 
center 
0.1-2 cups/d  0.93 (0.66-1.3) 
2-4 cups/d 0.81 (0.53-1.23) 
>4 cups/d 0.80 (0.46-1.39) 
Grobbee et al 
1990 
US 
men 2 40-75 411/ 
45,589 
0 cup/d  1.00 (1.00-1.00) CVD FFQ 
(baseline)/ 
Confirmed 
cases 
age, quintiles of Quetelet's 
index, smoking habits, 
history of diabetes, alcohol 
use, parental history of 
myocardial infarction, 
specific health profession, 
energy intake, cholesterol, 
and saturated, 
monounsaturated, and 
polyunsaturated fat 
0-1 cup/d 0.70 (0.51-0.97) 
2-3 cups/d 1.00 (0.79-1.26) 
≥4 cups/d 0.90 (0.67-1.22) 
Klatsky et al 
1990 
US 
Nested case-
control study 
both 8 
(media
n: 5) 
From 
<50 
to >60 
1914/ 
1,01,774 
MI  CHD Not specific 
diet 
questionnaire
(baseline)/ 
Hospitalizati
on for 
coronary 
disease 
age, race, cigarette 
smoking, alcohol intake, 
education, baseline disease, 
and tea use. 
0 cup/d  1.00 (1.00-1.00) 
<1cup/d 0.78 (0.56-1.07) 
1-3cups/d 1.16 (0.93-1.45) 
≥4 cups/d 1.42 (1.11-1.81) 
Other coronary cases 
0 cup/d  1.00 (1.00-1.00) 
<1cup/d 0.90 (0.72-1.11) 
1-3cups/d 0.89 (0.76-1.04) 
≥4 cups/d 1.03 (0.85-1.24) 
Tverdal et al 
1990 
Europe 
both 6.4 35-54 184/ 
38564 
no sugar in coffee CHD 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
Confirmed 
cases 
age, high density 
lipoprotein, total 
cholesterol, systolic blood 
pressure, no of 
cigarettes/day 
<1 cup/d 1.00 (1.00-1.00) 
≥9 cups/d 4.10 (1.30-13.20) 
sugar in coffee 
<1 cup/d 1.00 (1.00-1.00) 
≥9 cups/d 1.60 (0.60-4.30) 
Rosengren et men 7.1 51-59 399/ 0 cup/d  1.00 (1.00-1.00) CHD Not specific age, systolic blood 
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al 
1991 
Europe 
6765 ≥9 cups/d 1.40 (0.80-2.40) diet 
questionnaire
(baseline)/ 
National 
registries 
pressure, body mass index, 
diabetes, registration for 
alcohol abuse, family 
history of myocardial 
infarction, mental stress, 
physical activity, and 
occupational class, 
smoking  
Lindsted et al  
1992 
Europe 
men 15 ≥30  NA/ 
9484 
<1 cup/d 1.00 (1.00-1.00) CVD 
mortality 
FFQ 
(baseline)/ 
Confirmed 
cases 
Body mass index, stroke, 
heart disease, hypertension, 
race, exercise, sleep, 
marital status, education, 
smoking history, dietary 
pattern 
1-2 cups/d 1.38 (1.18-1.62) 
≥3 cups/d 1.44 (1.18-1.76) 
Klag et al 
1994 
US 
men  32 26 111/ 
1040 
0 cup/d 1.00 (1.00-1.00) CHD Not specific 
diet 
questionnaire
(baseline)/ 
National 
registries 
age at graduation, baseline 
serum cholesterol, calendar 
time, time-dependent 
hypertension status, 
number of cigarettes, 
diabetes, and body mass 
index 
1-2 cups/d 1.70 (0.78-3.68) 
3-4 cups/d 3.02 (1.37-6.65) 
≥5 cups/d 2.94 (1.27-6.81) 
Gyntelberg et 
al 
1995 
Europe 
men 6 53-74 184/ 
2975 
1-4 cups/d 1.00 (1.00-1.00) CHD Not specific 
diet 
questionnaire
(baseline)/ 
Confirmed 
cases 
age, alcohol, blood 
pressure, serum selenium 
level, social class, and 
triglycerides 
5-8 cups/d 1.00 (0.70-1.40) 
≥9 cups/d 0.60 (0.30-1.00) 
Hart et al 
1997 
Europe 
men 21 35-64 625/ 
5766 
0 cup/d 1.00 (1.00-1.00) CHD 
mortality 
Not specific 
diet 
questionnaire
(average)/ 
age, diastolic blood 
pressure, cholesterol, 
smoking, social class, age 
leaving full time education, 
0.5-1 cup/d 1.20 (0.87-1.64) 
1.5-2 cup/d 1.17 (0.83-1.65) 
2.5-4 cup/d 1.16 (0.81-1.66) 
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>4.5 cup/d 1.49 (0.89-2.47) National 
registries 
body mass index, angina, 
and ECG 
ischaemia 
Hakim et al 
1998 
US 
Hypertensive 
population 
men 25 55-68 76/499 0 cup/d 1.00 (1.00-1.00) Stroke 24h diet 
recall 
(baseline)/  
Confirmed 
cases 
age, systolic blood 
pressure, total cholesterol, 
triglycerides, diabetes, 
alcohol use, and the 
physical activity index as 
measured at the time of 
study enrollment 
≥6 cups/d 2.1 (1.2-3.7) 
Woodward et 
al 
1999 
Europe 
both 7.7 40–59 567/ 
11000 
Men CHD Food 
consumption 
table 
(baseline)/ 
Confirmed 
cases 
age, housing tenure, 
activity at work, activity in 
leisure, cigarette 
smoking status, body mass 
index, Bortner score, 
cotinine, systolic blood 
pressure, fibrinogen, total 
cholesterol, HDL-
cholesterol, 
triglycerides, alcohol, 
vitamin C, and tea.  
0 cup/d 1.00 (1.00-1.00) 
1-2 cups/d 0.68 (0.42-1.10) 
3-4 cups/d 0.39 (0.21-0.73) 
≥5 cups/d 0.68 (0.37-1.24) 
women 
0 cup/d 1.00 (1.00-1.00) 
1-2 cups/d 0.54 (0.22-1.34) 
3-4 cups/d 0.56 (0.20-1.56) 
≥5 cups/d 0.55 (0.18-1.66) 
Kleemola et 
al  
2000 
Europe 
both 10 30-59 1645/ 
20179 
men with nonfatal MI CHD, 
CHD 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
National 
registries 
age, smoking status, serum 
cholesterol level, blood 
pressure, and history of MI 
<1 cup/d 1.09 (0.78-1.54) 
1-3 cups/d 1.00 (1.00-1.00) 
4-7 cups/d 0.95 (0.79-1.15) 
>7 cups/d 0.79 (0.64-0.98) 
women with nonfatal MI 
 <1 cup/d 1.72 (1.01-2.92) 
1-3 cups/d 1.00 (1.00-1.00) 
4-7 cups/d 0.84 (0.62-1.13) 
>7 cups/d 0.93 (0.63-1.36) 
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men with CHD mortality 
<1 cup/d 1.88 (1.20-2.95) 
1-3 cups/d 1.00 (1.00-1.00) 
4-7 cups/d 1.23 (0.93-1.62) 
>7 cups/d 1.22 (0.90-1.65) 
women with CHD mortality 
 <1 cup/d 0.00 (0.00-0.00) 
1-3 cups/d 1.00 (1.00-1.00)  
4-7 cups/d 0.67 (0.41-1.07) 
>7 cups/d 0.57 (0.28-1.16) 
Jazbec et al  
2003 
Europe 
both 10 35-59 435/ 
3364 
men CVD 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
Confirmed 
cases 
age, number of cigarettes 
consumed per day, 
diastolic blood pressure, 
ulcer, feeling of well-
being, region 
0 cup/d 1.00 (1.00-1.00) 
<1 cups/d 0.70 (0.49-1.00) 
1-2 cups/d 0.82 (0.58-1.16) 
>2 cups/d 0.72 (0.44-1.18) 
women 
0 cup/d 1.00 (1.00-1.00) 
<1 cup/d 0.88 (0.56-1.39) 
1-2 cups/d 0.67 (0.43-1.05) 
>2 cups/d 0.62 (0.30-1.28) 
Happonen et 
al  
2004  
Europe 
Men 14 42-60 269/1971 None 0.84 (0.41-1.72) CHD 
mortality 
Diet record 
(baseline)/ 
National 
registries 
Age, packyears of 
smoking, ischemia in 
exercise test, diabetes, 
income, and serum insulin 
concentration. Physical 
activity; family history of 
CHD; 
intake of alcohol, tea, 
saturated fat, total energy, 
and total water; serum 
Light 1.22 (0.90-1.64) 
Moderate 1.00 (1.00-1.00) 
Heavy 1.43 (1.06-1.94) 
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glucose and plasma 
vitamin C concentration 
Lopez-
Garcia et al  
2006 
US 
both 20 men 53 
women 
46 
4427/ 
128493 
Women CHD FFQ 
(baseline)/ 
National 
registries 
age, smoking status, serum 
cholesterol level, blood 
pressure, and history of MI 
<0.033 cup/d 1.00 (1.00-1.00) 
0.033-0.57 cup/d 0.97 (0.83-
1.14) 
0.57-1 cup/d 1.02 (0.90-1.17) 
2-3 cups/d 0.84 (0.74-0.97) 
4-5 cups/d 0.99 (0.83-1.17) 
≥6 cups/d 0.87 (0.68-1.11) 
Men 
<0.033 cup/d 1.00 (1.00-1.00) 
0.033-0.57 cup/d 1.04 (0.91-
1.17) 
0.57-1 cup/d 1.02 (0.90-1.15) 
2-3 cups/d 0.97 (0.86-1.11) 
4-5 cups/d 1.07 (0.88-1.31) 
≥6 cups/d 0.72 (0.49-1.07) 
Andersen et 
al 
2006 
US 
wo
men 
15 55-69 1411/ 
27312 
0 cup/d 1.00 (1.00-1.00) CVD 
mortality 
FFQ 
(baseline)/ 
National 
registries 
age, smoking, and intake of 
alcohol, BMI, waist-hip 
ratio, education, physical 
activity, use of estrogens, 
<1 cup/d 0.85 (0.68-1.06) 
1-3 cups/d 0.76 (0.64-0.91) 
4-5 cups/d 0.81 (0.66-0.99) 
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≥6 cups/d 0.87 (0.69-1.09) use of multivitamin 
supplements, energy 
intake, and intakes of 
whole and refined grain, 
red meat, fish and seafood, 
and total fruit and 
vegetables 
Bidel  
et al 
2006 
Europe 
Type 2 
diabetic 
population 
both 20.8 25-74 909/3837 0-2 cups/d 1.00 (1.00-1.00) CVD 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
National 
registries 
age, sex, study year, BMI, 
systolic blood pressure, 
total cholesterol, education, 
alcohol and tea 
consumption, and smoking 
status 
3-4 cups/d 0.79 (0.64-0.97) 
5-6 cups/d 0.70 (0.57-0.86) 
≥7 cups/d 0.71 (0.56-0.90) 
Greenberg et 
al 
2007 
US 
 
both 8.8 32-86 426/ 
6594 
<65y  CVD 
mortality 
FFQ 
(baseline)/ 
Confirmed 
cases 
age, smoking, BMI, sex, 
race, physical activity, 
alcohol consumption, per 
capita 
income, educational level, 
and American-style diet 
<0.5 cup/d 1.00 (1.00-1.00) 
0.5-2 cups/d 0.95 (0.38-2.35) 
2-4 cups/d 0.79 (0.34-1.85) 
≥4 cups/d 0.86 (0.38-1.06) 
≥65y 
<0.5 cup/d 1.00 (1.00-1.00) 
0.5-2 cups/d 0.72 (0.52-0.99) 
2-4 cups/d 0.69 (0.52-0.92) 
>4 cups/d 0.53 (0.38-0.75) 
Silletta et al 
2007 
Europe 
both 3.5 52-63 1167/ 
11231 
0 cup/d 1.00 (1.00-1.00) CVD FFQ 
(average)/ 
Confirmed 
Age, gender, smoking, 
BMI, dietary habits, 
cardiovascular risk 
<2 cups/d 1.02 (0.87-1.20) 
2-4 cups/d 0.91 (0.75-1.09) 
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Myocardial 
infarction 
population 
>4 cups/d 0.88 (0.64-1.2) cases factors, history of MI 
before the index MI, time 
from the index MI 
to enrollment, post-MI 
complications, and 
pharmacological therapies, 
with inclusion of the 
allocation treatments 
Greenberg et 
al 
2008 
US 
both 10.1 65-97 523/ 
1354 
0 cup/d 1.00 (1.00-1.00) CVD 
events 
FFQ 
(baseline)/ 
Confirmed 
cases 
age, gender, smoking, body 
mass index, alcohol 
consumption, physical 
activity, marital status, BP, 
history of CVD, and 
antihypertensive 
medication use 
≥1 cup/d 1.00 (0.84- 1.20) 
Happonen et 
al 
2008 
Europe 
both 14.5 70-94 344/ 
817 
 0 cups/d 0.80 (0.47-1.35) CVD 
mortality 
Not specific 
diet 
questionnaire
(baseline)/ 
National 
registries 
sex, current age, calendar 
period, marital status, 
educational level, previous 
occupational group, current 
smoking, BMI, history of 
myocardial infarction, 
presence of diabetes 
mellitus, cognitive 
impairment, physical 
disability, and self-rated 
health 
1-2 cups/d 1.00 (1.00-1.00) 
3-4 cups/d 0.96 (0.72-1.27) 
5-6 cups/d 0.89 (0.64-1.24) 
≥7 cups/d 0.84 (0.48-1.47) 
Larsson et al 
2008 
Europe 
men 13.6 50-69 2702/ 
26556 
<2 cup/d 1.00 (1.00-1.00) Stroke FFQ 
(baseline)/ 
National 
registries 
age, supplementation 
group, No. of cigarettes 
smoked daily, body mass 
index, systolic and 
diastolic blood pressure, 
serum total cholesterol, 
serum HDL cholesterol, 
2-3 cups/d 0.91 (0.79-1.06) 
4-5 cups/d 0.88 (0.77-1.02) 
6-7 cups/d 0.77 (0.66-0.90) 
≥8 cups/d 0.77 (0.66-0.90) 
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histories of diabetes and 
coronary heart disease, 
leisure-time physical 
activity, alcohol intake, and 
tea consumption 
Mukamal et 
al 
2009 
Europe 
Myocardial 
infarction 
population 
both 6.9-9.9 45-70 331(MI), 
135(strok
e)/ 
1369 
MI CHD, 
stroke 
FFQ 
(baseline)/ 
National 
registries 
age, sex, diabetes, 
smoking, obesity, physical 
inactivity, alcohol 
consumption, tea 
consumption, education, 
and intake of boiled coffee 
0-1 cup/d 1.00 (1.00-1.00) 
1-3 cups/d 0.97 (0.65-1.45) 
3-5 cups/d 0.75 (0.50-1.13) 
5-7 cups/d 0.94 (0.61-1.44) 
≥7 cups/d 0.84 (0.51-1.40) 
Stroke 
0-1 cup/d 1.00 (1.00-1.00) 
1-3 cups/d 1.08 (0.57-2.02) 
3-5 cups/d 0.94 (0.49-1.78) 
5-7 cups/d 1.17 (0.59-2.29) 
≥7 cups/d 0.74 (0.31-1.75) 
Sugiyama et 
al 
2010 
Japan 
both 10.3 40–64 426/ 
37742 
men CVD mortality CVD 
mortality 
FFQ 
(baseline)/ 
Mortality 
certificates at 
the public 
health center  
age in years, sex, past 
history of hypertension and 
diabetes, education level, 
BMI , walking time, 
cigarette smoking , 
consumption of alcohol, 
green tea, oolong tea, black 
tea, intake of rice, miso 
soup, total meat, total dairy 
products, total fish, total 
vegetables, total fruits, and 
energy 
0 cup/d 1.00 (1.00-1.00) 
0-1 cup/d 1.09 (0.79-1.51) 
1-2 cups/d 0.85 (0.56-1.23) 
≥3 cups/d 0.88 (0.56-1.39) 
women CVD mortality 
0 cup/d 1.00 (1.00-1.00) 
0-1 cup/d 0.56 (0.36-0.86) 
1-2 cups/d 0.48 (0.29-0.80) 
≥3 cups/d 0.45 (0.20-1.03) 
Ahmed et al men 9 45-79 784/ ≤1 cup/d 1.00 (1.00-1.00) Heart FFQ age, body mass index, total 
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2009 
Europe 
37315 2 cups/d 0.87 (0.69-1.11) failure (baseline)/ 
Confirmed 
cases 
activity score, smoking, 
history of high 
cholesterol, family history 
of MI before age 60, 
education level, marital 
status, aspirin use, alcohol, 
tea, energy-adjusted fat 
intake, and energy-adjusted 
daily sodium intake 
3 cups/d 0.89 (0.70-1.14) 
4 cups/d 0.89 (0.69-1.15) 
≥5 cups/d 0.89 (0.69-1.15) 
 
Lopez-
Garcia et al  
2009 
US 
wo
men 
24 56 2280/ 
83076 
<0.03 cup/d 1.00 (1.00-1.00) Stroke FFQ 
(average)/ 
Confirmed 
cases 
age, smoking status, body 
mass index, physical 
activity, alcohol intake, 
menopausal status and use 
of hormone replacement 
therapy, aspirin use; total 
caloric intake; quintiles of 
calcium, potassium, 
sodium, and folate intake; 
glycemic load; whole grain 
intake; and tertiles of fruits, 
vegetables, and fish 
consumption, high blood 
pressure, 
hypercholesterolemia, and 
type 2 diabetes mellitus 
0.03-0.57 cup/d  0.96 (0.82-
1.13) 
0.57-1 cup/d 0.88 (0.77-1.02) 
2-3 cups/d 0.84 (0.72-0.98) 
≥4 cups/d 0.85 (0.69-1.06) 
Leurs et al both 10 55–69 1789(IH men with  MI mortality CHD FFQ age, current smoking, 
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2010 
Europe 
Case-cohort 
study 
D 
deaths), 
708(strok
e deaths)/ 
120852 
0-2 cups/d 1.00 (1.00-1.00) mortality, 
stroke 
mortality 
(baseline)/ 
National 
registries 
number of cigarettes 
smoked, years of active 
smoking and total energy 
intake 
2-4 cups/d 0.91 (0.71-1.16) 
3-6 cups/d 1.02 (0.79-1.31) 
>6 cups/d 1.17 (0.86-1.59) 
women with MI mortality 
0-2 cups/d 1.00 (1.00-1.00) 
2-4 cups/d 0.75 (0.58-0.97) 
3-6 cups/d 0.62 (0.46-0.84) 
>6 cups/d 0.71 (0.45-1.12) 
men with stroke mortality 
0-2 cups/d 1.00 (1.00-1.00) 
2-4 cups/d 0.84 (0.60-1.18) 
3-6 cups/d 0.72 (0.50-1.04) 
>6 cups/d 1.15 (0.74-1.77) 
women with stroke mortality 
0-2 cups/d 1.00 (1.00-1.00) 
2-4 cups/d 0.79 (0.57-1.09) 
3-6 cups/d 0.70 (0.48-1.02) 
>6 cups/d 1.10 (0.63-1.90) 
Gans et al 
2010 
Europe 
both 13 20-69 1387(CH
D cases), 
563(strok
e cases), 
123(CHD 
deaths), 
70(stroke 
deaths)/ 
37514 
CHD morbidity CHD, 
CHD 
mortality, 
Stroke,  
stroke 
mortality 
FFQ 
(baseline)/ 
National 
registries 
sex; age; educational level; 
physical activity; smoking 
status; waist 
circumference; menopausal 
status; alcohol, tea; total 
energy; and saturated fat, 
fiber, and vitamin C level 
<1 cup/d 1.00 (1.00-1.00) 
1-2 cups/d 0.85 (0.70-1.04) 
2-3 cups/d 0.79 (0.65-0.96) 
3-4 cups/d 0.82 (0.68-0.98) 
4-6 cups/d 0.86 (0.73-1.02) 
>6 cups/d 0.91 (0.74-1.11) 
stroke morbidity 
<1 cup/d 1.00 (1.00-1.00) 
1-2 cups/d 1.08 (0.79-1.47) 
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2-3 cups/d 1.15 (0.85-1.57) 
3-4 cups/d 1.10 (0.82-1.46) 
4-6 cups/d 1.11 (0.84-1.46) 
>6 cups/d 1.22 (0.88-1.70) 
CHD mortality 
<1 cup/d 1.00 (1.00-1.00) 
1-3 cups/d 1.06 (0.61-1.84) 
3-6 cups/d 0.64 (0.37-1.11) 
>6 cups/d 0.73 (0.37-1.42) 
Stroke mortality 
<1 cup/d 1.00 (1.00-1.00) 
1-3 cups/d 0.86 (0.39-1.87) 
3-6 cups/d 1.20 (0.59-2.47) 
>6 cups/d 1.34 (0.49-3.64) 
Larsson et al 
2011 
Europe 
wo
men 
10.4 49-83 1680/ 
34670 
<1 cup/d 1.00 (1.00-1.00) Stroke FFQ 
(baseline)/ 
National 
registries 
age; smoking status and 
pack-years of smoking; 
education; body mass 
index; total physical 
activity; history of 
diabetes; history of 
hypertension; aspirin use; 
family history of 
myocardial infarction; and 
intakes of total energy, 
alcohol, red meat, fish, 
fruits, and vegetables 
1-2 cups/d 0.78 (0.66-0.91) 
3-4 cups/d 0.75 (0.64-0.88) 
≥5 cups/d 0.77 (0.63-0.92) 
Mineharu et both 13.1 40-79 2012/ men CVD mortality CVD FFQ body mass index (BMI), 
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al 
2011 
Japan 
76979 <0.14 cup/d 1.00 (1.00-1.00) mortality (baseline)/ 
Mortality 
certificates at 
the public 
health center 
history of hypertension, 
history of diabetes, 
smoking status, alcohol 
intake, education, walking 
hours, hours of sports 
participation, 
perceived mental stress, 
multivitamin use, vitamin 
E supplement use, 
consumption of total fruits, 
total vegetable, total beans, 
total meat, total fish and 
seaweeds and total daily 
energy intake 
0.14-1 cup/d 0.71 (0.53-0.96) 
1-2 cups/d 0.84 (0.64-0.99) 
≥3 cups/d 1.17 (0.77-1.76) 
women CVD mortality 
<0.14 cup/d 1.00 (1.00-1.00) 
0.14-1 cup/d 0.87 (0.62-1.23) 
1-2 cups/d 0.77 (0.55-0.99) 
≥3 cups/d 2.30 (1.31-4.02) 
Floegel et al 
2012 
Europe 
both 8.9 35-65 704/ 
42659 
<1 cup/d 1.00 (1.00-1.00) CVD FFQ 
(baseline)/ 
Confirmed 
self-reported  
age at recruitment, center,  
sex, smoking, alcohol 
intake, physical activity, 
education, employment, 
vitamin and mineral 
supplement use during past 
4 weeks, total energy 
intake, tea intake, and 
decaffeinated coffee intake, 
BMI, waist-to-hip ratio, 
and prevalent hypertension 
1-2 cups/d 0.94 (0.64-1.36) 
2-3 cups/d 1.07 (0.81-1.42) 
3-4 cups/d 1.02 (0.75-1.38) 
>4 cups/d 1.10 (0.84-1.44) 
Rautiainen et 
al 
2012 
Europe 
wo
men 
9.9 49-83 1114/ 
32561 
≤2 cups/d 1.00 (1.00-1.00) CHD FFQ 
(baseline)/ 
National 
registries 
age, education, smoking, 
body mass index, physical 
activity, hypertension, 
hypercholesterolemia, 
3 cups/d 0.87 (0.68-1.12) 
4 cups/d 0.88 (0.69-1.13) 
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≥5 cups/d 0.96 (0.72-1.26) family history of 
myocardial infarction, 
aspirin use, hormone 
replacement therapy use, 
dietary supplement use, 
and intakes of total energy 
and alcohol 
Freedman et 
al 
2012 
US 
both 14 50-71 11828(C
HD 
deaths), 
2293(stro
ke 
deaths)/ 
402260 
men CHD mortality CHD 
mortality, 
stroke 
mortality 
FFQ 
(baseline)/ 
National 
registries 
age; 
body-mass index; race or 
ethnic group; level of 
education; alcohol 
consumption; the number 
of cigarettes smoked per 
day, use or nonuse of pipes 
or cigars, and time of 
smoking cessation; health 
status; diabetes; marital 
status; physical activity; 
total energy intake; 
consumption of fruits, 
vegetables, red meat, white 
meat, and saturated fat; use 
or nonuse of vitamin 
supplements; and use or 
nonuse of postmenopausal 
hormone therapy 
0 cup/d 1.00 (1.00-1.00) 
<1 cup/d 0.93 (0.85-1.02) 
1 cup/d 0.92 (0.84-1.01) 
2-3 cups/d 0.86 (0.79-0.94) 
4-5 cups/d 0.87 (0.79-0.96) 
≥6 cups/d 0.88 (0.78-1.00) 
women CHD mortality 
0 cup/d 1.00 (1.00-1.00) 
<1 cup/d 1.00 (0.89-1.13) 
1 cup/d 0.91 (0.81-1.03) 
2-3 cups/d 0.85 (0.76-0.95) 
4-5 cups/d 0.78 (0.68-0.90) 
≥6 cups/d 0.72 (0.59-0.88) 
men stroke mortality 
0 cup/d 1.00 (1.00-1.00) 
<1 cup/d 0.99 (0.79-1.24) 
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1 cup/d 0.92 (0.73-1.15) 
2-3 cups/d 0.84 (0.68-1.02) 
4-5 cups/d 0.65 (0.51-0.84) 
≥6 cups/d 0.83 (0.61-1.14) 
women stroke mortality 
0 cup/d 1.00 (1.00-1.00) 
<1 cup/d 1.15 (0.91-1.45) 
1 cup/d 0.89 (0.70-1.13) 
2-3 cups/d 0.93 (0.75-1.15) 
4-5 cups/d 0.82 (0.62-1.09) 
≥6 cups/d 0.84 (0.56-1.25) 
Kokubo et al 
2013 
Japan 
both 13 45-74 4335/ 
82369 
Total CVD CVD, 
CHD, 
stroke 
FFQ 
(baseline)/ 
Confirmed 
cases 
age; sex; smoking; alcohol; 
body mass index; history 
of diabetes mellitus; 
medication of 
antihypercholesterolemia 
and antihypertension; 
sports; dietary intake of 
fruits, vegetables, fish, and 
energy; public health 
centers; and green tea 
consumption 
0 cup/week 1.00 (1.00-1.00) 
1-2 cups/week 0.93 (0.86-1.01) 
3-6 cups/ week 0.89 (0.81-
0.98) 
1 cups/d 0.84 (0.76-0.92) 
≥2 cups/d 0.89 (0.80-0.99) 
Stroke 
0 cup/week 1.00 (1.00-1.00) 
1-2 cups/week 0.94 (0.85-1.02) 
3-6 cups/week 0.89 (0.80-0.99) 
1 cup/day 0.80 (0.72-0.90) 
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≥2 cups/day 0.81 (0.72-0.91) 
CHD 
0 cup/week 1.00 (1.00-1.00) 
1-2 cups/week 0.91 (0.76-1.10) 
3-6 cups/week 0.92 (0.75-1.14) 
1 cups/d 0.99 (0.81-1.23) 
≥2 cups/d 1.21 (0.98-1.50) 
 
CHD: coronary heart disease; CVD: cardiovascular disease; FFQ: food frequency questionnaire 
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Figure 1. Study selection process of coffee consumption and risk of CVD 
Articles identified initially (n=2587) 
Articles excluded on basis of title and abstract (n=2432) 
Articles retrieved for further evaluation (n=155) 
Articles excluded (n=103): 
Studies excluded because they were letters, reviews, meta-
analysis, posters, and meetings (n=38) 
Studies with cross-sectional study, randomized clinical trial, case 
control or case crossover design (n=28) 
Studies with the outcome of hypertension, atrial fibrillation, 
artery or venous diseases, and heart failure (n=37) 
 
Articles finally included in the meta-analysis with outcome CVD (n=36) 
 
Articles excluded (n=16): 
Articles excluded due to duplicate studies (n=14)  
Study without standard error (n=1)  
Nested case-control study with a retrospective design (n=1) 
 
Articles included initially (n=52) 
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Figure 2a. Forest plot of the association between third highest level of coffee consumption (median consumption: 1.5 cups/d; 
mean: 1.48 cups/d) and risk of CVD compared to the lowest level (median and mean consumption: 0 cup/d). In total 1,279,804 
study participants with 36,352 CVD cases were included. The overall effect was obtained from a fixed-effects model that 
accounted for correlated outcomes. MI means myocardial infarction incidence; CVD means cardiovascular disease incidence; 
stroke means stroke incidence.  
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Figure 2b. Forest plot of the association between second highest level of coffee consumption (median consumption: 3.5 cups/d; 
mean: 3 cups/d) and risk of CVD compared to the lowest level (median and mean consumption: 0 cups/d). In total 1,279,804 
study participants with 36,352 CVD cases were included. The overall effect was obtained from a fixed-effects model that 
accounted for correlated outcomes. MI means myocardial infarction incidence; CVD means cardiovascular disease incidence; 
stroke means stroke incidence.   
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Figure 2c. Forest plot of the association between highest level of coffee consumption (median consumption: 5 cups/d; mean: 5.5 
cups/d) and risk of CVD compared to the lowest level (median and mean consumption: 0 cups/d). In total 1,279,804 study 
participants with 36,352 CVD cases were included. The overall effect was obtained from a fixed-effects model that accounted 
for correlated outcomes. MI means myocardial infarction incidence; CVD means cardiovascular disease incidence; stroke 
means stroke incidence.  
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Figure 3. Stratified analysis of the association between coffee consumption and risk of CVD. The included studies for the 
stratified analysis were the same as that for the dose response analysis. n was the number of comparisons for the highest level 
of coffee consumption. NOS score: the score using the Newcastle–Ottawa scale; specific dietary assessment method: diet that 
was assessed by 24h diet recall, diet record or food frequency questionnaire.  
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Figure 4. Dose response relationships of coffee consumption with risk of CVD. n was the number of comparisons.  
                         a. Coffee consumption and risk of CVD (n = 47) 
                             b. Coffee consumption and risk of CHD (n = 31)                                          c. Coffee consumption and risk of stroke (n = 22)                                 
58 
 
 
 
Supplemental table 1: the quality assessment of included studies using the Newcastle–Ottawa scale 1 
  
Selection 
  
Comparability Outcome 
  Author Year Represe
n 
tativenes
s of 
Exposed 
Cohort 
Selectio
n of Non 
-
Exposed 
Cohort 
Ascerta
i 
nment 
of 
Exposu
re 
Demonstra 
tion That 
Outcome 
of Interest 
Was Not 
Present at 
Start of 
Study 
Did 
not 
adjust 
for 
smoki
ng 
compr
ehensi
vely 
Did not 
adjust for 
baseline 
hypertens
ion 
Assess
ment of 
outcom
e 
Follo
w-up 
length 
Loss to 
follow-
up rate 
Total 
Qualit
y 
Score  
Wilhelmsen et 
al 1977 1 1 0 1 1 1 1 1 0 7 
Legrady et al 1987 0 1 0 1 1 1 1 1 0 6 
Martin et al 1988 1 1 0 0 0 0 1 0 0 3 
Klatsky et al 1990 0 1 0 0 1 0 1 1 0 4 
Grobbee et al 1990 0 1 1 1 1 0 1 0 0 5 
Tverdal et al 1990 1 1 0 1 1 1 1 1 0 7 
Rosengren et al 1991 1 1 0 1 0 1 1 1 0 6 
Lindted et al 1992 0 1 0 1 0 1 1 1 0 5 
klag et al 1994 0 1 0 0 1 1 1 1 0 5 
Gyntelberg et al 1995 1 1 0 1 1 0 1 1 0 6 
Hart et al 1997 0 1 0 0 0 1 1 1 0 4 
Hakim et al 1998 1 1 1 1 1 0 1 1 0 7 
Woodward et al 1999 1 1 0 0 0 1 1 1 0 5 
Kleemola et al 2000 1 1 0 0 0 1 1 1 0 5 
Jazbec et al 2003 1 1 0 0 1 1 1 1 0 6 
Happonen et al 2004 1 1 0 1 1 1 1 1 0 7 
Andersen et al 2006 1 1 1 1 1 0 1 1 0 7 
Lopez-Garcia et 2006 0 1 1 1 1 1 1 1 0 7 
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al 
Bidel et al 2006 1 1 0 1 1 1 1 1 0 7 
Silletta et al 2007 0 1 0 0 0 1 1 0 0 3 
Greenberg et al 2007 1 1 0 1 1 0 1 1 0 6 
Happonen et al 2008 1 1 0 0 0 0 1 1 1 5 
Greenberg et al 2008 1 1 1 0 0 1 1 1 0 6 
Larsson et al 2008 1 1 1 0 1 1 1 1 0 7 
Mukamal et al 2009 1 1 0 0 0 0 1 1 0 4 
Ahmed et al 2009 1 1 1 1 0 0 1 1 0 6 
Lopez-Garcia et 
al 2009 0 1 1 1 1 0 1 1 0 6 
Gans et al 2010 1 1 1 1 0 0 1 1 0 6 
Leurs et al 2010 1 1 1 1 1 0 1 1 0 7 
Sugiyama et al 2010 1 1 1 1 1 1 1 1 0 8 
Mineharu et al 2011 1 1 1 1 1 1 1 1 0 8 
Larsson et al 2011 1 1 1 1 1 1 1 1 1 9 
Freedman et al 2012 0 1 1 1 1 0 1 1 0 6 
Rautiainen et al 2012 1 1 1 1 0 1 1 1 1 8 
Floegel et al 2012 1 1 0 1 1 1 1 1 0 7 
Kokubo et al 2013 1 1 1 1 1 1 1 1 1 9 
 
The quality of included studies was assessed by the Newcastle Ottawa scale. A study can be awarded a maximum of one star for each 
numbered item within the Selection and Outcome categories and a maximum of two stars for Comparability.  
Selection: 1) Representativeness of exposed cohort: 1, study population truly or somewhat representative of a community/ population 
based study; 0, study population was sampled from a special population, ie. population from a company, hospital patients, data from 
the health insurance company or health examination organization, nurses, Adventist group. 
 2) Selection of non-exposed cohort: 1, drawn from the same community as the exposed cohort.  
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3) Ascertainment of exposure: 1, specific dietary assessment method of coffee consumption (FFQ/diet record/24h diet recall) with 
validation; 0, no specific dietary assessment method or specific dietary assessment method without validation 
4) Demonstration that outcome was not present at start of study: 1, exclusion of participants with a history of CVD at the beginning of 
the study.  
Comparability: 1) 1, whether a study adjusted for smoking deliberately (not only adjust for the smoking status, but also the number 
of cigarettes or duration of smoking); 1, whether a study adjusted for baseline hypertension.   
Outcome: 1) Assessment of outcome:1, CVD cases were confirmed by medical records or record linkage; 0, self-reported.  
2) Was follow-up long enough for outcomes to occur: 1, duration of follow-up >= 5 year; 0, if duration of follow-up < 5 year.  
3) Loss to follow-up rate: 1, complete follow-up or loss to follow up rate <=20 %; 0, follow-up rate < 80% or no description of those 
lost.   
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Supplemental table 2: Egger’s test for the publication bias on coffee consumption and risk of type 2 diabetes 
 
P value of Egger’s test 
 
Total publications 
Highest 0.28 
Second highest 0.42 
Third highest 0.32 
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Supplemental figures 
 
 
 
 
Supplemental figure 1: Dose response relationship of coffee consumption with cardiovascular disease risk choosing only one 
outcome for correlated outcomes within the same study. n was the number of comparisons. 
 
 
    a. Coffee consumption and risk of CVD choosing CHD for correlated outcomes (n=36)   b. Coffee consumption and risk of CVD choosing stroke for correlated outcomes (n=37) 
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Supplemental figure 2. Dose response relationship of coffee consumption with cardiovascular disease risk from models 
adjusted for different confounders. Red curve: included studies only adjusted for age; Black curve: included studies with 
multivariate adjusted models 
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c. The highest category of coffee consumption 
Supplemental figure 3: Egger’s test for publication bias for the association between coffee consumption and risk of CVD 
            a. The third highest category of coffee consumption                                      b. The second highest category of coffee consumption 
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The study selection process:  
Of the 53 initially included studies, we excluded 14 studies due to duplicate publication 
2-15
, one study with point estimate without 
standard error 
16
, and one nested case control study with a retrospective design 
17
. Thirty-six studies were remained in the meta-
analysis
18-53
.  
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ABSTRACT 
Background-The association between consumption of caffeinated and decaffeinated coffee and 
risk of mortality remains inconclusive. 
Methods and Results-We examined the associations of consumption of total, caffeinated, and 
decaffeinated coffee with risk of subsequent total and cause-specific mortality among 74,890 
women in the Nurses’ Health Study (NHS), 93,054 women in the NHS 2, and 40,557 men in the 
Health Professionals Follow-up Study. Coffee consumption was assessed at baseline using a 
semi-quantitative food frequency questionnaire. During 4,690,072 person-years of follow-up, 
19,524 women and 12,432 men died. Consumption of total, caffeinated, and decaffeinated coffee 
were non-linearly associated with mortality. Compared to non-drinkers, coffee consumption one 
to five cups/d was associated with lower risk of mortality, while coffee consumption more than 
five cups/d was not associated with risk of mortality. However, when restricting to never 
smokers, compared to non-drinkers, the HRs of mortality were 0.94 (0.89 to 0.99) for ≤ 1 cup/d, 
0.92 (0.87 to 0.97) for 1.1-3 cups/d, 0.85 (0.79 to 0.92) for 3.1-5 cups/d, and 0.88 (0.78 to 0.99) 
for > 5 cups/d (p for non-linearity = 0.32; p for trend < 0.001). Significant inverse associations 
were observed for caffeinated (p for trend < 0.001) and decaffeinated coffee (p for trend = 0.022). 
Significant inverse associations were observed between coffee consumption and deaths due to 
cardiovascular disease, neurological diseases, and suicide. No significant association between 
coffee consumption and total cancer mortality was found.  
Conclusions-Higher consumption of total coffee, caffeinated coffee, and decaffeinated coffee 
was associated with lower risk of total mortality.  
Key Words: caffeinated coffee, decaffeinated coffee, smoking, mortality 
71 
 
 
 
INTRODUCTION 
Coffee is one of the most commonly consumed beverages worldwide. The associations between 
coffee consumption and risks of several disease outcomes have been investigated. Coffee 
consumption has been inversely associated with risks of type 2 diabetes 
1
, liver cancer 
2
, 
endometrial cancer 
3
, lethal prostate cancer 
4
, basal cell carcinoma of the skin 
5
, and neurological 
diseases 
6
, as well as with risk of cardiovascular disease (CVD) when consumed in moderation 
7
.  
      The association between coffee consumption and risk of total mortality has also been 
investigated. Recent studies showed an inverse association between moderate coffee 
consumption and risk of mortality, and an inverse or null association between heavy coffee 
consumption and risk of mortality 
8-16
. However, some earlier studies
17-19
 and a recent study
20
 
found heavy coffee consumption to be associated with higher risk of mortality. Summarizing 
individual studies, meta-analyses have concluded that coffee consumption is not associated with 
higher risk of mortality; however, there was significant between-study heterogeneity in the effect 
estimates
21-23
. The associations between coffee consumption and cause-specific mortality, 
especially CVD and cancer mortality, have been sporadically investigated together with total 
mortality, 
8, 10, 11, 23
 with most studies finding an inverse association with CVD mortality, and no 
association with cancer mortality.  
      Based on the results of previous studies, four questions remain unanswered: first, does a non-
linear relationship exist between coffee consumption and risk of mortality, i.e., is moderate 
coffee consumption associated with lower risk of mortality and heavy coffee drinking not 
associated with risk of mortality or even with an increased risk? Second, if a non-linear 
association exists, is it truly a biological effect of coffee or is it an artifact due to the confounding 
of smoking? Third, what are the associations of coffee consumption with risks of cause-specific 
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mortality? Fourth, do caffeinated and decaffeinated coffee have similar associations with risk of 
mortality?  
      We therefore examined the association of coffee consumption with total and cause-specific 
mortality in three large, ongoing, independent cohort studies of men and women. This analysis 
updated our earlier publication on coffee consumption and total mortality in the Nurses’ Health 
Study (NHS) and Health Professionals Follow-up Study (HPFS) with 6,888 total deaths and 
extended to a younger cohort of nurses (Nurses’ Health Study II).  These cohorts provide 
measures of caffeinated and decaffeinated coffee consumption, extensive data on known or 
suspected confounders, and up to 30 years of follow-up, during which more than 30,000 deaths 
have been recorded.  
 
METHODS 
Study Population 
The NHS began in 1976, when 121,700 female registered nurses aged 30-55 y residing in 11 
states were recruited to complete a baseline questionnaire about their lifestyle and medical 
history. The NHS II was established in 1989 and consisted of 116,671 younger female registered 
nurses, aged 25-42 y at baseline. These nurses responded to a baseline questionnaire similar to 
the NHS. The HPFS was initiated in 1986, and was composed of 51,529 male dentists, 
pharmacists, veterinarians, optometrists, osteopathic physicians, and podiatrists, aged 40-75 y at 
baseline. The male participants returned a baseline questionnaire about detailed medical history, 
lifestyle, and usual diet. In all three cohorts, questionnaires were collected at baseline and 
biennially thereafter, to update information on lifestyle factors and the occurrence of chronic 
diseases. All of the three cohorts consist of approximate 95% Caucasians.  
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For the current analysis, we excluded participants who reported CVD, or cancer at 
baseline (1984 for the NHS, 1991 for the NHS II, and 1986 for the HPFS). We further excluded 
participants with missing caffeinated or decaffeinated coffee consumption at baseline, those who 
left more than 70 food items blank or had daily energy intakes < 600 or > 3500 kcal for women 
and < 800 or > 4200 kcal for men. The study protocol was approved by the institutional review 
boards of Brigham and Women’s Hospital and Harvard School of Public Health.  
Assessment of Coffee Consumption 
In 1984, a 116-item food frequency questionnaire (FFQ) was administered to the NHS 
participants to obtain information on usual intake of food and beverages. Starting in 1986, an 
expanded 131-item FFQ was administered every 4 years to update diet. Using a similar FFQ, 
dietary data was collected every four years from the NHS II participants starting in 1991 and 
from the HPFS participants starting in 1986. In all FFQs, participants were asked how often 
(from “never or less than once per month” to “6 or more times per day”) on average they 
consumed a standard portion size of each food item during the previous year. The questionnaire 
items for coffee included “caffeinated coffee” and “decaffeinated coffee”. Consumption of total 
coffee was calculated as the sum of intakes of caffeinated and decaffeinated coffee. The validity 
and reproducibility of the FFQ has been described in detail elsewhere
24-27
. In brief, the validation 
study found a correlation coefficient of 0.78 between coffee intake assessed on the baseline FFQ 
and coffee intake assessed on four 1-week dietary records collected over a one year period
26
. As 
mean coffee consumption did not change in NHS 2 and decreased slightly in NHS and HPFS 
over time (Supplemental figure 1), we used baseline coffee consumption as primary exposure 
and further conducted several sensitivity analyses using updated dietary information. 
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Assessment of Covariates 
In the biennial follow-up questionnaires, updated information was collected on age, weight, 
smoking status, physical activity, medication use, family history of diabetes, and self-reported 
diagnosis of diseases, including hypertension, hypercholesterolemia, CVD, and cancer. For NHS 
and NHS 2 participants, we also ascertained data on menopausal status and postmenopausal 
hormone use. We calculated the Alternate Healthy Eating Index (aHEI) as an overall measure of 
diet quality using FFQ data
28
.  
Assessment of Deaths 
Our primary end point was death from any cause. We performed systematic searches of the vital 
records of states and of the National Death Index. This search was supplemented by reports from 
family members and postal authorities. Using these methods, we were able to ascertain more 
than 98% of the deaths in each cohort 
29
. A physician who was blinded to data on coffee 
consumption and other risk factors reviewed death certificates and medical records to classify the 
cause of death according to the eighth and ninth revisions of the International Classification of 
Diseases. Deaths were grouped into nine major categories (Supplemental Table 1).  
Statistical Analysis 
We calculated each individual’s person-time from the date of the return of the baseline 
questionnaire to the date of death or the end of follow-up (31 December 2012 for the NHS, 31 
December 2012 for the NHS 2, and 31 December 2012 for the HPFS), whichever came first. We 
used Cox proportional hazards regression models to examine the association between coffee 
consumption (five categories) and risk of mortality. The regression models included calendar 
time in 2-y intervals as the time scale, and were stratified by age in years. In the multivariable 
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analysis, we further adjusted for body mass index (BMI), physical activity, overall dietary 
pattern (aHEI), total energy intake, smoking status, sugar-sweetened beverage consumption and 
alcohol consumption, all of which were updated from follow-up questionnaires. We additionally 
adjusted for baseline hypertension, hypercholesterolemia, and diabetes status in both men and 
women, and menopausal status, and postmenopausal hormone use among women.  
We also used restricted cubic splines with 3 knots to flexibly model the association between 
coffee consumption and risk of mortality.  To test for a potential non-linear association between 
coffee consumption and risk of mortality, a likelihood ratio test (LRT) was used comparing the 
model with only the linear term of coffee consumption to the model with both the linear and the 
cubic spline terms, with P value < 0.05 denoting significant non-linearity. All analyses were 
performed separately in each cohort, and then pooled to obtain the overall hazard ratio using a 
fixed-effects model.  
Stratified analyses were conducted according to BMI (≤ 25 kg/m2, > 25 kg/m2), age (≤ 70y, > 
70y), aHEI (≤ median score, > median score), physical activity (≤ median, > median), smoking 
status (never smokers, ever smokers), sex (male, female), and individual cohort. We tested for 
potential effect modification by these stratification variables by including interaction terms 
between the exposure and potential effect modifier in the multivariate adjusted model, and 
conducting a likelihood ratio test (LRT) comparing the models with and without interaction 
terms.  
The proportional hazard assumption of the Cox model was tested by adding interaction terms 
between exposure and the dichotomized indicator of time intervals to the multivariate adjusted 
model within each cohort, and conducting a likelihood ratio test comparing the models with and 
without interaction terms. 
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All statistical tests were 2-sided and performed using SAS version 9.2 for UNIX (SAS Institute 
Inc). 
 
RESULTS 
Coffee Consumption and Dietary and Lifestyle Factors 
The percentages of never coffee drinkers were 12% in NHS, 30% in NHS 2, and 17% in HPFS. 
The percentages of those who drank more than 5 cups/d were 8% in NHS, 3% in NHS 2, and 5% 
in HPFS. There was a strong correlation between frequent coffee consumption and smoking 
status (Table 1). The proportions of never smokers among those who did not drink coffee were 
63%, 80%, and 71% in NHS, NHS 2, and HPFS respectively, while the proportions of never 
smokers among those who drank more than 5 cups/d were 24%, 35%, and 25% in NHS, NHS 2, 
and HPFS. Those who drank coffee more frequently were also more likely to consume alcohol, 
and consumed less sugar-sweetened beverages and fruits, but more red meats.  
Coffee Consumption and All-cause Mortality 
During 28 years of follow-up (1,894,292 person-years) among women in the NHS, we 
documented 17,468 deaths; during 21 years of follow up (1,882,464 person-years) among 
women in the NHS 2, we documented 2,056 deaths; during 26 years of follow-up (913,316 
person-years) among men in the HPFS, we documented 12,432 deaths. In total, 31,956 deaths 
were recorded during 4,690,072 person-years of follow-up across all three cohorts.  
Age-adjusted analysis showed that the highest categories of consumption of total and caffeinated 
coffee were associated with a higher risk of all-cause mortality across the three cohorts. The 
association between consumption of total, caffeinated, and decaffeinated coffee and all-cause 
77 
 
 
 
mortality attenuated significantly after further adjusting for smoking. Multivariate-adjusted 
analysis showed a non-linear association between consumption of total, caffeinated, and 
decaffeinated coffee and all-cause mortality (P values for non-linearity using LRT < 0.001; P 
values for non-linear trend < 0.001) (Table 2). Relative to no consumption of coffee, the pooled 
hazard ratio for death was 0.95 (95% CI: 0.91 to 0.99) for ≤ 1cup of total coffee per day, 0.91 
(95% CI: 0.88 to 0.95) for 1.1 - 3 cups per day, 0.93 (95% CI: 0.89 to 0.97) for 3.1 - 5 cups per 
day, and 1.02 (95% CI: 0.96 to 1.07) for > 5 cups per day. Similar results were found when 
caffeinated and decaffeinated coffee was examined separately. Examining the three cohorts 
individually, the non-linear associations between consumption of total coffee, caffeinated coffee, 
and decaffeinated coffee and risk of all-cause mortality were most pronounced in NHS (Table 2, 
Supplemental figures 2 - 4).  
As smoking is a strong confounder of the coffee-mortality relationship, we repeated the analysis 
among never smokers only. In this analysis, 10,505 deaths were documented during 2,451,970 
person-years of follow-up after pooling data from the three cohorts. Overall, the association of 
total coffee, caffeinated coffee, and decaffeinated coffee consumption with risk of all-cause 
mortality changed from a non-linear association in the overall population to a linear inverse 
association when restricting to never smokers (total coffee: P for non-linearity = 0.32, P for 
linear trend < 0.001; Caffeinated coffee: P for non-linearity = 0.40, P for linear trend < 0.001; 
Decaffeinated coffee: P for non-linearity = 0.18, P for linear trend = 0.02) (Table 3, Figure 1).  
Coffee Consumption and Cause-specific Mortality 
The association between coffee consumption and leading causes of mortality was further 
investigated (Supplemental table 2). In the whole population, coffee consumption was inversely 
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associated with risk of mortality due to CVD, non-linearly associated with risk mortality due to 
type 2 diabetes, and positively associated with risks of mortality due to lung cancer and 
respiratory diseases (Supplemental table 3). However, when restricting to never smokers, coffee 
consumption was no longer associated with risk of mortality due to lung cancer and respiratory 
disease, but was inversely associated only with risks of mortality due to CVD, neurological 
disease, and suicide. No associations of coffee consumption with risks of mortality due to 
colorectal cancer and breast cancer were found (Table 4). The associations of coffee 
consumption with cause-specific mortality were similar to the associations shown in the whole 
population (Supplemental table 4).  
In the total population, a 1-cup per day increment in coffee consumption was positively 
associated with mortality due to lung cancer (P < 0.0001) and respiratory disease (P < 0.05), and 
inversely associated with mortality due to CHD, stroke, neurological disease, and type 2 diabetes 
(P < 0.05). However, after restricting to never smokers, the positive association disappeared for 
lung cancer and respiratory disease and significant inverse associations remained for mortality 
due to CHD, neurological disease, and suicide (P < 0.05) (Figure 2).   
Stratified Analysis 
Significant interactions were found between coffee consumption and risk of mortality by age (P 
for interaction = 0.003) and smoking (P for interaction = 0.015) (Supplemental table 5). The 
association appeared to be stronger among those aged < 70 years than older individuals and was 
stronger among never smokers than smokers. There were no significant differences in the 
associations between coffee consumption and risk of total mortality when stratified by aHEI 
score, BMI, physical activity, sex, and cohort.   
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The proportional hazard assumption was violated in NHS (but not in NHS 2 or HPFS), with a 
stronger association between coffee consumption and mortality in earlier time intervals. 
However, non-linear associations between coffee consumption and risk of mortality were found 
in both subgroups stratified by time interval in NHS (Supplemental table 6).  We further assessed 
the proportional hazard assumption among never smokers in NHS, and the proportional hazard 
assumption was no longer violated (P for interaction = 0.60).  
Sensitivity Analysis 
We further evaluated the association between coffee consumption and mortality using 
cumulatively updated coffee consumption and stopping updating of coffee consumption when 
intermediate diseases developed (hypertension, hypercholesterolemia, type 2 diabetes, cancer, 
and CVD); using time-varying coffee consumption with 4-year lag; using time-varying coffee 
consumption adjusting for hypercholesterolemia as a time-varying covariate; and using baseline 
coffee consumption excluding the hypertensive or hypercholesterolemia cases at baseline. The 
associations between consumption of total coffee, caffeinated coffee, and decaffeinated coffee 
and risk of mortality did not change substantially in these analyses (Supplemental table 7-8, 
Supplemental figure 5 - 9).  
To further evaluate whether the change of the association from non-linear in the whole 
population to inverse linear among never smokers was due to the differences in the composition 
of total mortality between the overall population and never smokers, Cox models with inverse 
probability weighting were applied in the never smokers assessing the association between 
coffee consumption and risk of mortality and the results did not change substantially 
(Supplemental table 9).   
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DISCUSSION 
In this analysis of three large ongoing cohort studies, we observed a non-linear association 
between coffee consumption and risk of mortality in the overall population, with moderate coffee 
consumption being associated with lower mortality risk, and high coffee consumption not being 
associated with mortality risk. Given that this association became linear and inverse after 
restricting to never smokers, it is likely that the non-linear association observed in the total 
population was due to the residual confounding by smoking. This was further strengthened by 
the observation that the positive association between coffee consumption and death due to lung 
cancer and respiratory diseases in the overall population, for both of which smoking is an 
important risk factor, disappeared when restricting to never smokers. The inverse association 
between coffee consumption and risk of mortality did not change substantially when using a 
weighted Cox model among never smokers, excluding the possibility that the different 
associations in overall population and never smokers were due to the different composition of 
total mortality. For both caffeinated and decaffeinated coffee consumption, the non-linear 
associations in the total population and the inverse associations among the never smokers 
decreased the possibility that the non-linear association was due to the biological effect of 
caffeine.  
Our results for the associations between coffee consumption and cause-specific mortality are 
consistent with the associations between coffee consumption and cause-specific diseases from 
previous studies. Numerous prospective cohort studies have shown coffee consumption to be 
associated with lower risk of type 2 diabetes 
1
. There are several plausible biological 
mechanisms that could explain this observation. The chlorogenic acid, lignans, quinides, 
trigonelline, and magnesium in coffee reduce insulin resistance and systematic inflammation 
30, 31
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32-34
 
35
. Chlorogenic acid may have this putative effect by reducing glucose absorption in the 
intestine by competitively inhibiting glucose-6-phosphate translocase and reducing sodium-
dependent glucose transport in the brush border membrane vesicles 
36
; by reducing oxidative 
stress as a result of its antioxidant properties; and by reducing liver glucose output 
37
. In our 
study, an inverse association between coffee drinking and risk of mortality due to CVD was 
observed. Given that diabetes and CVD share common disease pathways, the mechanism of 
inverse association between coffee consumption and risk of CVD mortality might be similar to 
that for diabetes mortality. Studies have also shown coffee consumption to be associated with a 
lower risk of Parkinson’s diseases (PD) 6, 38, 39, which is consistent with our finding of an inverse 
association between coffee consumption and risk of neurological mortality. In a 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD, caffeine was shown to 
attenuate MPTP - induced striatal dopamine loss, striatal dopamine transporter binding sites loss, 
and dopaminergic neurons loss, which might be mediated through A2A  adenosine receptors 
40
. 
Three published cohort studies have shown an inverse association between coffee consumption 
and risk of suicide 
17, 41, 42
, however, one study showed a J-shaped association where heavy 
coffee consumption was associated with a higher risk of suicide 
43
. Our study had shown an 
inverse association of both caffeinated and decaffeinated coffee consumption with risk of suicide 
in both the whole population and never smokers, indicating that coffee consumption might have 
antidepressant effects. Studies have shown an inverse association between coffee consumption 
and risk of liver diseases or risk of mortality due to liver diseases
2, 44-47
, however, no association 
of coffee consumption with risk of mortality due to liver diseases was found in our study, which 
might be due to the limited power given the small number of cases. Previous cohort studies 
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showed no association between coffee consumption and risk of colorectal cancer 
48, 49
, which was 
consistent with our results.  
Our results showed similar associations of caffeinated and decaffeinated coffee consumption 
with risk of total and cause-specific mortality in both the overall population and never smokers, 
further showing that other components in coffee besides caffeine might play a beneficial role 
mediating the association between long-term coffee consumption and risk of mortality. However, 
short-term metabolic studies have shown that caffeine could acutely increase blood pressure by 
antagonizing the adenosine A1 and A2A receptor 
50-52
, and could also acutely adversely affect 
arterial stiffness and endothelium dependent vasodilation 
53, 54
. Case crossover studies showed 
that coffee consumption transiently increased the risk of nonfatal myocardial infarction, ischemic 
stroke onset, and sudden cardiac death 
55-57
. One cohort study assessed the association of coffee 
consumption with total mortality in subsequent 2 years among CVD participants, and no 
association was found 
14
. However, it is still difficult to differentiate acute effects from long-term 
effects of habitual coffee consumption. 
Our analysis has several strengths. The large sample size, long follow-up time, and a large 
number of deaths provided sufficient power to detect a non-linear association in the overall 
population and to perform further analyses among never smokers. The large number of deaths 
also allowed us to conduct analyses on cause-specific mortality. In addition, we had detailed 
measures of both caffeinated and decaffeinated coffee consumption as well as other dietary and 
lifestyle factors.  
Several potential limitations also need to be considered. First, given the observational nature of 
the study design, we could not directly establish a cause-effect relationship between coffee and 
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mortality.  Second, assessment of coffee intake was based on FFQs and thus measurement errors 
are inevitable. However, our validation studies have demonstrated high validity (Pearson 
correlation = 0.74) of the coffee intake by the FFQs as compared to multiple week diet records, 
and high reproducibility (Pearson correlation = 0.80) by comparing two consecutive FFQs 
26
. 
Moreover, coffee intake was also one of the food items showing the highest validity and 
reproducibility by the FFQs in Europe 
58
 and Asia 
59, 60
, indicating that coffee was a beverage  
less prone to misreporting. Finally, since our cohort participants comprise medical and health 
professionals and the vast majority of them are white, the results may not be generalizable to 
other populations.  
In conclusion, regular consumption of coffee was inversely associated with risk of total mortality 
and mortality due to CVD, and neurological disease. Similar associations of caffeinated and 
decaffeinated coffee consumption with risk of total and cause-specific mortality were found. 
Results from this and previous studies indicate that coffee consumption can be incorporated into 
a healthy lifestyle. 
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Table 1. Age-adjusted baseline characteristics of participants by frequency of total coffee consumption (including caffeinated 
and decaffeinated coffee) in NHS, NHS 2, and HPFS 
 NHS (1984)    NHS 2 (1991)    HPFS (1986)    
Cups/d 0  ≤ 1  1.1 - 3  3.1-5  > 5  0  ≤ 1  1.1 - 3  3.1-5  > 5  0  ≤ 1  1.1 - 3  3.1-5  > 5  
N 9,233 14,740 30,420 14,760 5,737 27,888 22,837 29,239 10,049 3,041 6,863 11,402 14,264 5,861 2,167 
Age (year) 48.4 50.5 50.7 50.5 50.0 35.2 35.5 37.6 38.0 38 50.9 54.0 53.7 52.9 52.0 
Caffeinated coffee (cups/d) 0 0.4 1.7 3.2 4.7 0 0.4 1.9 3.4 5.15 0 0.4 1.6 3.0 4.3 
Decaffeinated coffee 
(cups/d) 
0 0.3 0.6 1.2 1.6 0 0.2 0.4 0.9 1.1 0 0.3 0. 7 1.3 2.0 
Physical activity  
(MET-h/wk) 
14.1 14.1 14.4 13.8 13.3 23.1 24.8 25.5 24.2 25.6 21.7 22.2 21.1 20.3 18.2 
aHEI 
#
 46.9 48.0 47.8 47.8 47.3 46.0 49.0 50.2 49.7 48.5 51.9 53.7 52.7 51.7 50.2 
Total energy intake (kcal/d) 1720 1684 1748 1786 1815 1779 1768 1790 1836 1883 1934 1887 1973 2026 2086 
Sugar-sweetened beverages 
(serving/d) 
1.30 1.2 1.1 1.0 0.9 1.4 1.2 1.1 0.9 0.9 1.4 1.3 1.1 1.0 0.9 
Alcohol (grams/d) 3.7 5.8 7.8 7.7 7.1 1.6 2.7 4.3 4.4 4.2 5.7 10.0 13.1 14.1 14.8 
Dairy  (serving/d) 1.9 1.9 2.0 2.07 2.1 2.1 2.2 2.4 2.4 2.6 2.2 2.1 2.2 2.4 2.5 
Fruits (serving/d) 2.2 2.3 2.2 2.1 1.9 1.8 2.0 1.9 1.8 1.6 2.6 2.4 2.2 2.1 2.0 
Vegetables (serving/d) 3.0 3.0 3.1 3.1 3.1 3.2 3.5 3.6 3.7 3.8 3.0 3.0 3.0 3.0 3.0 
Meats (serving/d) 1.4 1.4 1.5 1.5 1.6 1.4 1.4 1.4 1.4 1.5 1.4 1.4 1.6 1.6 1. 8 
Fish (serving/d) 0.2 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 
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BMI (kg/m
2
) 24.4 24.2 23.8 23.6 23.4 25.4 24.7 24.2 24.4 24.8 24.7 24.7 25.0 25.2 25. 
Never smokers, % 63 53 42 34 24 80 70 57 47 35 71 54 42 33 25 
Hypertension,% 9 10 8 7 6 4 4 3 3 3 18 21 20 19 17 
Hypercholesterolemia, % 4 4 4 3 3 10 10 9 9 11 10 11 11 10 11 
Postmenopausal women, % 48 48 48 49 49 3 3 3 3 4 NA NA NA NA NA 
Current postmenopausal 
hormone use, (% among 
total women) 
15 14 14 13 12 3 3 3 3 3 NA NA NA NA NA 
 
aHEI: alternative healthy eating index; BMI: body mass index. 
# aHEI ranges from 0 – 100, with a higher score indicating healthier diet.  
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Table 2. HRs (95% CI) for the association between consumption of total coffee, caffeinated coffee, and decaffeinated coffee 
and risk of mortality  
Total coffee         
Intake (cups/d) 0 ≤ 1 cup/d 1.1-3 cups/d 3.1-5 cups/d >5 cups/d Per cup 
increase 
P for non-
linearity* 
P for linear 
trend 
Cases/Person-
time  
4,166/ 
958,267 
7,826/ 
1,086,683 
12,198/ 
1,681,922 
5,456/ 
709,646 
2,310/ 
253,554 
   
NHS         
Age-adjusted  1.00 0.98 
(0.93, 1.04) 
0.91 
(0.87, 0.96) 
0.96 
(0.91, 1.02) 
1.24 
(1.16, 1.33) 
1.02 
(1.01, 1.03) 
< 0.001 < 0.001 
Age and 
smoking-adjusted 
1.00 0.94 
(0.89, 0.99) 
0.82 
(0.78, 0.86) 
0.81 
(0.76, 0.86) 
0.92 
(0.86, 0.98) 
0.98 
(0.97, 0.99) 
< 0.001 < 0.001 
Multivariate-
adjusted model  
1.00 0.94 
(0.88, 0.99) 
0.90 
(0.86, 0.95) 
0.93 
(0.88, 0.99) 
1.02 
(0.95, 1.09) 
1.00 
(0.99, 1.01) 
< 0.001 0.50 
NHS 2         
Age-adjusted  1.00 0.89 
(0.79, 1.00) 
0.83 
(0.74, 0.92) 
0.93 
(0.80, 1.07) 
1.37 
(1.12, 1.67) 
0.98 
(0.95, 1.01) 
0.003 0.23 
Age and 
smoking-adjusted 
1.00 0.86 
(0.76, 0.97) 
0.74  
(0.66, 0.83) 
0.74 
(0.64, 0.86) 
0.92 
(0.75, 1.13) 
0.93 
(0.90, 0.96) 
0.015 < 0.001 
Multivariate-
adjusted model  
1.00 0.91 
(0.81, 1.03) 
0.84  
(0.75, 0.95) 
0.86 
(0.74, 1.01) 
1.02 
(0.83, 1.26) 
0.96  
(0.93, 1.00) 
0.17 0.03 
HPFS         
Age-adjusted  1.00 1.06 
(1.00, 1.12) 
1.05 
(0.99, 1.11) 
1.09 
(1.02, 1.16) 
1.30 
(1.19, 1.42) 
1.02 
(1.00, 1.03) 
0.98 0.007 
Age and 
smoking-adjusted 
1.00 1.00 
(0.94, 1.06) 
0.95 
(0.90, 1.01) 
0.94 
(0.88, 1.01) 
1.05 
(0.96, 1.15) 
0.98 
(0.94, 1.02) 
0.24 
 
0.36 
Multivariate-
adjusted model  
1.00 1.00 
(0.94, 1.06) 
0.97  
(0.90, 1.01) 
0.95 
(0.88, 1.02) 
1.02 
(0.93, 1.12) 
0.99 
(0.97, 1.00) 
0.13 0.04 
Pooled         
Multivariate-
adjusted model 
1.00 0.95 
(0.91, 0.99) 
0.91 
(0.88, 0.95) 
0.93 
(0.89, 0.97) 
1.02 
(0.96, 1.07) 
0.98 
(0.97, 0.99) 
< 0.001 < 0.001 
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Caffeinated 
coffee 
        
Intake (cups/d) 0 ≤ 1 cup/d 1.1-3 cups/d 3.1-5 cups/d >5 cups/d Per cup 
increase 
P for non-
linearity* 
P for linear 
trend 
Cases/Person-
time 
8,615/ 
1,454,869 
10,105/ 
1,404,192 
8,495/ 
1,255,722 
3,304/ 
419,049 
1,437/ 
156,238 
   
NHS         
Multivariate-
adjusted model 
1.00 0.96 
(0.92, 1.00) 
0.92 
(0.89, 0.96) 
1.01 
(0.96, 1.07) 
1.07 
(0.99, 1.14) 
1.00 
(0.99, 1.01) 
< 0.001 0.78 
NHS 2         
Multivariate-
adjusted model 
1.00 0.97 
(0.86, 1.09) 
0.91 
(0.80, 1.02) 
0.99 
(0.83, 1.17) 
1.11 
(0.88, 1.40) 
0.99 
(0.96, 1.02) 
0.38 0.47 
HPFS         
Multivariate-
adjusted model 
1.00 1.00 
(0.96, 1.05) 
0.94 
(0.90, 0.99) 
1.00 
(0.93, 1.07) 
1.11 
(1.00, 1.24) 
0.99 
(0.98, 1.00) 
0.046 0.11 
Pooled         
Multivariate-
adjusted model 
1.00 0.97 
(0.94, 1.00) 
0.93 
(0.90, 0.96) 
1.00 
(0.96, 1.05) 
1.08 
(1.02, 1.14) 
0.98 
(0.97, 0.99) 
0.015 < 0.001 
Decaffeinated 
coffee 
        
Intake (mg/d) 0 ≤ 1 cup/d 1.1-3 cups/d >3 cups/d  Per cup 
increase 
P for non-
linearity* 
P for linear 
trend 
Cases/Person-
time 
16,393/ 
2,607,891 
10,637/ 
1,516,930 
3,777/ 
445,908 
1,149/ 
119,341 
    
NHS         
Multivariate-
adjusted model  
1.00 0.94 
(0.90, 0.97) 
0.92 
(0.87, 0.96) 
0.96 
(0.89, 1.04) 
 0.96 
(0.95 0.98) 
0.008 < 0.001 
NHS 2         
Multivariate-
adjusted model 
1.00 0.83 
(0.74, 0.92) 
0.86 
(0.70, 1.04) 
0.93 
(0.64, 1.35) 
 0.92 
(0.86, 1.00) 
0.009 0.035 
HPFS         
Multivariate-
adjusted model 
1.00 0.91 
(0.88, 0.95) 
0.92 
(0.87, 0.98) 
0.91 
(0.83, 1.01) 
 0.97 
(0.95, 0.99) 
0.006 0.014 
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Pooled         
Multivariate-
adjusted model 
1.00 0.92 
(0.89, 0.94) 
0.91 
(0.88, 0.94) 
0.94 
(0.88, 1.00) 
 0.96 
(0.94, 0.97) 
< 0.001 < 0.001 
 
* A likelihood ratio test was performed.  
Multivariate-adjusted model: further adjusted for baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 
21-22.9, 23-24.9, 25-29.9, 30-34.9, ≥ 35 kg/m2), physical activity ( < 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary 
pattern (aHEI score, in quintiles), total energy intake (quintiles), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 
cigarettes/d), former (15 - 24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), 
former (unknown cigarettes/d), current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 
cigarettes/d), current (35 - 44 cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), sugar-sweetened beverage 
consumption (quintiles) and alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes 
vs. no), and postmenopausal hormone use (yes vs. no) for women. Caffeinated and decaffeinated coffee adjusted for each other.  
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Table 3. HRs (95% CI) for the association between consumption of total coffee, caffeinated coffee, and decaffeinated coffee 
and risk of mortality among never smokers  
Total coffee         
Intake (cups/d) 0 ≤ 1 cup/d 1.1-3 cups/d 3.1-5 cups/d >5 cups/d Per cup 
increase 
P for non-
linearity* 
P for linear 
trend 
Cases/Person-time  2,190/ 
704,010 
3,032/ 
638,687 
3,759/ 
779,966 
1,211/ 
262,069 
313/ 
67,238 
   
NHS         
Age-adjusted model 1.00 0.92 
(0.85, 0.99) 
0.80 
(0.74, 0.86) 
0.73 
(0.66, 0.80) 
0.76 
(0.65, 0.88) 
0.93 
(0.91, 0.95) 
0.09 
 
< 0.001 
Multivariate-
adjusted model 
1.00 0.92 
(0.85, 0.99) 
0.88 
(0.81, 0.95) 
0.84 
(0.76, 0.92) 
0.82 
(0.71, 0.96) 
0.96 
(0.95, 0.98) 
0.09 < 0.001 
NHS 2         
Age-adjusted model 1.00 0.84 
(0.71, 0.98) 
0.84 
(0.72, 0.98) 
0.76 
(0.60, 0.97) 
0.85 
(0.55, 1.32) 
0.95 
(0.91, 1.00) 
0.20 0.07 
Multivariate-
adjusted model 
1.00 0.89 
(0.76, 1.05) 
0.98 
(0.84, 1.15) 
0.88 
(0.69, 1.13) 
0.91 
(0.59, 1.42) 
1.00 
(0.95, 1.05) 
0.77 0.96 
HPFS         
Age-adjusted model 1.00 0.99 
(0.90, 1.08) 
0.96 
(0.88, 1.05) 
0.83 
(0.73, 0.95) 
1.06 
(0.84, 1.33) 
0.96 
(0.94, 0.99) 
0.20 0.005 
Multivariate-
adjusted model 
1.00 0.98 
(0.89, 1.08) 
0.97 
(0.88, 1.06) 
0.84 
(0.73, 0.97) 
0.98 
(0.78, 1.24) 
0.96 
(0.94, 0.99) 
0.38 0.009 
Pooled         
Multivariate-
adjusted model 
1.00 0.94 
(0.89, 0.99) 
0.92 
(0.87, 0.97) 
0.85 
(0.79, 0.92) 
0.88 
(0.78, 0.99) 
0.97 
(0.95, 0.98) 
0.32 < 0.001 
         
Caffeinated coffee         
Intake (cups/d) 0 ≤ 1 cup/d 1.1-3 cups/d 3.1-5 cups/d >5 cups/d Per cup 
increase 
P for non-
linearity* 
P for linear 
trend 
Cases/Person-time 3,702/ 
962,732 
3,637/ 
771,531 
2,409/ 
542,629 
595/ 
138,375 
162/ 
36,700 
   
NHS         
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Multivariate-
adjusted model 
1.00 0.95 
(0.89, 1.01) 
0.89 
(0.83, 0.96) 
0.84 
(0.75, 0.94) 
0.82 
(0.67, 1.00) 
0.96 
(0.94, 0.98) 
0.34 < 0.001 
NHS 2         
Multivariate-
adjusted model 
1.00 0.99 
(0.85, 1.15) 
1.07 
(0.90, 1.27) 
1.05 
(0.78, 1.42) 
1.04 
(0.60, 1.81) 
1.02 
(0.98, 1.08) 
0.95 0.42 
HPFS         
Multivariate-
adjusted model 
1.00 1.03 
(0.95, 1.11) 
0.92 
(0.84, 1.02) 
0.95 
(0.80, 1.14) 
1.06 
(0.78, 1.44) 
0.97 
(0.95, 1.00) 
0.76 0.08 
Pooled         
Multivariate-
adjusted model 
1.00           0.98 
(0.93, 1.03) 
0.92 
(0.87, 0.97) 
0.89 
(0.81, 0.97) 
0.90 
(0.77, 1.06) 
0.97 
(0.95, 0.99) 
0.40 < 0.001 
Decaffeinated 
coffee 
        
Intake (mg/d) 0 ≤ 1 cup/d 1.1-3 cups/d >3 cups/d  Per cup 
increase 
P for non-
linearity* 
P for linear 
trend 
Cases/Person-time 5,436/ 
1,423,563 
3,775/ 
799,017 
1,084/ 
191,219 
210/ 
38,171 
    
NHS         
Multivariate-
adjusted model 
1.00 0.97 
(0.91, 1.03) 
0.92 
(0.85, 1.00) 
0.97 
(0.82, 1.14) 
 0.97 
(0.93, 1.00) 
0.56 0.03 
NHS 2         
Multivariate-
adjusted model 
1.00 0.82 
(0.70, 0.95) 
0.87 
(0.65, 1.16) 
0.70 
(0.33, 1.47) 
 0.93 
(0.83, 1.04) 
0.06 0.21 
HPFS         
Multivariate-
adjusted model 
1.00 0.96 
(0.88, 1.03) 
0.94 
(0.83, 1.06) 
0.70 
(0.52, 0.95) 
 0.98 
(0.93, 1.02) 
0.61 0.33 
Pooled         
Multivariate-
adjusted model 
1.00 0.95 
(0.91, 0.99) 
0.93 
(0.86, 0.99) 
0.89 
(0.77, 1.02) 
 0.97 
(0.94, 0.99) 
0.18 0.02 
 
* A likelihood ratio test was performed.  
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Multivariate-adjusted model: further adjusted for baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 
21-22.9, 23-24.9, 25-29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern 
(AHEI score, in quintiles), total energy intake (quintiles), sugar-sweetened beverages consumption (quintiles) and alcohol 
consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal 
hormone use (yes vs. no) for women. Caffeinated and decaffeinated coffee adjusted for each other.  
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Table 4. Multivariate HRs (95% CI) for the association between consumption of total coffee and risk of cause-specific 
mortality among never smokers  
           0 ≤ 1 cup/d 1.1-3 cups/d 3.1-5 cups/d >5 cups/d P for 
nonlinearity* 
P for linear 
trend 
CVD mortality 
(2587 cases) 
       
Multivariate-adjusted model 1.00 0.95 
(0.85, 1.07) 
0.94 
(0.84, 1.05) 
0.81 
(0.70, 0.95) 
0.91 
(0.71, 1.17) 
0.77 0.004 
CHD mortality 
(1815 cases) 
       
Multivariate-adjusted model 1.00 0.90 
(0.78, 1.03) 
0.90 
(0.79, 1.03) 
0.81 
(0.68, 0.98) 
0.89 
(0.66, 1.20) 
0.90 0.01 
Stroke mortality 
(656 cases) 
       
Multivariate-adjusted model 1.00 1.04 
(0.82, 1.31) 
1.01 
(0.80, 1.27) 
0.76 
(0.56, 1.04) 
0.93 
(0.56, 1.54) 
0.81 0.06 
Cancer mortality 
(3664 cases) 
       
Multivariate-adjusted model 1.00 0.99 
(0.90, 1.09) 
0.99 
(0.90, 1.08) 
0.88 
(0.77, 0.99) 
0.84 
(0.68, 1.03) 
0.34 0.08 
Colorectal cancer mortality 
(380 cases) 
       
Multivariate-adjusted model 1.00 0.88 
(0.65, 1.19) 
0.92 
(0.69, 1.23) 
0.92 
(0.63, 1.33) 
0.94 
(0.51, 1.75) 
0.78 0.91 
Lung cancer mortality  
(217 cases) 
       
Multivariate-adjusted model 1.00 1.11 
(0.73, 1.69) 
1.14 
(0.76, 1.71) 
1.15 
(0.70, 1.90) 
0.89 
(0.37, 2.12) 
0.32 0.82 
Pancreatic cancer mortality 
(321 cases) 
       
Multivariate-adjusted model 1.00 1.47 
(1.04, 2.06) 
1.10 
(0.78, 1.55) 
1.06 
(0.69, 1.62) 
0.41 
(0.15, 1.14) 
0.056 0.06 
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Breast cancer mortality  
(567 cases) 
       
Multivariate-adjusted model 1.00 0.96 
(0.76, 1.22) 
0.91 
(0.72, 1.14) 
0.79 
(0.58, 1.07) 
0.62 
(0.36, 1.09) 
0.84 0.16 
Premenopausal breast cancer 
mortality  
(77 cases) 
       
Multivariate-adjusted model NA       
Postmenopausal breast cancer 
mortality  
(490 cases) 
       
Multivariate-adjusted model 1.00 0.94 
(0.72, 1.21) 
0.83 
(0.64, 1.07) 
0.79 
(0.57, 1.08) 
0.67 
(0.38, 1.18) 
0.57 0.10 
Ovary cancer mortality  
(250 cases) 
       
Multivariate-adjusted model 1.00 0.73 
(0.50, 1.05) 
0.85 
(0.61, 1.19) 
0.51 
(0.31, 0.83) 
0.63 
(0.30, 1.33) 
0.71 0.20 
Endometrial cancer mortality 
(115 cases) 
       
Multivariate-adjusted model 1.00 0.99 
(0.55, 1.80) 
1.24 
(0.72, 2.15) 
0.90 
(0.43, 1.85) 
2.17 
(0.94, 5.05) 
0.26 0.94 
Prostate cancer mortality  
(210 cases) 
       
Multivariate-adjusted model 1.00 0.75 
(0.51, 1.10) 
0.87 
(0.59, 1.28) 
0.74 
(0.42, 1.29) 
0.83 
(0.30, 2.35) 
0.42 0.48 
Respiratory disease mortality 
(385 cases) 
       
Multivariate-adjusted model 1.00 0.91 
(0.67, 1.23) 
0.88 
(0.66, 1.19) 
0.94 
(0.65, 1.36) 
0.62 
(0.30, 1.31) 
0.31 0.95 
Neurological disease mortality 
(243 cases) 
       
Multivariate-adjusted model 1.00 0.91 
(0.62, 1.32) 
0.80 
(0.55, 1.15) 
0.63 
(0.39, 1.01) 
0.79 
(0.38, 1.62) 
0.83 0.004 
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Diabetes mortality  
(128 cases) 
       
Multivariate-adjusted model 1.00 0.96 
(0.59, 1.56) 
0.67 
(0.40, 1.11) 
0.76 
(0.38, 1.49) 
0.76 
(0.26, 2.20) 
0.19 0.09 
Injury mortality  
(233 cases) 
       
Multivariate-adjusted model 1.00 1.01 
(0.70, 1.46) 
0.90 
(0.62, 1.31) 
0.71 
(0.42, 1.22) 
1.28 
(0.62, 2.65) 
0.28 0.22 
Suicide mortality  
(134 cases) 
       
Multivariate-adjusted model 1.00 1.36 
(0.88, 2.10) 
0.73 
(0.45, 1.21) 
0.64 
(0.30, 1.35) 
0.80 
(0.24, 2.65) 
0.58 0.02 
Other disease mortality  
(3108 cases) 
       
Multivariate-adjusted model 1.00 0.86 
(0.77, 0.95) 
0.81 
(0.73, 0.90) 
0.81 
(0.71, 0.93) 
0.94 
(0.76, 1.16) 
0.011 0.008 
 
 
* A likelihood ratio test was performed.  
The model adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 25-
29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), sugar-sweetened beverages consumption (quintiles) and alcohol consumption (0, 0-5, 5-10, 
10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal hormone use (yes vs. no) for 
women. Caffeinated and decaffeinated coffee adjusted for each other. 
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                                   Figure 1a.                                                            Figure 1b.                                                           Figure 1c. 
Figure 1. The association between coffee consumption and risk of mortality in the overall population and among never smokers pooled across 
the three cohorts. 1a. Total coffee consumption and risk of mortality 1b. Caffeinated coffee consumption and risk of mortality 1c. Decaffeinated 
coffee consumption and risk of mortality.  
Multivariate-adjusted models adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 25-29.9, 30-34.9, ≥ 35 
kg/m
2
), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former (15 - 24 
cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), former (unknown cigarettes/d), current (1 - 4 cigarettes/d), current (5 - 14 
cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), overall 
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dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), sugar-sweetened beverages consumption (quintiles) and alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 
15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal hormone use (yes vs. no) for women. Caffeinated and decaffeinated coffee adjusted 
for each other. 
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Figure 2. The association of a 1-cup per day increment in coffee consumption with risk of 
cause-specific mortality pooled across the three cohorts. The black squares stand for the overall 
population. The red squares stand for never smokers. * P value < 0.05. ** P value < 0.001. 
Multivariate-adjusted models adjusted for age, baseline disease status (hypertension, hypercholesterolemia, 
diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 25-29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 
18-26.9, ≥ 27 MET-h/wk), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former 
(15 - 24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), 
former (unknown cigarettes/d), current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 
cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 cigarettes/d), current (≥ 45 cigarettes/d), current 
(unknown cigarettes/d)), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), sugar-
sweetened beverages consumption (quintiles) and alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We 
additionally adjusted for menopausal status (yes vs. no), and postmenopausal hormone use (yes vs. no) for 
women. Caffeinated and decaffeinated coffee adjusted for each other. 
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Supplemental Table 1. Categories for causes of death. 
Causes of death                                         ICD-8 code 
Cardiovascular disease 390-458 
   Heart disease 390-429, 440-458 
   Stroke 430-438 
Cancer 140-207 
   Colorectal cancer 153, 154 
   Lung cancer 162 
   Pancreatic cancer 157 
   Breast cancer 174 
   Ovary cancer 183 
   Prostate cancer 185 
Respiratory disease 460-519 
Diabetes 250 
Neurological disease 290, 340, 342, 348 
Injury 800-950, 959-999 
Suicide 950-959 
All other causes The rest of the ICD codes 
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Supplemental Table 2. The disease composition of overall mortality. 
 
NHS NHS 2 HPFS Total population 
Cardiovascular disease 3844 211 3781 7836 
Coronary heart disease 2545 157 2966 5668 
Stroke 1062 43 750 1855 
Other diseases 4667 680 2925 8272 
Respiratory disease 1383 52 924 2359 
Injury 144 10 500 654 
Neurological disease 460 48 22 530 
Suicide 84 98 192 374 
Type 2 diabetes 214 32 92 338 
Renal disease 48 3 26 77 
Cancer 6624 922 3970 11516 
Lung cancer 1596 107 745 2448 
Breast cancer 961 261 0 1222 
     Premenopausal breast cancer 42 83 0 125 
     Postmenopausal breast cancer 911 178 0 1089 
Colorectal cancer 549 69 417 1035 
Pancreatic cancer 487 49 338 874 
Non-Hodgkin lymphoma 398 54 295 747 
Prostate cancer 0 0 572 572 
Ovary cancer 496 82 0 578 
Brain cancer 195 58 167 420 
Leukemia 193 30 175 398 
Myeloma 162 7 145 314 
Renal cell cancer 142 10 119 271 
Bladder cancer 107 5 160 272 
Skin cancer 105 26 126 257 
Endometrial cancer 211 31 0 242 
Esophagus cancer 71 5 133 209 
Stomach cancer 102 9 87 198 
Head and neck cancer 83 8 84 175 
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Liver cancer 72 5 60 137 
Gall bladder cancer 89 13 32 134 
Small intestine cancer 26 8 9 43 
Cervix cancer 28 11 0 39 
Hodgkin lymphoma 14 4 11 29 
Total mortality 17,468 2,056 12,432 31,956 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
 
 
Supplemental Table 3. HRs (95% CI) for the association between consumption of total coffee and risk of cause-specific 
mortality  
 0 cup/d <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d P non-
linearity* 
P for 
linear 
trend 
CVD mortality 
(7836 cases) 
1.00 1.01 
(0.93, 1.09) 
0.95 
(0.87, 1.01) 
0.88 
(0.81, 0.96) 
1.02 
(0.91, 1.14) 
0.49 < 0.001 
CHD mortality 
(5668 cases)  
1.00 0.98 
(0.90, 1.07) 
0.92 
(0.85, 1.01) 
0.90 
(0.81, 0.99) 
1.03 
(0.91, 1.17) 
0.21 0.01 
 Stroke mortality 
(1855 cases) 
1.00 1.05 
(0.89, 1.23) 
0.95 
(0.81, 1.11) 
0.81 
(0.67, 0.97) 
1.00 
(0.79, 1.25) 
0.89 0.002 
 Cancer mortality 
(11,516 cases) 
1.00 1.01 
(0.94, 1.08) 
1.01 
(0.95, 1.08) 
1.03 
(0.95, 1.10) 
1.16 
(1.06, 1.27) 
0.88 0.40 
 Colorectal cancer mortality  
(1,035 cases) 
1.00 1.03 
(0.83, 1.28) 
0.95 
(0.77, 1.17) 
0.95 
(0.75, 1.20) 
0.94 
(0.69, 1.29) 
0.91 0.48 
 Lung cancer mortality  
(2448 cases) 
1.00 1.03 
(0.86, 1.23) 
1.15 
(0.98, 1.36) 
1.39 
(1.17, 1.65) 
1.82 
(1.51, 2.19) 
0.39 < 0.001 
 Pancreatic cancer mortality  
(874 cases) 
1.00 1.35 
(1.05, 1.72) 
1.17 
(0.92, 1.49) 
1.08 
(0.83, 1.42) 
1.25 
(0.89, 1.74) 
0.64 0.64 
 Liver cancer 
(137 cases) 
1.00 1.72 
(0.89, 3.33) 
1.37 
(0.71, 2.61) 
1.76 
(0.88, 3.52) 
0.62 
(0.19, 1.94) 
0.53 0.90 
 Breast cancer mortality  
(1222 cases) 
1.00 0.97 
(0.81, 1.18) 
0.97 
(0.81, 1.16) 
0.92 
(0.75, 1.14) 
1.00 
(0.77, 1.31) 
0.50 0.21 
 Postmenopausal breast cancer mortality  
(1089 cases) 
1.00 0.96 
(0.78, 1.19) 
0.94 
(0.78, 1.14) 
0.93 
(0.74, 1.16) 
1.05 
(0.80, 1.39) 
0.80 0.23 
 Ovary cancer mortality  
(578 cases) 
1.00 0.72 
(0.54, 0.97) 
0.88 
(0.68, 1.14) 
0.82 
(0.61, 1.10) 
0.90 
(0.62, 1.31) 
0.73 0.98 
Endometrial Cancer  
(242 cases)  
1.00 1.11 
(0.70, 1.75) 
1.19 
(0.78, 1.82) 
1.12 
(0.69, 1.82) 
1.18 
(0.63, 2.21) 
0.17 0.68 
 Prostate cancer mortality  
(572 cases) 
1.00 0.76  
(0.59, 0.98) 
0.76 
(0.59, 0.98) 
0.73 
(0.54, 1.00) 
0.50 
(0.30, 0.85) 
0.08 0.12 
 Respiratory disease mortality  1.00 0.90 0.84 1.04 1.32 < 0.001 0.04 
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(2,359 cases) (0.77, 1.05) (0.73, 0.97) (0.89, 1.22) (1.10, 1.58) 
 Neurological disease mortality  
(530 cases) 
1.00 0.91 
(0.68, 1.21) 
0.80 
(0.61, 1.04) 
0.69 
(0.50, 0.95) 
0.60 
(0.38, 0.94) 
0.17 0.01 
 Diabetes mortality  
(338 cases) 
1.00 0.90 
(0.65, 1.24) 
0.59 
(0.43, 0.82) 
0.65 
(0.43, 0.97) 
0.57 
(0.32, 1.01) 
0.03 0.003 
 Injury mortality  
(654 cases) 
1.00 0.88 
(0.68, 1.13) 
0.91 
(0.71, 1.16) 
0.84 
(0.62, 1.12) 
0.98 
(0.67, 1.44) 
0.58 0.44 
 Suicide 
(374 cases) 
1.00 1.10 
(0.81, 1.48) 
0.76 
(0.56, 1.03) 
0.58 
(0.39, 0.86) 
0.54 
(0.31, 0.92) 
0.70 < 0.001 
 Other disease mortality  
(8,272 cases) 
1.00 0.88 
(0.82, 0.95) 
0.80 
(0.75, 0.86) 
0.81 
(0.74, 0.87) 
0.79 
(0.71, 0.88) 
< 0.001 < 0.001 
* A likelihood ratio test was performed.  
The model adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 25-
29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former (15 - 
24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), former (unknown cigarettes/d), 
current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 
cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), sugar-sweetened beverages consumption (quintiles) and 
alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal 
hormone use (yes vs. no) for women. Caffeinated and decaffeinated coffee adjusted for each other.  
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Supplemental Table 4. HRs (95% CI) for the association between consumption of total coffee and risk of cause-specific 
mortality among ever smokers 
 0 cup/d <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d P non-
linearity* 
P for 
linear 
trend 
CVD mortality 
 
1.00 1.03 
(0.93, 1.14) 
0.94 
(0.85, 1.04) 
0.93 
(0.83, 1.04) 
1.14 
(1.00, 1.30) 
0.005 0.11 
CHD mortality 
 
1.00 1.03 
(0.91, 1.16) 
0.95 
(0.84, 1.07) 
0.96 
(0.84, 1.10) 
1.17 
(1.00, 1.36) 
0.01 0.3 
 Stroke mortality 
 
1.00 1.02 
(0.82, 1.28) 
0.91 
(0.74, 1.12) 
0.81 
(0.64, 1.03) 
1.05 
(0.80, 1.38) 
0.15 0.13 
 Cancer mortality 
 
1.00 1.04 
(0.95, 1.14) 
1.07 
(0.98, 1.16) 
1.16 
(1.06, 1.27) 
1.41 
(1.27, 1.57) 
0.009 < 0.001 
 Colorectal cancer mortality  
 
1.00 1.23 
(0.89, 1.68) 
1.04 
(0.77, 1.41) 
1.06 
(0.76, 1.47) 
1.02 
(0.69, 1.51) 
0.47 0.66 
 Lung cancer mortality  
 
1.00 1.00 
(0.82, 1.22) 
1.19 
(0.99, 1.42) 
1.56 
(1.29, 1.88) 
2.37 
(1.94, 2.89) 
0.03 < 0.001 
 Pancreatic cancer mortality  
 
1.00 1.23 
(0.86, 1.76) 
1.20 
(0.85, 1.68) 
1.11 
(0.77, 1.61) 
1.57 
(1.04, 2.35) 
0.92 0.63 
 Liver cancer 
 
1.00 1.72 
(0.89, 3.33) 
1.37 
(0.71, 2.61) 
1.76 
(0.88, 3.52) 
0.62 
(0.19, 1.94) 
0.55 0.45 
 Breast cancer mortality  
 
1.00 1.11 
(0.80, 1.53) 
1.09 
(0.81, 1.47) 
1.08 
(0.78, 1.49) 
1.32 
(0.92, 1.90) 
0.52 0.31 
 Postmenopausal breast cancer mortality  
 
1.00 1.12 
(0.79, 1.60) 
1.14 
(0.82, 1.58) 
1.12 
(0.79, 1.59) 
1.42 
(0.97, 2.09) 
0.73 0.19 
 Ovary cancer mortality  
 
1.00 0.81 
(0.50, 1.33) 
1.01 
(0.66, 1.55) 
1.12 
(0.71, 1.75) 
1.17 
(0.70, 1.93) 
0.71 0.12 
Endometrial Cancer  
 
1.00 1.28 
(0.62, 2.67) 
1.11 
(0.56, 2.20) 
1.15 
(0.56, 2.39) 
0.71 
(0.28, 1.81) 
0.22 0.27 
 Prostate cancer mortality  
 
1.00 0.72  
(0.51, 1.01) 
0.67 
(0.48, 0.94) 
0.68 
(0.46, 1.01) 
0.42 
(0.23, 0.78) 
0.38 0.03 
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 Respiratory disease mortality  
 
1.00 0.88 
(0.73, 1.05) 
0.82 
(0.69, 0.97) 
1.07 
(0.90, 1.29) 
1.42 
(1.16, 1.74) 
< 0.001 < 0.001 
 Neurological disease mortality  
 
1.00 0.90 
(0.58, 1.39) 
0.75 
(0.50, 1.13) 
0.68 
(0.43, 1.06) 
0.49 
(0.27, 0.88) 
0.77 0.02 
 Diabetes mortality  
 
1.00 0.82 
(0.53, 1.27) 
0.52 
(0.33, 0.80) 
0.60 
(0.36, 0.99) 
0.54 
(0.27, 1.06) 
0.02 0.03 
 Injury mortality  
 
1.00 0.79 
(0.56, 1.13) 
0.89 
(0.64, 1.23) 
0.87 
(0.60, 1.25) 
0.93 
(0.59, 1.48) 
0.41 0.75 
 Suicide 
 
1.00 0.91 
(0.60, 1.38) 
0.75 
(0.50, 1.11) 
0.58 
(0.36, 0.94) 
0.58 
(0.31, 1.06) 
0.95  0.001 
 Other disease mortality  
 
1.00 0.88 
(0.79, 0.97) 
0.79 
(0.71, 0.87) 
0.81 
(0.73, 0.90) 
0.80 
(0.70, 0.91) 
0.003 < 0.001 
* A likelihood ratio test was performed.  
The model adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 25-
29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former (15 - 
24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), former (unknown cigarettes/d), 
current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 
cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), sugar-sweetened beverages consumption (quintiles) and 
alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal 
hormone use (yes vs. no) for women. Caffeinated and decaffeinated coffee adjusted for each other.  
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Supplemental Table 5. Stratified analysis for the association between coffee consumption and risk of total mortality  
 
 
Categories of total coffee consumption 
 
 
0  <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d  P for 
interaction† 
Stratified by age 
     
0.003 
Age ≤ 70 years 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.97  
(0.92-1.03) 
0.87 
 (0.83-0.92) 
0.86  
(0.81-0.92) 
0.96  
(0.88-1.04)  
Age > 70 years 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.96  
(0.91-1.01) 
0.93  
(0.89-0.98) 
0.95  
(0.89-1.00) 
1.06  
(0.99-1.14)  
Stratified by BMI 
     
0.076 
BMI ≤ 25 kg/m2 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.93 
 (0.88-0.99) 
0.92  
(0.87-0.97) 
0.93  
(0.87-0.99) 
1.03  
(0.95-1.11)  
 BMI > 25 kg/m
2
 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.97  
(0.92-1.02) 
0.90  
(0.86-0.95) 
0.91 
(0.86-0.97) 
0.98  
(0.91-1.05)  
Stratified by aHEI 
     
0.96 
aHEI ≤  median level 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.95 
(0.90-1.00) 
0.90  
(0.86-0.95) 
0.92  
(0.87-0.98) 
1.00  
(0.93-1.07)  
aHEI > median level 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.95 
(0.90-1.01) 
0.92  
(0.87-0.97) 
0.94  
(0.88-1.00) 
1.04  
(0.96-1.13)  
Stratified by physical activity 
   
0.20 
Physical activity ≤ median level 
     
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.91 
(0.87-0.96) 
0.88  
(0.84-0.92) 
0.92  
(0.87-0.97) 
1.00  
(0.93-1.07)  
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Physical activity > median level 
     
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
1.01 
 (0.94-1.07) 
0.96  
(0.91-1.02) 
0.95  
(0.88-1.02) 
1.06  
(0.97-1.16)  
Stratified by smoking status 
    
 < 0.001 
Never 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.94 
 (0.89-1.00) 
0.92  
(0.87-0.97) 
0.85  
(0.79-0.92) 
0.88  
(0.78-0.99)  
Ever 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.96  
(0.91-1.01) 
0.92  
(0.87-0.97) 
0.96  
(0.91-1.01) 
1.04  
(0.98-1.11)  
Stratified by sex 
    
0.39 
Female 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.93 
 (0.88-0.97) 
0.89  
(0.85-0.93) 
0.93  
(0.88-0.98) 
1.02  
(0.95-1.08)  
Male 
      
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 1.00 
(0.94, 1.06) 
0.97 
(0.91, 1.03) 
0.96 
(0.90, 1.03) 
1.05 
(0.96, 1.14)  
Stratify by individual 
cohort (cohort effect) 
      
NHS       
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 0.94 
(0.88, 1.00) 
0.90 
(0.85, 0.95) 
0.92 
(0.88, 0.98) 
1.02 
(0.96, 1.10) 
 
NHS 2 
     
 
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 0.92 
(0.81, 1.04) 
0.85  
(0.75, 0.95) 
0.86 
(0.73, 1.01) 
0.97 
(0.78, 1.20) 
 
HPFS 
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Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 1.00 
(0.94, 1.06) 
0.97  
(0.91, 1.03) 
0.96 
(0.90, 1.03) 
1.05 
(0.96, 1.14) 
 
 
Abbreviations: CI, confidence interval; BMI, body mass index; aHEI, alternative health eating index 
* Models were adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 
25-29.9, 30-34.9, ≥ 35 kg/m2), physical activity ( < 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former (15 - 
24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), former (unknown cigarettes/d), 
current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 
cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), sugar-sweetened beverages consumption (quintiles) and 
alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal 
hormone use (yes vs. no) for women. 
* †  Likelihood ratio tests were performed.  
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Supplemental Table 6. The tests of proportional hazard assumption in NHS, NHS 2, and HPFS.  
 
Categories of total coffee consumption Pinteraction† 
 
0  <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d 
 
Stratified by follow-up 
time in NHS 
     < 0.001 
< 20 years       
Multivariate-adjusted     
hazard ratio (95% CI)  
1.00 
0.93 
(0.85, 1.02) 
0.87 
(0.80, 0.94) 
0.84 
(0.76, 0.92) 
0.89 
(0.79, 0.99) 
 
≥ 20 years       
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.94 
(0.87, 1.01) 
0.93 
(0.87, 0.99) 
1.00 
(0.92, 1.07) 
1.12 
(1.02, 1.22) 
 
Stratified by follow-up 
time in NHS2 
     0.49 
< 14 years       
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.92  
(0.74, 1.13) 
0.99  
(0.81, 1.21) 
0.96  
(0.74, 1.25) 
1.04  
(0.72, 1.48) 
 
≥ 14 years       
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.91 
(0.78, 1.06) 
0.78  
(0.67, 0.91) 
0.83  
(0.68, 1.00) 
1.01  
(0.78, 1.31) 
 
Stratified by follow-up 
time in HPFS 
     0.53 
< 20 years       
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
1.00  
(0.92, 1.09) 
0.96 
(0.88, 1.04) 
0.93  
(0.85, 1.03) 
1.00 
 (0.88, 1.14) 
 
≥ 20 years       
Multivariate-adjusted 
hazard ratio (95% CI) 
1.00 
0.98  
(0.90, 1.07) 
0.95 
(0.87, 1.03) 
0.96  
(0.87, 1.06) 
1.03 
 (0.90, 1.17) 
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* Models were adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 
25-29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former (15 - 
24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), former (unknown cigarettes/d), 
current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 
cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), sugar-sweetened beverages consumption (quintiles) and 
alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal 
hormone use (yes vs. no) for women. 
* †  Likelihood ratio tests were performed.  
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Supplemental Table 7. Sensitivity analyses for the association between coffee consumption and total mortality in the overall 
population, and pooled multivariate-adjusted hazard ratio was shown 
 
Categories of total coffee P non-linearity* 
 
0  <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d 
Using cumulative coffee 
consumption, and 
stopping updating after 
cancer and diabetes 
1.00 
0.96 
(0.92, 1.00) 
0.89 
(0.86, 0.92) 
0.91 
(0.87, 0.95) 
0.94 
(0.88, 0.99) 
< 0.001 
Using cumulative coffee 
consumption, and further 
stopping updating after 
hypertension, 
hypercholesterolemia,  
and CVD 
 
1.00 0.96 
(0.92, 1.00) 
0.89 
(0.86, 0.92) 
0.91 
(0.87, 0.95) 
0.97 
(0.92, 1.03) 
< 0.001 
Continue updating after 
diagnosis of chronic 
disease with 4-year lag 
1.00 
0.99 
(0.96, 1.04) 
0.93 
(0.88, 0.97) 
0.94 
(0.89, 0.98) 
0.94 
(0.87, 1.00) 
< 0.001 
Continue updating after 
diagnosis of chronic 
disease adjusting for time-
varying 
hypercholesterolemia 
1.00 
1.02 
(0.97, 1.06) 
0.92 
(0.88, 0.96) 
0.92 
(0.87, 0.96) 
0.86 
(0.80, 0.92) 
0.04 
Using baseline exposure 
with exclusion of 
hypertension and 
hypercholesterolemia at 
baseline  
1.00 
0.98 
(0.93, 1.02) 
0.93 
(0.88, 0.97) 
0.95 
(0.91, 1.00) 
1.04 
(0.98, 1.10) 
< 0.001 
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Categories of caffeinated coffee  
 
0  <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d  
Using cumulative coffee 
consumption, and 
stopping updating after 
cancer and diabetes 
1.00 0.98 
(0.95, 1.01) 
0.93 
(0.90, 0.96) 
0.98 
(0.94, 1.03) 
0.98 
(0.91, 1.04) 
< 0.001 
Using cumulative coffee 
consumption, and further 
stopping updating after 
hypertension, 
hypercholesterolemia,  
and CVD 
1.00 0.98 
(0.95, 1.01) 
0.91 
(0.88, 0.94) 
0.98 
(0.94, 1.03) 
1.02 
(0.96, 1.09) 
< 0.001 
Continue updating after 
diagnosis of chronic 
disease with 4-year lag 
1.00 
1.00 
(0.97, 1.04) 
0.95 
(0.92, 0.99) 
0.99 
(0.95, 1.03) 
0.98 
(0.91, 1.07) 
0.014 
Continue updating after 
diagnosis of chronic 
disease adjusting for time-
varying 
hypercholesterolemia 
1.00 
1.00 
(0.97, 1.04) 
0.94 
(0.91, 0.97) 
0.95 
(0.91, 1.00) 
0.87 
(0.80, 0.95) 
< 0.001 
Using baseline exposure 
with exclusion of 
hypertension and 
hypercholesterolemia at 
baseline 
1.00 0.98 
(0.95, 1.01) 
0.93 
(0.90, 0.96) 
1.00 
(0.96, 1.06) 
1.10 
(1.03, 1.14) 
< 0.001 
 
         Categories of decaffeinated coffee  
 
0 <1 cup/d 1-3 cups/d >3 cups/d   
117 
 
 
 
Using cumulative coffee 
consumption, and 
stopping updating after 
cancer and diabetes 
1.00 0.89 
(0.86, 0.91) 
0.87 
(0.84, 0.90) 
0.94 
(0.88, 0.99) 
 < 0.001 
Using cumulative coffee 
consumption, and further 
stopping updating after 
hypertension, 
hypercholesterolemia,  
and CVD 
 
1.00 0.86 
(0.86, 0.88) 
0.84 
(0.82, 0.88) 
0.95 
(0.88, 1.01) 
 < 0.001 
Continue updating after 
diagnosis of chronic 
disease with 4-year lag 
1.00 
0.90 
(0.88, 0.92) 
0.89 
(0.87, 0.93) 
0.91 
(0.85, 0.98) 
 < 0.001 
Continue updating after 
diagnosis of chronic 
disease adjusting for time-
varying 
hypercholesterolemia 
1.00 
0.90 
(0.87, 0.92) 
0.88 
(0.86, 0.92) 
0.90 
(0.84, 0.97) 
 < 0.001 
Using baseline exposure 
with exclusion of 
hypertension and 
hypercholesterolemia at 
baseline 
1.00 
0.93 
(0.89, 0.96) 
0.93 
(0.89, 0.97) 
0.93 
(0.86, 1.00) 
 < 0.001 
 
Models were adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 
25-29.9, 30-34.9, ≥ 35 kg/m2), physical activity ( < 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), smoking status (never, former (1 - 4 cigarettes/d), former (5 - 14 cigarettes/d), former (15 - 
24 cigarettes/d), former (25 - 34 cigarettes/d), former (35 - 44 cigarettes/d), former (≥ 45 cigarettes/d), former (unknown cigarettes/d), 
current (1 - 4 cigarettes/d), current (5 - 14 cigarettes/d), current (15 - 24 cigarettes/d), current (25 - 34 cigarettes/d), current (35 - 44 
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cigarettes/d), current (≥ 45 cigarettes/d), current (unknown cigarettes/d)), sugar-sweetened beverages consumption (quintiles) and 
alcohol consumption (0, 0-5, 5-10, 10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal 
hormone use (yes vs. no) for women. 
 
* A likelihood ratio test was performed.  
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Supplemental Table 8. Sensitivity analyses for the association between coffee consumption and total mortality among never 
smokers, and pooled multivariate-adjusted hazard ratio was shown. 
 
Categories of total coffee P non-linearity* 
 
0  <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d 
Using cumulative coffee 
consumption, and 
stopping updating after 
cancer and diabetes 
1.00 
0.93 
(0.87, 0.99) 
0.89 
(0.83, 0.95) 
0.83 
(0.76, 0.90) 
0.83 
(0.72, 0.96) 
0.26 
Using cumulative coffee 
consumption, and further 
stopping updating after 
hypertension, 
hypercholesterolemia,  
and CVD 
 
1.00 0.93 
(0.87, 0.99) 
0.89 
(0.83, 0.95) 
0.84 
(0.78, 0.91) 
0.85 
(0.74, 0.97) 
0.87 
Continue updating after 
diagnosis of chronic 
disease with 4-year lag 
1.00 
0.96 
(0.90, 1.03) 
0.93 
(0.88, 1.00) 
0.80 
(0.73, 0.86) 
0.85 
(0.72, 1.00) 
0.25 
Continue updating after 
diagnosis of chronic 
disease adjusting for time-
varying 
hypercholesterolemia 
1.00 
0.99 
(0.93, 1.06) 
0.91 
(0.85, 0.96) 
0.79 
(0.73, 0.85) 
0.73 
(0.61, 0.87) 
0.30 
Using baseline exposure 
with exclusion of 
hypertension and 
hypercholesterolemia at 
baseline 
1.00 
0.95 
(0.87, 1.01) 
0.93 
(0.88, 1.00) 
0.82 
(0.75, 0.89) 
0.91 
(0.79, 1.04) 
0.88 
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Categories of caffeinated coffee  
 
0  <1 cup/d  1-3 cups/d  3-5 cups/d  >5 cups/d  
Using cumulative coffee 
consumption, and 
stopping updating after 
cancer and diabetes 
1.00           1.00 
(0.95, 1.05) 
0.91 
(0.86, 0.96) 
0.87 
(0.79, 0.95) 
0.80 
(0.65, 0.99) 
0.34 
Using cumulative coffee 
consumption, and further 
stopping updating after 
hypertension, 
hypercholesterolemia,  
and CVD 
 
1.00 1.00 
(0.93, 1.05) 
0.88 
(0.83, 0.93) 
0.89 
(0.82, 0.98) 
0.79 
(0.66, 0.97) 
0.91 
Continue updating after 
diagnosis of chronic 
disease with 4-year lag 
1.00           0.99 
(0.94, 1.05) 
0.90 
(0.85, 0.96) 
0.85 
(0.76, 0.94) 
0.81 
(0.63, 1.06) 
0.084 
Continue updating after 
diagnosis of chronic 
disease adjusting for time-
varying 
hypercholesterolemia 
1.00           0.99 
(0.94, 1.05) 
0.89 
(0.84, 0.94) 
0.80 
(0.72, 0.88) 
0.77 
(0.59, 1.01) 
0.07 
Using baseline exposure 
with exclusion of 
hypertension and 
hypercholesterolemia at 
baseline 
1.00           0.97 
(0.92, 1.02) 
0.92 
(0.87, 0.99) 
0.85 
(0.76, 0.94) 
0.94 
(0.78, 1.12) 
0.91 
 
         Categories of decaffeinated coffee  
 
0 <1 cup/d 1-3 cups/d >3 cups/d   
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Using cumulative coffee 
consumption, and 
stopping updating after 
cancer and diabetes 
1.00 0.92 
(0.87, 0.96) 
0.90 
(0.84, 0.95) 
0.93 
(0.81, 1.08) 
 0.016 
Using cumulative coffee 
consumption, and further 
stopping updating after 
hypertension, 
hypercholesterolemia,  
and CVD 
 
1.00 0.90 
(0.86, 0.95) 
0.89 
(0.84, 0.95) 
0.97 
(0.85, 1.12) 
 0.008 
Continue updating after 
diagnosis of chronic 
disease with 4-year lag 
1.00 
0.95 
(0.90, 0.99) 
0.97 
(0.91, 1.03) 
0.91 
(0.76, 1.09) 
 0.22 
Continue updating after 
diagnosis of chronic 
disease adjusting for time-
varying 
hypercholesterolemia 
1.00 
0.94 
(0.90, 0.98) 
0.92 
(0.87, 0.98) 
0.89 
(0.75, 1.06) 
 0.20 
Using baseline exposure 
with exclusion of 
hypertension and 
hypercholesterolemia at 
baseline 
1.00 0.95 
(0.90, 0.99) 
0.93 
(0.87, 0.99) 
0.87 
(0.74, 1.04) 
 0.17 
 
* A likelihood ratio test was performed.  
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Supplemental Table 9. The association between coffee consumption and risk of total mortality among never smokers by Cox 
model with inverse probability weighting 
Total coffee      
Intake (cups/d) 0 <1 cup/d 1-3 cups/d 3-5 cups/d >5 cups/d 
Multivariate-
adjusted hazard ratio 
(95% CI) 
1.00 0.95 
(0.90, 1.00) 
0.93 
(0.87, 0.98) 
0.86 
(0.80, 0.93) 
0.87 
(0.77, 0.98) 
Caffeinated coffee      
Intake (cups/d) 0 <1 cup/d 1-3 cups/d 3-5 cups/d >5 cups/d 
Multivariate-
adjusted hazard ratio 
(95% CI) 
1.00           0.97 
(0.94, 1.02) 
0.92 
(0.87, 0.96) 
0.90 
(0.82, 0.98) 
0.89 
(0.76, 1.05) 
Decaffeinated 
coffee 
     
Intake (mg/d) 0 <1 cup/d 1-3 cups/d >3 cups/d  
Multivariate-
adjusted hazard ratio 
(95% CI) 
1.00 0.95 
(0.91, 0.99) 
0.93 
(0.87, 0.99) 
0.89 
(0.78, 1.03) 
 
 
The model adjusted for age, baseline disease status (hypertension, hypercholesterolemia, diabetes), BMI (< 20.9, 21-22.9, 23-24.9, 25-
29.9, 30-34.9, ≥ 35 kg/m2), physical activity (< 3, 3-8.9, 9-17.9, 18-26.9, ≥ 27 MET-h/wk), overall dietary pattern (AHEI score, in 
quintiles), total energy intake (quintiles), sugar-sweetened beverages consumption (quintiles) and alcohol consumption (0, 0-5, 5-10, 
10-15, ≥ 15 g/d). We additionally adjusted for menopausal status (yes vs. no), and postmenopausal hormone use (yes vs. no) for 
women. Caffeinated and decaffeinated coffee adjusted for each other.  
For the weight calculation, the weight for the non-cases was 1, while the weights for the death cases were calculated in a way that the 
composition of the total mortality among the never smokers was the same as the overall population.  
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                                    1a.                                                                      1b.                                                                     1c. 
 
Supplemental Figure 1. Baseline coffee consumption and risk of mortality in the overall population and among never smokers 
in NHS. 2a. Total coffee consumption and risk of mortality. 2b. Caffeinated coffee consumption and risk of mortality. 2c. 
Decaffeinated coffee consumption and risk of mortality.  
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                                  2a.                                                                         2b.                                                                                2c. 
 
Supplemental Figure 2. Baseline coffee consumption and risk of mortality in the overall population and among never smokers 
in NHS 2. 2a. Total coffee consumption and risk of mortality. 2b. Caffeinated coffee consumption and risk of mortality. 2c. 
Decaffeinated coffee consumption and risk of mortality.  
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                               3a.                                                             3b.                                                           3c. 
Supplemental Figure 3. Baseline coffee consumption and risk of mortality in the overall population and among never smokers 
in HPFS. 3a. Total coffee consumption and risk of mortality. 3b. Caffeinated coffee consumption and risk of mortality. 3c. 
Decaffeinated coffee consumption and risk of mortality.  
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                                4a.                                                             4b.                                                           4c. 
Supplemental Figure 4. Cumulative coffee consumption and stopping updating when cancer and diabetes develop, and risk of 
mortality in the overall population and among never smokers by pooled across the three cohorts. 4a. Total coffee consumption 
and risk of mortality. 4b. Caffeinated coffee consumption and risk of mortality. 4c. Decaffeinated coffee consumption and risk 
of mortality.  
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                                     5a.                                                                         5b.                                                               5c. 
Supplemental Figure 5. Cumulative coffee consumption and further stopping updating when hypertension, 
hypercholesterolemia develop, and risk of mortality in the overall population and among never smokers by pooled across the 
three cohorts. 5a. Total coffee consumption and risk of mortality. 5b. Caffeinated coffee consumption and risk of mortality. 5c. 
Decaffeinated coffee consumption and risk of mortality.  
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                               6a.                                                              6b.                                                             6c. 
Supplemental Figure 6.  Continue updating coffee consumption after diagnosis of chronic disease with 4-year lag and risk of 
mortality in the overall population and among never smokers pooled across the three cohorts. 6a. Total coffee consumption 
and risk of mortality. 6b. Caffeinated coffee consumption and risk of mortality. 6c. Decaffeinated coffee consumption and risk 
of mortality.  
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7a.                                                              7b.                                                             7c. 
Supplemental Figure 7.  Continue updating coffee consumption after diagnosis of chronic disease adjusting for 
hypercholesterolemia as a time varying covariates and risk of mortality in the overall population and among never smokers 
pooled across the three cohorts. 7a. Total coffee consumption and risk of mortality. 7b. Caffeinated coffee consumption and 
risk of mortality. 7c. Decaffeinated coffee consumption and risk of mortality.  
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                                    8a.                                                                8b.                                                              8c. 
Supplemental Figure 8. Baseline coffee consumption and risk of mortality in the overall population and among never smokers 
further excluding hypertension, hypercholesterolemia, and diabetes cases at baseline, pooled across the three cohorts. 8a. Total 
coffee consumption and risk of mortality. 8b. Caffeinated coffee consumption and risk of mortality. 8c. Decaffeinated coffee 
consumption and risk of mortality.  
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ABSTRACT 
Background Evidence regarding the consumption of soy foods and isoflavones in relation 
to risk of type 2 diabetes (T2D) is scarce.  
Objective To evaluate the association between soy food and isoflavone consumption and 
risk of T2D in US men and women.  
Methods We followed 63,115 women in the Nurses’ Health Study (1998-2012), 79,061 
women in the Nurses’ Health Study II (1999-2013), and 21,281 men in the Health 
Professionals Follow-Up Study (2002-2010). Diet was assessed by a validated food-
frequency questionnaire, and was updated every 4 y. Self-reports of incident T2D was 
confirmed by a validated supplementary questionnaire.  
Results During 1,966,321 person-years of follow-up, 9,185 incident T2D cases were 
documented. After multivariate adjustment for covariates, consumption of soy foods (tofu 
and soy milk) was not associated with a lower T2D risk. Compared to non-consumers of 
soy foods, the hazard ratio (HR) was 1.00 (95% CI: 0.93, 1.07) for <1 serving/week, and 
0.93 (95% CI: 0.83, 1.03) for ≥1 serving/week of soy foods (P for trend = 0.14). In 
contrast, intake of total isoflavones was inversely associated with T2D risk. Comparing 
extreme quintiles of isoflavones, the HR was 0.89 (95% CI: 0.83, 0.96; P for trend = 
0.009). Inverse associations were also found for consumption of major individual 
isoflavones, including daidzein and genistein, with risk of T2D. 
Conclusions Intake of isoflavones was associated with a modestly lower T2D risk in US 
men and women who typically consumed low to moderate amounts of soy foods. These 
findings warrant replications in other populations with similar soy intake levels. 
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INTRODUCTION 
Type 2 diabetes (T2D) is a chronic disease with increasing prevalence worldwide. The 
total number of people with diabetes, globally, is estimated to reach 592 million by the 
year 2035.
1
 Identification of modifiable lifestyle and dietary risk factors for T2D 
prevention is of high priority. Specific components of plant-based foods have been shown 
to exert significant health benefits.
2
 For example, consumption of coffee and blueberries 
has been associated with a lower risk of T2D in Western populations, and certain 
flavonoid subclasses, such as phenolic acids and anthocyanins, may contribute to the 
health benefits of these foods.
3-5
 In contrast, evidence regarding other plant-based foods, 
such as soy foods, that are regarded as healthful but not intrinsic to the traditional 
Western diet is sparse. 
         Soy foods are uniquely rich in isoflavones compared to other foods.
6
 Isoflavones 
have a structure analogous to 17-β-estradiol and have weak estrogen-like effects by 
binding to estrogen receptors.7 Several clinical trials have been conducted to examine the 
effects of soy foods and isoflavones on glucose homeostasis, and results have suggested 
that soy foods and soy-rich diets may lower blood glucose.
8-11
 However, these clinical 
trials are limited by small sample sizes and short durations of follow-up. Few prospective 
studies have been conducted to evaluate the associations between intakes of soy foods 
and isoflavones and T2D risk in Western populations who consume low to moderate 
amounts of soy foods 
12
. 
           We conducted a prospective analysis of data collected in 3 large US cohorts, the 
Nurses’ Health Study (NHS), the NHSII, and the Health Professionals Follow-Up Study 
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(HPFS) to examine the associations between consumption of soy food and isoflavones 
and risk of T2D.  
 
METHODS 
Study population 
The NHS began in 1976, when 121,700 female registered nurses aged 30-55 y residing in 
11 states were enrolled and completed a baseline questionnaire about their lifestyle and 
medical history. The NHSII was established in 1989 and consisted of 116,671 younger 
female registered nurses aged 25-42 y at baseline. These women responded to a baseline 
questionnaire similar to the one used in NHS. The HPFS was initiated in 1986, and was 
composed of 51,529 male dentists, pharmacists, veterinarians, optometrists, osteopathic 
physicians, and podiatrists aged 40-75 y at baseline. The male participants returned a 
baseline questionnaire about their medical history, lifestyle, and usual diet. In all three 
cohorts, questionnaires were administered at baseline and biennially thereafter to update 
information on lifestyle factors and the occurrence of chronic diseases.   
For the current analysis, we excluded participants who reported diagnosed 
diabetes (including type 1 and type 2 diabetes, and gestational diabetes), cardiovascular 
disease (CVD), or cancer at baseline (1998 for the NHS, 1999 for the NHSII, and 2002 
for the HPFS). We further excluded participants with missing soy or isoflavone 
consumption at baseline (when soy milk was first included) and those who left more than 
70 food items blank or had daily energy intakes <600 or > 3500 kcal for women and 
<800 or >4200 kcal for men. Overall, 21,665 NHS participants, 8,537 NHSII participants, 
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and 16,120 HPFS participants were excluded from the analysis. After these exclusions, 
data from 63,115 NHS participants, 79,061 NHSII participants, and 21,281 HPFS 
participants were available for the analysis. The study protocol was approved by the 
institutional review boards of Brigham and Women’s Hospital and Harvard School of 
Public Health. The completion of the self-administered questionnaire was considered to 
imply informed consent. 
Assessment of isoflavone and soy food consumption 
In 1984, a 116-item food frequency questionnaire (FFQ) was administered to the NHS 
participants to obtain information on usual intake of food and beverages. Since 1986, an 
expanded FFQ has been administered every 4 years to update diet. Using a similar FFQ, 
dietary data were collected every four years from the NHSII participants since 1991 and 
from the HPFS participants since 1986. In all FFQs, participants were asked how often 
(from “never or less than once per month” to “6 or more times per day”) on average they 
consumed each food item of a standard portion size during the previous year. Major soy 
foods, i.e., tofu and soy milk, have been simultaneously included on the FFQs since 1998 
in the NHS, 1999 in the NHSII, and 2002 in the HPFS. We therefore used these years as 
study baselines. Intake of isoflavones and other nutrients was calculated by multiplying 
the consumption frequency of each food item by the nutrient content of the specified 
portion and summing the contributions from all food items. We calculated consumption 
of genistein, daidzein, and glycitein from foods. Isoflavones from supplements were not 
included in these calculations. The food composition of isoflavones was created primarily 
from the USDA Database for the Isoflavone Content of Selected Foods, Release 2.0 
6
. 
Consumption of total soy food was calculated as the sum of the consumption of tofu and 
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soy milk in servings/day. The validity and reproducibility of the FFQ has been described 
in detail elsewhere.
13-16
 The correlation coefficient for tofu consumption assessed by 
FFQs and diet records was 0.56.
13
  
Assessment of covariates 
In the biennial follow-up questionnaires, we collected and updated information on age, 
body weight and height, smoking status, physical activity, medication use, family history 
of diabetes, and disease status, including hypertension, hypercholesterolemia, CVD, and 
cancer. We also ascertained data on menopausal status and postmenopausal hormone use 
in both NHS and NHSII, as well as oral contraceptive use in NHSII. An overall 
measurement of diet quality was derived using the alternate Healthy Eating Index (aHEI) 
score excluding tofu and soy milk.  
Assessment of type 2 diabetes (T2D) 
Participants with self-reported incident T2D were mailed a validated supplementary 
questionnaire regarding symptoms, diagnostic tests, and hypoglycemic therapy to 
confirm the diagnosis of diabetes. Cases were ascertained using the American Diabetes 
Association criteria:
17
 1) one or more classic symptoms (excessive thirst, polyuria, weight 
loss, hunger) and fasting plasma glucose concentrations ≥7.0 mmol/L or random plasma 
glucose concentrations ≥11.1 mmol/L; 2) ≥2 elevated plasma glucose concentrations on 
different occasions (fasting concentrations ≥7.0 mmol/L, random plasma glucose 
concentrations ≥11.1 mmol/L, and/or concentrations of ≥11.1 mmol/L after  ≥2 h shown 
by oral-glucose-tolerance testing) in the absence of symptoms; or 3) treatment with 
hypoglycemic medication (insulin or oral hypoglycemic agent). In addition, hemoglobin 
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A1c≥6.5% was added to the diagnosis criteria since 2010. Only cases confirmed by the 
supplemental questionnaires were included in our analysis.  
The validity of the supplementary questionnaire for the diagnosis of diabetes has 
been documented previously. In a validation study, of the 62 cases in the NHS and 59 
cases in HPFS who were confirmed by the supplemental questionnaire, 61 (98%) and 57 
(97%) were reconfirmed by reviewing medical records.
18,19
  
Statistical analysis  
We calculated person-time for each individual from the date of the return of the baseline 
questionnaire to the date of diagnosis of T2D, death, or the end of follow-up (30 June 
2012 for the NHS, 30 June 2013 for the NHSII, and 31 January 2010 for the HPFS), 
whichever came first. We used cumulative averages of soy food or isoflavone 
consumption to reflect long-term dietary habits. We stopped updating diet after incident 
cancer or CVD as these diseases may result in changes of diet that might confound the 
association between soy foods and risk of T2D. In addition, to minimize missing values 
during follow-up, we replaced missing soy food/isoflavone intakes during follow-up with 
valid values in the previous cycle. We used Cox proportional hazards regression models 
to examine the associations between soy foods and isoflavone consumption (quintiles) 
and risk of T2D. The regression models included calendar time in 2-y intervals as the 
time scale, and were stratified by age in years. The pooled hazard ratios (HRs) were 
estimated by a stratified Cox model, which allowed baseline hazard to be different across 
the three cohorts while gave common effect estimates of the covariates. In multivariable 
analysis, we further adjusted for race (Causation, African American, Asian, and others), 
family history of T2D (yes, no), baseline disease status (hypertension and 
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hypercholesterolemia), BMI (<20.9, 21-22.9, 23-24.9, 25-29.9, 30-34.9, ≥35 kg/m2), 
physical activity (quintiles, met-hr/week), aHEI score (in quintiles), total energy intake 
(quintiles), and smoking status (never smoked, past smoker, currently smoked 1-14 
cigarettes/d, and currently smoked >14 cigarettes/d). We additionally adjusted for 
menopausal status (yes, no), and postmenopausal hormone use (yes, no) in women. Test 
for linear trend was conducted by assigning the median value of exposure in each 
category to that category and treating the median value as a continuous variable in the 
regression model, with P < 0.05 denoting a significant association. 
Analyses were performed separately in each cohort first. We examined potential 
effect modifications by BMI, age, and aHEI score for both men and women, and 
menopausal status and postmenopausal hormone use for women. Meta-regressions were 
used to test for potential interactions, with P value <0.05 denoting effect modification. 
The tests for interaction were conducted in analyses within individual cohorts as well as 
in analyses based on pooled data from all three cohorts. Previous studies showed that 
coffee intake also contributes to total isoflavone intake 
20
 and was associated with a lower 
T2D risk in these cohorts.
5
 To examine whether the association of isoflavones with 
diabetes risk may be due to coffee intake, we further calculated coffee-adjusted residuals 
of isoflavones using generalized equation estimation (GEE), and conducted a sensitivity 
analysis by using these residuals as the main exposure. All statistical tests were 2-sided 
and performed using SAS version 9.3 (SAS Institute Inc.). The meta-analysis was 
performed using STATA, version 9.2 (StataCorp).  
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RESULTS 
Baseline characteristics according to soy food consumption 
Baseline characteristics of the participants in each cohort according to soy food 
consumption are shown in Table 1. Most of the participants were non-consumers of soy 
foods at baseline in the three cohorts. Soy food consumers had a higher aHEI score, 
higher consumption of fruit, vegetables, and fish, lower consumption of meat and soda 
(including sugar-sweetened beverages), and were more physically active than non-
consumers.  
The association of soy foods with risk of T2D 
In the age-adjusted model, soy food consumption was inversely associated with risk of 
T2D. After multivariate adjustment, the association was attenuated and soy food 
consumption was non-significantly associated with a lower risk of T2D (Table 2). 
Compared with those who did not consume soy foods, the HR (95% CI) was 1.00 (0.93, 
1.07) for those consuming < 1 serving/week of soy foods, and 0.93 (0.83, 1.03; P = 0.14) 
for those consuming ≥1 serving/week of soy foods in the pooled analysis. We further 
examined the association separately with tofu and soy milk intake. Compared with non-
consumers, the HR was 1.00 (95% CI: 0.93, 1.08) for those consuming < 1 serving/week 
of tofu, and 0.93 (95% CI: 0.84, 1.04) for those consuming ≥1 serving/week of tofu. For 
soy milk, compared with non-consumers, the HR was 0.92 (95% CI: 0.83, 1.02) for soy 
milk consumers. No significant associations of total soy foods, tofu, and soy milk with 
risk of T2D were found in the NHS, NHSII, and HPFS cohorts, and the associations did 
not vary significantly across the three cohorts (all P values for heterogeneity >0.30).  
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The association of isoflavone consumption with risk of T2D 
Total isoflavone consumption was significantly, inversely associated with risk of T2D 
(Table 3). As compared with the lowest quintile of isoflavones consumption, the HRs (95% 
CIs) were 0.89 (0.83, 0.96) for highest quintiles in the pooled analysis (P for trend = 
0.009). We further evaluated individual isoflavones with meaningful intake levels in our 
cohorts (Table 4). For daidzein, the HR (95% CI) was 0.87 (0.81, 0.94) comparing 
extreme quintiles (P for trend = 0.0003). For genistein, the HR (95% CI) was 0.91 (0.85, 
0.98) for the same comparison (P for trend = 0.02).  
Of note, on average, regular soy food consumers (≥1 serving/week) had higher isoflavone 
intake levels than participants in the highest quintile of total isoflavones, but the 
associations for soy food intake were not significant, suggesting that the association for 
isoflavones may not be linear at relatively high intake level. However, when we further 
examined the dose-response relationship between isoflavone intake and risk of T2D using 
spline regression, we did not observe a clear non-linear association (P for non-linearity: 
0.76; P for trend = 0.02; Supplemental figure 1).  
Stratified analysis 
We conducted analyses stratified by menopausal status (premenopausal vs 
postmenopausal; women only), BMI (<30 kg/m
2
 vs ≥30 kg/m2), age (<60 y vs ≥60 y), 
and aHEI score (< median vs ≥ median), and no significant interactions were found 
between soy food and risk of T2D: P values for interaction were 0.20 for menopausal 
status, 0.78 for BMI, 0.34 for age, and 0.52 for aHEI score (Supplemental Table 1). No 
significant interactions were found between isoflavones consumption and these factors in 
141 
 
 
relation to T2D risk (Supplemental Table 2). We further tested effect modification by 
postmenopausal hormone use on the associations between consumptions of soy food and 
isoflavones and risk of T2D among postmenopausal women, but no significant effect 
modification was found. We performed further analyses restricted within postmenopausal 
women who were never users of hormone therapy and within women who were never 
users of soy supplements. The associations between intakes of soy foods and isoflavones 
and risk of T2D did not change substantially.   
Sensitivity analysis 
As coffee was one of the food sources of isoflavones consumption,
20
 we conducted 
sensitivity analysis using coffee-adjusted residuals of isoflavones consumption. Similar to 
the results of isoflavones, inverse associations of residual consumption of isoflavones, 
daidzein, and genistein with risk of T2D were found (Supplemental table 3). As soy food 
consumption was associated with a healthy lifestyle, we further repeated our analysis on 
the association of soy food and isoflavones with risk of T2D using propensity score 
analysis. The results did not change significantly comparing with the main analysis 
(Supplemental table 4, 5).  
DISCUSSION 
In three large US cohorts of men and women, we found that isoflavone consumption was 
modestly associated with a lower risk of T2D, whereas the two major soy foods, i.e., tofu 
and soy milk, were not associated with T2D risk. These associations were independent of 
established and potential lifestyle and dietary risk factors of T2D.  
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The association of soy foods and isoflavones with risk of T2D has been 
investigated primarily among Asian populations who have much higher intake levels 
compared with Western populations, and the results have been largely mixed. Villegas et 
al. found that higher intakes of soybean and soy milk were significantly associated with a 
lower T2D incidence in the Shanghai Women’s Health Study.21 In the Singapore Chinese 
Health Study, Mueller et al. further documented that intakes of unsweetened soy products 
(servings/week), but not sugar-sweetened soy foods, were associated with a lower T2D 
risk.
22
 However, a Japanese study found that intake of total soy foods (gram/day) with 
various soy protein densities was not associated with T2D risk,
23
 whereas intake of total 
soy foods (gram/day) was associated with a higher T2D risk in a multi-ethnic population 
living in Hawaii.
24
 Lastly, no association between total isoflavone intake and risk of T2D 
was found in the EPIC-InterAct Study.
12
 The sources of heterogeneity in these findings 
are unclear, although study participant characteristics, different exclusion criteria, various 
cooking methods, and measurement error in soy food or isoflavone assessment may 
partially explain the mixed results. In the current analysis, we evaluated both major soy 
foods and isoflavones in relation to T2D risk and found the associations did not vary 
significantly across three cohorts of men and women.  
In contrast to the paucity of evidence from long-term prospective observational 
studies, data from short-term clinical trials that examined the effects of soy foods or 
isoflavones on diabetes risk factors were abundant, and results were mixed. In a 
comprehensive meta-analysis of randomized controlled trials, supplementation of soy 
foods or isoflavones did not significantly lower fasting glucose or insulin levels, although 
a subgroup analysis showed that whole soy foods might reduce fasting glucose.
9
 In 
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another meta-analysis that focused on premenopausal and postmenopausal non-Asian 
women who did not take hormone replacement therapy, isoflavone supplementation 
significantly lowered fasting insulin and HOMA-IR levels, although no effects were 
observed on fasting glucose levels.
8
 In addition, soy products improved blood lipid 
profiles among diabetes patients, although the effects on glucose metabolism parameters 
were not substantiated.
10
 
Isoflavones have a structure analogous to 17-β-estradiol, which enables isoflavones bind to 
estrogen receptors β with 103-104 less potency than estradiol.7 Isoflavones exert either estrogenic 
or anti-estrogenic effect depending on the concentration of serum estradiol. Isoflavones exert 
estrogen-like effects when the concentration of endogenous estrogen is low, otherwise, 
isoflavones might have anti-estrogenic effect. 
25
 Isoflavones also activate nuclear receptors 
including peroxisome-proliferator activated receptors (PPAR) α , PPAR γ, sterol 
regulated element binding protein, and liver X binding receptor  to regulate lipid and 
glucose metabolism.
26-28
 Isoflavones have been shown to improve hyperglycemia, 
glucose tolerance, and circulating insulin concentrations.
29
 Isoflavones also stimulate the 
phosphorylation of AMP-activated protein kinase and acetyl-CoA carboxylase to increase 
glucose uptake and fatty acid oxidation.
30
 Estrogen increases insulin sensitivity in the 
liver, promotes pancreas β cell proliferation and differentiation, modulates appetite and 
energy expenditure by regulating the expression of leptin and ghrelin, effects glucose 
disposal in muscle by upregulating expression of  glucose transporter 4 and proteins 
involving the insulin signaling pathway,
31
 and inhibits lipogenesis in adipose tissue by 
inhibiting the activity of lipoprotein lipase.
32
 Whether isoflavones have those effects 
analogous to estrogen is speculated and needs further investigation.  
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      Our study has several strengths. First, the analysis was based on three well-
characterized large cohorts with detailed measurements of diet and lifestyle. Second, 
consumption of isoflavones and soy products was assessed every 4 years during the 
follow-up. The repeated measurements not only reduce measurement error but also 
represent long-term dietary habits. Third, the aHEI score was used to adjust for 
confounding of the overall diet quality. We also controlled for a wide range of lifestyle 
factors in the analysis. Our study also has several limitations. First, although we used the 
comprehensive USDA food composition database of isoflavones to derive isoflavone 
intake and included major soy foods in the current analysis, measurement error may still 
exist and may attenuate the true associations towards the null due to the longitudinal 
study design. Second, the low consumption levels of soy products in our cohorts (90% of 
participants were non-consumers), typically seen among Western populations, limited the 
statistical power for the analysis of soy food. Third, residual confounding by lifestyle 
factors (e.g., dietary factors, physical activity, and smoking) may still exist due to model-
misspecification and measurement error of potential confounders. Last, our study was 
conducted primarily among white health professionals, and thus the results may not be 
generalizable to other populations. 
       In conclusion, our analysis showed that consumption of isoflavones, but not tofu or 
soy milk, was associated with a modest reduction in risk of T2D in three large cohorts of 
U.S. men and women. Further studies are needed to replicate these observations in other 
populations, especially those with similar isoflavone intake levels.  
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Table 1. Baseline characteristics of participants by consumption of soy foods in the NHS, NHS II, and HPFS 
 NHS (1998)  NHS II (1999)  HPFS (2002)  
 Non-
consumer 
< 1 serving/week ≥1 
serving/
week 
Non-
consum9er 
< 1 
serving/
week 
≥1 
serving/
week 
Non-
consumer 
< 1 
serving/
week 
≥1 
serving/
week 
N 56,858 4,259 1,998 66,608 7,930 4,523 16,517 2,785 1,979 
Age (year) 64 62 62 44 45 45 67 66 66 
Total soy food (serving/d) 0 0.09 0.83 0 0.09 0.85 0 0.09 0.88 
Soy milk (serving/d) 0 0 0.46 0 0.01 0.49 0 0.01 0.47 
Tofu (serving/d) 0 0.08 0.37 0 0.08 0.36 0 0.08 0.41 
Isoflavones (mg/d) 0.62 2.00 10.58 0.70 2.55 12.20 0.63 2.62 13.13 
Daidzein (mg/d) 0.27 0.74 3.89 0.30 0.92 4.46 0.29 1.04 5.08 
Genistein (mg/d) 0.31 1.10 5.05 0.37 1.41 5.87 0.31 1.25 5.70 
Glycecin (mg/d) 0.04 0.17 1.72 0.04 0.21 1.88 0.03 0.33 2.34 
Physical activity  
(MET-h/wk) 
18 24 26 18 23 27 35 40 44 
aHEI 53 61 64 50 59 63 56 63 68 
Total energy intake (kcal/d) 1719 1816 1865 1809 1879 1928 1983 2009 2050 
Fruits (serving/d) 2.36 2.93 3.12 1.76 2.26 2.57 2.57 3.09 3.52 
Vegetables (serving/d) 3.07 3.92 4.25 3.19 4.10 4.60 3.36 4.04 4.48 
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Meat (serving/d) 1.24 1.01 0.85 1.42 1.17 0.92 1.58 1.33 1.12 
Fish (serving/d) 0.22 0.29 0.30 0.19 0.27 0.28 0.28 0.38 0.38 
Total soda (serving/d) 0.58 0.43 0.31 1.17 0.77 0.55 0.65 0.57 0.43 
Coffee (cups/d) 1.82 1.62 1.30 1.51 1.56 1.31 1.64 1.45 1.22 
Total alcoholic beverages 
(serving/d) 
0.47 0.48 0.37 0.32 0.42 0.34 0.96 0.91 0.74 
Dairy products 
(serving/d) 
2.22 2.37 2.07 2.25 2.36 2.54 2.81 2.53 2.16 
BMI (kg/m
2
) 26 25 25 24 23 22 26 26 25 
Hypertension,% 41 37 35 13 11 8 44 43 39 
Hypercholesterolemia, % 56 54 54 24 22 21 55 60 55 
Family history of diabetes, % 27 27 25 35 34 32 21 22 21 
Postmenopausal women, % 94 93 94 15 13 14 NA NA NA 
Current menopausal hormone 
use, (% among total women) 
53 54 47 14 11 10 NA NA NA 
Current smokers, % 17 13 11 9 6 4 4 2 2 
Race, Caucasian, % 98 92 91 97 93 92 97 91 92 
Race, Asian,  % 0 6 6 1 5 6 0 6 5 
aHEI, Alternative Healthy Eating Index, with a higher score indicating healthier dietary pattern; BMI, body mass index; HPFS, Health 
Professionals Follow-up Study; MET, metabolic-equivalent task; NHS, Nurses’ Health Study. 
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Table 2. Hazard ratios (HRs) for the associations between soy containing foods and risk of type 2 diabetes in the three cohorts 
Total soy food Non-consumer < 1 serving/week ≥1 serving/week P for trend 
NHS (1998-2012)     
Cases/Person-years 3,886/645,060 399/81,561 234/54,968  
Median intake (g/d) 0 0.05 0.43  
(range) 0 (0.02, 0.14) (0.14, 6.00)  
Age-adjusted Model 1.00 0.86 (0.77, 0.95) 0.75 (0.66, 0.86) 0.004 
Multivariate-adjusted Model  1.00 0.98 (0.88, 1.09) 0.97 (0.84, 1.11) 0.83 
NHS II (1999-2013)     
Cases/Person-years 3,147/771,898 502/156,467 271/108,577  
Median intake (g/d) 0 0.07 0.43  
(range) 0 (0.02, 0.14) (0.14, 8.50)  
Age-adjusted Model 1.00 0.79 (0.72, 0.87) 0.59 (0.52, 0.67) < 0.001 
Multivariate-adjusted Model  1.00 1.03 (0.93, 1.14) 0.92 (0.80, 1.05) 0.20 
HPFS (2002-2010)     
Cases/Person-years 589/109,009 96/22,026 57/16,238  
Median intake (g/d) 0 0.07 0.50  
(range) 0 (0.04, 0.14) (0.18, 10.50)  
Age-adjusted Model 1.00 0.83 (0.66, 1.02) 0.67 (0.51, 0.87) 0.003 
Multivariate-adjusted Model  1.00 0.89 (0.71, 1.11) 0.88 (0.66, 1 .17) 0.37 
Overall pooled     
Multivariate-adjusted Model  1.00 1.00 (0.93, 1.07) 0.93 (0.83, 1.03) 0.14 
Tofu Non-consumer < 1 serving/week ≥1 serving/week  
NHS (1998-2012)     
Cases/Person-years 3,999/668,830 334/69,805 186/42,955  
Median intake (g/d) 0 0.05 0.22  
(range) 0 (0.02, 0.07) (0.09, 6.00)  
Age-adjusted Model 1.00 0.84 (0.75, 0.94) 0.75 (0.65, 0.87) 0.001 
Multivariate-adjusted Model  1.00 0.98 (0.88, 1.10) 0.98 (0.84, 1.14) 0.97 
NHS II (1999-2013)     
Cases/Person-years 3,282/812,630 416/130,915 222/93,398   
Median intake (g/d) 0 0.05 0.22  
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(range) 0 (0.02, 0.07) (0.09, 6.00)  
Age-adjusted Model 1.00 0.79 (0.71, 0.87) 0.58 (0.50, 0.66) < 0.001 
Multivariate-adjusted Model  1.00 1.02 (0.92, 1.14) 0.91 (0.78, 1.05) 0.25 
HPFS (2002-2010)     
Cases/Person-years 614/114,355 77/17,834 51/15,083  
Median intake (g/d) 0 0.07 0.29  
(range) 0 (0.04, 0.07) (0.11, 6.00)  
Age-adjusted Model 1.00 0.83 (0.65, 1.05) 0.64 (0.48, 0.85) 0.002 
Multivariate-adjusted Model  1.00 0.90 (0.71, 1.15) 0.81 (0.60, 1.10) 0.23 
Overall pooled     
Multivariate-adjusted Model  1.00 1.00 (0.93, 1.08) 0.93 (0.84, 1.04) 0.19 
Soy milk Non-consumer Consumer   
NHS (1998-2012)     
Cases/Person-years 4,287/726,315 232/55,274   
Median intake (g/d) 0 0.22   
(range) 0 (0.02, 6.00)   
Age-adjusted Model 1.00 0.79 (0.69, 0.90)  0.24 
Multivariate-adjusted Model  1.00 0.96 (0.84, 1.10)  0.84 
 NHS II (1999-2013)     
Cases/Person-years 3,621/920,118 299/116,823   
Median intake (g/d) 0 0.17   
(range) 0 (0.02, 6.00)   
Age-adjusted Model 1.00 0.65 (0.58, 0.73)  < 0.001 
Multivariate-adjusted Model  1.00 0.90 (0.80, 1.02)  0.11 
HPFS  (2002-2010)    
Cases/Person-years 691/133,130 51/14,143   
Median intake (g/d) 0 0.43   
(range) 0 (0.04, 6.00)   
Age-adjusted Model 1.00 0.72 (0.54, 0.95)  0.02 
Multivariate-adjusted Model  1.00 0.93 (0.69, 1.24)  0.58 
Overall pooled     
Multivariate-adjusted Model 1.00 0.92 (0.83, 1.02)  0.11 
Abbreviations: NHS, Nurses’ Health Study; HPFS, Health Professionals Follow-up Study; 
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Multivariate-adjusted model: adjusted for race (Caucasians, African Americans, Asian Americans, and others), family history of T2D 
(yes vs. no), baseline disease status (hypertension, hypercholesterolemia), body mass index (<21, 21-22.9, 23-24.9, 25-29.9, 30-34.9, 
≥35 kg/m2), physical activity (quintiles), overall dietary pattern (Alternative Healthy Eating Index score, in quintiles), total energy 
intake (quintiles), coffee consumption (quintiles), smoking status (never, former, current 1-14 cigarettes/d, current >14 cigarettes/d). 
Menopausal status (yes vs. no) and postmenopausal hormone use (yes vs. no) were further adjusted for in women. 
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Table 3. Associations between isoflavone consumption and risk of type 2 diabetes in the three cohorts 
 Q1 Q2 Q3 Q4 Q5 P for 
trend 
NHS (1998-2012)       
Cases/Person-years 894/151,060 1042/160,232 934/157,173 848/155,786 801/157,339  
Median intake  
(range ♯) (mg/d) 
0.17 
(0.01, 0.44) 
0.29 
(0.17, 0.59) 
0.40 
(0.26, 0.80) 
0.62 
(0.37, 1.78) 
2.78 
(0.57, 76.57) 
 
Age-adjusted Model 1.00 1.09 (1.00, 1.19) 1.00 (0.91, 1.10) 0.92 (0.83, 1.01) 0.85 (0.77, 0.93) < 0.001 
Multivariate-adjusted Model  1.00 1.08 (0.99, 1.18) 1.02 (0.93, 1.12) 0.96 (0.87, 1.05) 0.97 (0.88, 1.07) 0.13 
NHS II (1999-2013)       
Cases/Person-years 913/199,825 905/210,571 753/209,716 724/208,238 625/208,591  
Median intake (mg/d) 0.17 0.31 0.48 1.10 5.73  
(range) (0.01, 0.46) (0.17, 0.75) (0.27, 1.50) (0.42, 3.97) (1.14, 130.50)  
Age-adjusted Model 1.00 0.94 (0.86, 1.03) 0.77 (0.70, 0.85) 0.74 (0.67, 0.81) 0.63 (0.57, 0.70) < 0.001 
Multivariate-adjusted Model  1.00 0.95 (0.86, 1.04) 0.82 (0.74, 0.90) 0.85 (0.77, 0.94) 0.85 (0.76, 0.95) 0.11 
HPFS (2002-2010)       
Cases/Person-years 170/29,598 144/29,356 151/29,252 160/29,530 117/29,537  
Median intake  0.31 0.47 0.64 1.10 5.09  
(range) (mg/d) (0.01, 0.49) (0.35, 0.66) (0.48, 0.93) (0.66, 2.27) (1.87, 238.02)  
Age-adjusted Model 1.00 0.86 (0.68, 1.07) 0.90 (0.73, 1.13) 0.95 (0.76, 1.18) 0.69 (0.54, 0.87) 0.004 
Multivariate-adjusted Model  1.00 0.83 (0.67, 1.04) 0.87 (0.70, 1.09) 0.93 (0.74, 1.15) 0.80 (0.62, 1.02) 0.24 
Pooled       
Multivariate-adjusted Model  1.00 0.99 (0.93, 1.06) 0.91 (0.86, 0.97) 0.91 (0.85, 0.97) 0.89 (0.83, 0.96) 0.009 
 
#: Overlap of range was due to that the quintile was divided within each time interval of the Cox model.  
NHS, Nurses’ Health Study; HPFS, Health Professionals Follow-up Study 
Multivariate-adjusted for race (Caucasians, African Americans, Asian Americans, and others), family history of T2D (yes vs. no), 
baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 30-34.9, ≥35 kg/m2), physical 
activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), smoking status (never, former, 
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current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no) and postmenopausal hormone use (yes vs. no) 
were further adjusted for in women.   
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Table 4. Hazard ratio (HR) for the association between subtypes of isoflavone consumption and risk of type 2 diabetes in the three 
cohorts 
 Q1 Q2 Q3 Q4 Q5 P for 
trend 
Daidzein       
NHS (1998-2012) 904/148,554 1069/163,641 947/155,285 811/156,098 788/158,012  
Median intake  0.08 0.15 0.23 0.33 1.05   
(range #) (mg/d) (0.01, 0.20) (0.08, 0.28) (0.14, 0.39) (0.22, 0.72) (0.35, 25.46)  
Age-adjusted Model 1.00 1.06 (0.97, 1.15) 1.00 (0.91, 1.09) 0.85 (0.77, 0.93) 0.80 (0.73, 0.88) < 0.001 
Multivariate-adjusted Model  1.00 1.05 (0.96, 1.15) 1.02 (0.93, 1.12) 0.90 (0.81, 0.99) 0.92 (0.84, 1.02) 0.01 
NHS II (1999-2013) 908/198,618 966/209,843 727/210,988 699/208,319 620/209,174  
Median intake (mg/d) 0.07 0.16 0.27 0.49 2.09  
(range) (0.01, 0.22) (0.08, 0.36) (0.14, 0.63) (0.25, 1.50) (0.50, 41.70)  
Age-adjusted Model 1.00 1.00 (0.92, 1.10) 0.74 (0.67, 0.82) 0.71 (0.64, 0.78) 0.62 (0.56, 0.69) < 0.001 
Multivariate-adjusted Model  1.00 0.99 (0.91, 1.09) 0.80 (0.73, 0.89) 0.84 (0.75, 0.93) 0.85 (0.76, 0.94) 0.03 
HPFS (2002-2010) 166/29,178 158/30,164 153/28,814 146/29,621 119/29,496  
Median intake  0.14 0.22 0.32 0.53 1.98  
(range) (mg/d) (0.01, 0.22) (0.16, 0.31) (0.24, 0.45) (0.35, 0.92) (0.77, 75.11)  
Age-adjusted Model 1.00 0.91 (0.74, 1.14)  0.94 ( 0.76, 1.17)  0.87 (0.69,  1.08) 0.71 (0.56,  0.89) 0.005 
Multivariate-adjusted Model  1.00 0.90 (0.72, 1.12) 0.91 (0.73, 1.14) 0.83 (0.67, 1.04) 0.81 (0.64, 1.04) 0.23 
Pooled       
Multivariate-adjusted Model  1.00 1.01 (0.95, 1.07) 0.91 (0.85, 0.97) 0.86 (0.81, 0.92) 0.87 (0.81, 0.94) 0.0003 
Genistein       
NHS (1998-2012) 910/156,013 965/158,628 913/153,330 927/156,833 804/156,785  
Median intake (mg/d) 0.08 0.13 0.17 0.26 1.38  
(range) (0.01, 0.21) (0.09, 0.27) (0.12, 0.37) (0.15, 0.87) (0.22, 44.72)  
Age-adjusted Model 1.00 1.04 (0.95, 1.14) 1.03 (0.94, 1.13) 1.01 (0.92, 1.11) 0.87 (0.79, 0.96) 0.003 
Multivariate-adjusted Model  1.00 1.04 (0.95, 1.14) 1.03 (0.94, 1.13) 1.02 (0.93, 1.12) 0.98 (0.89, 1.08) 0.27 
NHS II (1999-2013) 903/205,677 820/196,157 816/220,327 759/206,270 622/208,510  
Median intake (mg/d) 0.09 0.15 0.19 0.54 2.87  
(range) (0.01, 0.22) (0.09, 0.34) (0.12, 0.74) (0.17, 1.99) (0.58, 78.62)  
Age-adjusted Model 1.00 0.95 (0.87, 1.05) 0.84 (0.76, 0.92) 0.82 (0.74, 0.90) 0.66 (0.59, 0.73) < 0.001 
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Multivariate-adjusted Model  1.00 0.97 (0.88, 1.07) 0.86 (0.78, 0.95) 0.91 (0.82, 1.00) 0.87 (0.78, 0.97) 0.11 
HPFS (2002-2010) 158/28,674 148/29,339 161/29,819 158/29945 117/29,496  
Median intake  0.15 0.21 0.28 0.51 2.29  
(range) (mg/d) (0.01, 0.24) (0.17, 0.32) (0.22, 0.43) (0.29, 1.08) (0.88, 142.09)  
Age-adjusted Model 1.00 0.91 (0.73, 1.14) 0.97 (0.78, 1.22) 0.96 (0.77, 1.20) 0.71 (0.56, 0.91) 0.005 
Multivariate-adjusted Model  1.00 0.90 (0.72, 1.13) 0.94 (0.75, 1.17) 0.96 (0.77, 1.21) 0.84 (0.65, 1.07) 0.28 
Pooled       
Multivariate-adjusted Model  1.00 0.99 (0.93, 1.06) 0.95 (0.89, 1.01) 0.97 (0.91, 1.03) 0.91 (0.85, 0.98) 0.02 
 
#: Overlap of range was due to that the quintile was divided within each time interval of the Cox model.  
Age-adjusted Model: age-adjusted model. 
Multivariate-adjusted model: multivariate model adjusted for race (Caucasians, African Americans, Asian Americans, and others), 
family history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 
30-34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), 
smoking status (never, former, current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no) and 
postmenopausal hormone use (yes vs. no) were further adjusted for in women. 
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Supplemental Figure 1. The association between isoflavones consumption and risk of type 2 diabetes (T2D) in a dose response manner 
by pooling the three cohorts. 
Multivariate-adjusted model: multivariate model adjusted for race (Caucasians, African Americans, Asian Americans, and others), 
family history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 
30-34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), 
smoking status (never, former, current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no), and 
postmenopausal hormone use (yes vs. no) were further adjusted for in women. 
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Supplemental Table 1. Stratified analysis of the association between total soy food consumption (consumer vs. non-consumer) and 
risk of type 2 diabetes (T2D). 
 NHS NHS II HPFS Pooled P for 
interaction 
Menopausal status      
Premenopausal 1.09 (0.95, 1.26) 1.06 (0.93, 1.20)   1.07 (0.98, 1.18)  
Postmenopausal 0.94 (0.84, 1.05) 0.94 (0.83, 1.05)  0.94 (0.87, 1.02) 0.20 
Postmenopausal hormone and 
isoflavones supplement use 
     
Neither 1.08 (0.94, 1.25) 0.99 (0.89, 1.11)  1.02 (0.94, 1.12)  
Only postmenopausal hormone 0.87 (0.75, 1.00) 1.40 (0.76, 2.55)  1.00 (0.66, 1.54)  
Only isoflavones supplement 1.05 (0.86, 1.29) 1.03 (0.90, 1.19)  1.04 (0.92, 1.16)  
Both 2.20 (0.71, 6.84) 1.11 (0.55, 2.21)  1.34 (0.74, 2.45) 0.78 
BMI      
BMI (< 30 kg/m
2
) 1.00 (0.87, 1.14) 0.82 (0.68, 0.98) 0.96 (0.76, 1.20)  0.94 (0.85, 1.03)  
BMI (≥ 30 kg/m2) 0.97 (0.85, 1.11) 1.07 (0.96, 1.19) 0.66 (0.46, 0.94) 1.01 (0.93, 1.09) 0.78 
Age      
Age (< 60 y) 0.94 (0.53, 1.66) 1.02 (0.92, 1.12) 0.95 (0.72, 1.25) 1.01 (0.92, 1.11)  
Age (≥ 60 y) 0.98 (0.89, 1.07) 0.91 (0.77, 1.09) 0.82 (0.63, 1.05) 0.95 (0.88, 1.03) 0.34 
aHEI score      
aHEI (< median) 0.92 (0.78, 1.09) 0.96 (0.85, 1.10) 0.66 (0.43, 1.01)  0.93 (0.84, 1.02)  
aHEI (≥ median) 0.96 (0.87, 1.07) 0.98 (0.87, 1.09) 0.94 (0.76, 1.15) 0.97 (0.90, 1.04) 0.52 
 
Multivariate-adjusted model : multivariate model adjusted for race (Caucasians, African Americans, Asian Americans, and others), 
family history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 
30-34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), 
smoking status (never, former, current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no), and 
postmenopausal hormone use (yes vs. no) were further adjusted for in women. 
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Supplemental Table 2. Stratified analysis of the association between consumption of isoflavones (dichotomized) and risk of type 2 
diabetes (T2D) 
 NHS  NHSII HPFS Pooled P for 
interaction 
Menopausal status      
Premenopausal 1.07 (0.93, 1.23) 0.85 (0.78, 0.94)  0.91 (0.84, 0.98)  
Postmenopausal 0.89 (0.83, 0.96) 0.87 (0.78, 0.96)  0.88 (0.83, 0.93) 0.56 
Postmenopausal hormone and 
isoflavones supplement use 
     
Neither 1.07 (0.93, 1.24) 0.85 (0.78, 0.93)  0.95 (0.76, 1.19)  
Only postmenopausal hormone NA 0.89 (0.48, 1.63)  0.89 (0.48, 1.64)  
Only isoflavones supplement   0.87 (0.79, 0.95) 0.91 (0.80, 1.04)  0.88 (0.82, 0.95) 0.89 
Both 3.41 (1.03, 11.31) 1.27 (0.60, 2.67)  1.85 (0.72, 4.75)  
BMI      
BMI (< 30 kg/m
2
) 0.90 (0.82, 0.99) 0.81 (0.69, 0.95) 1.05 (0.80, 1.39)  0.89 (0.82, 0.96)  
BMI (≥ 30 kg/m2) 0.96 (0.87, 1.05) 0.89 (0.82, 0.97) 0.74 (0.51, 1.07) 0.91 (0.86, 0.97) 0.67 
Age      
Age (< 60 y) 0.91 (0.66, 1.24) 0.88 (0.82, 0.95) 0.82 (0.60, 1.11) 0.88 (0.82, 0.94)  
Age (≥ 60 y) 0.93 (0.87, 0.99) 0.78 (0.66, 0.92) 1.17 (0.86, 1.59) 0.92 (0.87, 0.97) 0.67 
aHEI score      
aHEI (< median) 0.90 (0.83, 0.99) 0.87 (0.80, 0.95) 0.94 (0.70, 1.26)  0.90 (0.84, 0.95)  
aHEI (≥ median) 0.95 (0.87, 1.04) 0.83 (0.73, 0.94) 1.05 (0.76, 1.44) 0.91 (0.85, 0.99) 0.69 
 
Multivariate-adjusted model : multivariate model adjusted for race (Caucasians, African Americans, Asian Americans, and others), 
family history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 
30-34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), 
smoking status (never, former, current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no), and 
postmenopausal hormone use (yes vs. no) were further adjusted for in women. 
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Supplemental Table 3. Hazard ratio (HR) for the associations between residual isoflavones consumption after adjusting for coffee and 
risk of type 2 diabetes in the three cohorts 
 Q1 Q2 Q3 Q4 Q5 P for trend 
Isoflavones       
NHS (1998-2012)       
Multivariate-adjusted 
Model  
1.00 1.06 (0.97, 1.16) 1.00 (0.91, 1.09) 0.89 (0.81, 0.98) 0.92 (0.83, 1.01) 0.14 
NHS II (1999-2013)       
Multivariate-adjusted 
Model  
1.00 0.94 (0.86, 1.03) 0.81 (0.73, 0.89) 0.85 (0.77, 0.94) 0.84 (0.76, 0.94) 0.11 
HPFS (2002-2010)       
Multivariate-adjusted 
Model  
1.00 0.82 (0.65, 1.03) 0.85 (0.68, 1.06) 0.80 (0.63, 1.01) 0.76 (0.59, 0.98) 0.21 
Pooled       
Multivariate-adjusted 
Model  
1.00 0.97 (0.86, 1.09) 0.89 (0.76, 1.04) 0.86 (0.81, 0.92) 0.87 (0.80, 0.94) 0.03 
Daidzein       
NHS (1998-2012)       
Multivariate-adjusted 
Model  
1.00 1.05 (0.96, 1.14) 1.04 (0.95, 1.14) 0.90 (0.82, 0.99) 0.93 (0.84, 1.02) 0.01 
NHS II (1999-2013)       
Multivariate-adjusted 
Model  
1.00 1.00 (0.91, 1.10) 0.90 (0.81, 0.99) 0.92 (0.83, 1.02) 0.89 (0.79, 0.99) 0.03 
HPFS (2002-2010)       
Multivariate-adjusted 
Model  
1.00 0.82 (0.66, 1.03) 0.89 (0.71, 1.10) 0.71 (0.57, 0.90) 0.73 (0.57, 0.94) 0.17 
Pooled       
Multivariate-adjusted 
Model  
1.00 0.99 (0.89, 1.10) 0.95 (0.85, 1.07) 0.87 (0.78, 0.97) 0.89 (0.81, 0.98) 0.001 
Genistein       
NHS (1998-2012)       
Multivariate-adjusted 1.00 1.08 (0.99, 1.18) 0.95 (0.87, 1.05) 0.92 (0.84, 1.01) 0.91 (0.83, 1.01) 0.27 
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Model  
NHS II (1999-2013)       
Multivariate-adjusted 
Model  
1.00 0.95 (0.86, 1.04) 0.79 (0.71, 0.87) 0.84 (0.76, 0.93) 0.83 (0.74, 0.92) 0.11 
HPFS (2002-2010)       
Multivariate-adjusted 
Model  
1.00 0.84 (0.67, 1.05) 0.87 (0.69, 1.09) 0.84 (0.67, 1.05) 0.77 (0.60, 0.99) 0.21 
Pooled       
Multivariate-adjusted 
Model  
1.00 0.98 (0.87, 1.11) 0.87 (0.76, 0.99) 0.88 (0.82, 0.94) 0.86 (0.79, 0.94) 0.04 
 
Multivariate-adjusted model: multivariate model adjusted for race (Caucasians, African Americans, Asian Americans, and others), 
family history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 
30-34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), 
smoking status (never, former, current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no) and 
postmenopausal hormone use (yes vs. no) were further adjusted for in women. 
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Supplemental Table 4. Hazard ratios (HRs) for the associations between soy containing foods and risk of type 2 diabetes in the three 
cohorts using propensity score analysis 
Total soy food Non-consumer < 1 serving/week ≥1 serving/week P for trend 
NHS (1998-2012) 1.00 0.97 (0.87, 1.08) 0.95 (0.83, 1.09) 0.36 
NHS II (1999-2013) 1.00 1.04 (0.94, 1.15) 0.87 (0.77, 1.00) 0.05 
HPFS (2002-2010) 1.00 0.98 (0.79, 1.23) 0.88 (0.66, 1.17) 0.38 
Overall pooled 1.00 1.01 (0.95, 1.09) 0.90 (0.83, 0.99) 0.03 
Tofu Non-consumer < 1 serving/week ≥1 serving/week  
NHS (1998-2012) 1.00 0.97 (0.87, 1.09) 0.95 (0.81, 1.11) 0.58 
NHS II (1999-2013) 1.00 1.03 (0.93, 1.14) 0.87 (0.75, 1.00) 0.09 
HPFS (2002-2010) 1.00 0.97 (0.76, 1.23) 0.83 (0.61, 1.11) 0.22 
Overall pooled 1.00 1.01 (0.94, 1.09) 0.91 (0.82, 1.00) 0.05 
Soy milk Non-consumer Consumer   
NHS (1998-2012) 1.00 0.95 (0.83, 1.09)  0.91 
NHS II (1999-2013) 1.00 0.89 (0.79, 1.01)  0.06 
HPFS (2002-2010) 1.00 0.92 (0.69, 1.24)  0.56 
Overall pooled 1.00 0.91 (0.84, 1.00)  0.11 
 
Abbreviations: NHS, Nurses’ Health Study; HPFS, Health Professionals Follow-up Study; 
Covariates adjusted for in the propensity score model: adjusted for race (Caucasians, African Americans, Asian Americans, and 
others), family history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), body mass index (<21, 21-
22.9, 23-24.9, 25-29.9, 30-34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (Alternative Healthy Eating Index 
score, in quintiles), total energy intake (quintiles), coffee consumption (quintiles), smoking status (never, former, current 1-14 
cigarettes/d, current >14 cigarettes/d). Menopausal status (yes vs. no) and postmenopausal hormone use (yes vs. no) were further 
adjusted for in women.  
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Supplemental Table 5. Associations between isoflavone consumption and risk of type 2 diabetes in the three cohorts using propensity 
score analysis 
 Q1 Q2 Q3 Q4 Q5 P for trend 
Isoflavones       
NHS (1998-2012) 1.00 1.07 (0.97, 1.17) 1.01 (0.92, 1.10) 0.94 (0.85, 1.03) 0.95 (0.86, 1.05) 0.06 
NHS II (1999-2013) 1.00 0.98 (0.90, 1.08) 0.83 (0.75, 0.91) 0.87 (0.79, 0.96) 0.89 (0.80, 0.99) 0.29 
HPFS (2002-2010) 1.00 0.85 (0.68, 1.06) 0.88 (0.71, 1.10) 0.97 (0.78, 1.21) 0.86 (0.67, 1.10) 0.49 
Pooled 1.00 0.99 (0.89, 1.10) 0.89 (0.80, 0.99) 0.89 (0.84, 0.95) 0.91 (0.85, 0.97) 0.06 
Genistein       
NHS (1998-2012) 1.00 1.03 (0.94, 1.12) 1.01 (0.92, 1.10) 1.00 (0.91, 1.10) 0.95 (0.87, 1.05) 0.15 
NHS II (1999-2013) 1.00 0.98 (0.89, 1.08) 0.89 (0.81, 0.98) 0.95 (0.86, 1.04) 0.90 (0.80, 1.00) 0.16 
HPFS (2002-2010) 1.00 0.92 (0.73, 1.15) 0.99 (0.80, 1.24) 1.02 (0.82, 1.27) 0.91 (0.71, 1.17) 0.50 
Pooled 1.00 1.00 (0.94, 1.07) 0.96 (0.87, 1.06) 0.99 (0.93, 1.05) 0.93 (0.87, 1.00) 0.03 
Daidzein       
NHS (1998-2012) 1.00 1.04 (0.95, 1.14) 1.01 (0.92, 1.11) 0.88 (0.80, 0.97) 0.91 (0.83, 1.00) 0.01 
NHS II (1999-2013) 1.00 1.08 (0.98, 1.18) 0.84 (0.76, 0.93) 0.89 (0.81, 0.99) 0.92 (0.83, 1.03) 0.20 
HPFS (2002-2010) 1.00 0.91 (0.73, 1.13) 0.91 (0.73, 1.13) 0.90 (0.72, 1.12) 0.89 (0.70, 1.14) 0.55 
Pooled 1.00 1.05 (0.99, 1.11) 0.90 (0.82, 0.99) 0.88 (0.82, 0.94) 0.91 (0.85, 0.98) 0.03 
 
NHS, Nurses’ Health Study; HPFS, Health Professionals Follow-up Study 
Covariates adjusted for in the propensity score model: race (Caucasians, African Americans, Asian Americans, and others), family 
history of T2D (yes vs. no), baseline disease status (hypertension, hypercholesterolemia), BMI (<21, 21-22.9, 23-24.9, 25-29.9, 30-
34.9, ≥35 kg/m2), physical activity (quintiles), overall dietary pattern (AHEI score, in quintiles), total energy intake (quintiles), 
smoking status (never, former, current (1-14 cigarettes/d), current (>14 cigarettes/d)). Menopausal status (yes vs. no) and 
postmenopausal hormone use (yes vs. no) were further adjusted for in women.  
 
164 
 
 
CHAPTER 4 
URINARY ISOFLAVONES AND RISK OF TYPE 2 DIABETES: A 
PROSPECTIVE INVESTIGATION IN U.S. WOMEN 
 
Ming Ding 
1
, Adrian A. Franke 
2
, Bernard A. Rosner 
 3, 4
, Edward Giovannucci 
1,3
, Rob M. van 
Dam 
1, 5
, Shelley S. Tworoger 
3,6
, Frank B. Hu 
1,3,6
, Qi Sun 
1,3 
1
Department of Nutrition, Harvard School of Public Health, Boston, MA 
2University of Hawai‘i Cancer Center, Honolulu, HI, United States 
3 Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard 
Medical School, Boston, MA 
4
Department of Statistics, Harvard School of Public Health, Boston, MA 
5 
Saw Swee Hock School of Public Health and Yong Loo Lin School of Medicine, National 
University of Singapore and National University Health System, Singapore 
6
Department of Epidemiology, Harvard School of Public Health, Boston, MA  
 
 
 
165 
 
 
 
ABSTRACT 
Background To examine the association between urinary excretion of isoflavonoids and risk of 
type 2 diabetes (T2D),  
Method we conducted a nested case-control study among 1,111 T2D pairs identified during 
1995 - 2008 in the Nurses’ Health Study (NHS) and NHSII who were free of diabetes, 
cardiovascular disease, and cancer at urine sample collection. Urinary excretion of daidzein and 
genistein, as well as their metabolites desmethylangolensin, dihydrogenistein (DHGE), 
dihydrodaidzein (DHDE) was assayed by liquid chromatography mass spectrometry. Incident 
self-reported T2D cases were confirmed using a validated questionnaire.  
Results Higher urinary excretion of daidzein and genistein was associated with a lower risk of 
T2D in the combined cohorts. Comparing extreme tertiles of the urinary markers, the odds ratios 
(ORs) of T2D were 0.71 (95% CI: 0.55, 0.93) for daidzein and 0.74 (95% CI: 0.56, 0.97) for 
genistein, although the test for linear trend was not significant for genistein (P for trend = 0.03 
and 0.15, respectively). DMA, DHDE, and DHGE were not significantly associated with risk of 
T2D. The inverse association of daidzein with T2D risk was stronger among postmenopausal 
women who did not use hormone replacement therapy (P for interaction = 0.001): the OR (95% 
CI) was 0.58 (0.34, 0.97; P for trend = 0.06) comparing extreme tertiles among these women.  
Conclusion In conclusion, urinary excretion of daidzein might be associated with lower T2D 
risk, especially among postmenopausal women who did not use hormone. However, further 
research is warranted to replicate these observations. 
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INTRODUCTION 
Type 2 diabetes (T2D) is a chronic disease with increasing prevalence worldwide. The total 
number of diabetes patients is estimated to reach 592 million globally by the year 2035
(1)
. 
Seeking effective dietary and lifestyle measures for T2D prevention has been a priority to 
counteract the increasing diabetes prevalence and incidence
 (36; 8; 23)
. Women may be at a 
particularly high risk at middle-life when menopause and aging may jointly increase the risk of 
T2D 
(5; 35; 9)
. Large clinical trials and prospective cohort studies have consistently shown that 
hormone replacement therapy may reduce risk of T2D in postmenopausal women 
(10; 14
 
15
 
31)
. 
However, it is unclear whether natural phytoestrogens, such as isoflavones, may be associated 
with T2D risk.  
          Clinical trials showed that isoflavone supplements did not improve glucose control 
(12
 
39)
, 
although these clinical trials were limited by small sample size and short duration of follow-up. 
Several cohort studies have evaluated the associations of isoflavone intakes assessed using food 
frequency questionnaire (FFQ) with risk of T2D, and mixed results were observed 
(26; 24; 40)
. One 
potential reason for the inconsistent findings in the observational studies may lie in the 
difficulties of using FFQs to assess isoflavone intakes. Soy foods are the main source of 
isoflavone intakes while other foods contain various amount of isoflavones as well 
(3)
. Isoflavone 
intake estimated from FFQs is thus subject to measurement errors 
(33)
, especially in Western 
populations who infrequently consume soy foods. In addition, isoflavone intake estimated from 
FFQs does not take into account inter-individual variations in bioavailability 
(41)
. In addition, 
FFQs cannot be used to estimate the gut microbiota metabolites of isoflavones, including O-
desmethylangolensin 
(6)
, dihydrogenistein (DHGE), and dihydrodaidzein (DHDE), and equol 
(28)
, 
which may exert biological effects in additional to their parent compounds (i.e., daidzein and 
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genistein) 
(25)
. In this regard, use of isoflavone metabolites in blood or urine as objective markers 
of isoflavone intake is an appealing approach 
(17; 32)
.  
        In the current investigation we utilized data from a combined cohort based on two well-
characterized cohorts of U.S. women, the Nurses’ Health Study (NHS) and NHSII, to 
prospectively evaluate the association of urinary excretion of isoflavone metabolites with risk of 
T2D. We also examined the hypothesis that isoflavone excretion may especially be associated 
with lower T2D risk among postmenopausal women who do not receive replacement therapy and 
thus have a low exposure to exogenous estrogens. 
METHODS 
Study population 
The NHS began in 1976, when 121,700 female registered nurses aged 30-55 y residing in 11 
states were enrolled and completed a baseline questionnaire about their lifestyle and medical 
history. The NHSII was established in 1989 and consisted of 116,430 younger female registered 
nurses aged 25-42 y at baseline. These nurses also responded to a baseline questionnaire similar 
to the NHS. In both cohorts, questionnaires were collected at baseline and biennially thereafter, 
to update information on age, weight, smoking status, physical activity, medication use, 
menopausal status, postmenopausal hormone use, and disease status, including hypertension, 
hypercholesterolemia, cardiovascular disease (CVD), and cancer.  
Urine sample collection 
A total of 18,743 NHS participants aged 53 to 80 years provided blood and urine samples from 
2000 to 2002, and 29,611 NHSII participants aged 32 to 52 years provided blood and urine 
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samples from 1996 to 1999. For both cohorts the samples were returned to a central 
biorepository via overnight courier and were immediately processed upon arrival and aliquoted 
into cryotubes, which were stored in the vapor phase of liquid nitrogen freezers at ≤ -130 C. 
Loss to follow-up was < 10% among participants who provided blood and urine samples.  
Prospective case-control study design 
We conducted prospective, nested case-control studies among participants who provided urine 
samples and were free of self-reported diabetes, CVD, and cancer at urine collection in NHS and 
NHSII separately. T2D cases diagnosed within the first year since urine sample collection were 
excluded from selection in order to reduce the potential for reverse causation bias. During 
follow-up from urine collection through 2008 (NHS)/2007 (NHSII), we prospectively identified 
and confirmed 1,111 T2D cases (NHS: 456; NHSII: 655) and randomly selected one control for 
each case.
29
 The cases and controls were matched for age at sample collection, month of sample 
collection, fasting status (≥ 8 h or not), first morning urine (yes or no), and race (white or other 
races) in both cohorts. In NHSII, we additionally matched for menopausal status (yes, no), luteal 
day of the menstrual cycle (date of next period minus date of sample collection) for 
premenopausal women, and hormone replacement therapy (yes or no) for postmenopausal 
women. The study protocol was approved by the institutional review board of the Brigham and 
Women’s Hospital and the Human Subjects Committee Review Board of Harvard School of 
Public Health. 
Ascertainment of T2D 
We sent a validated supplemental questionnaire to those who reported a physician diagnosis of 
T2D to confirm the incidence 
(16). We used at least one of the following American Diabetes 
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Association 1998 criteria to confirm self-reported T2D diagnosis: (1) an elevated glucose 
concentration (fasting plasma glucose ≥7.0mmol/l, random plasma glucose ≥11.1mmol/l, or 
plasma glucose ≥11.1mmol/l after an oral glucose load), and at least one symptom related to 
diabetes; no symptoms, but elevated glucose concentrations on two separate occasions; or 
treatment with insulin or oral hypoglycemic medication. Only confirmed T2D cases were 
included in the current study. 
Assessment of diet  
Validated FFQs have been administered since 1984 in NHS or 1991 in NHSII 
38
. Similar FFQs 
were subsequently sent to participants every two to four years to update diet. In these FFQs, we 
inquired about the consumption frequency of 118-166 food items in the past year and how often 
(from “never or less than once per month” to “6 or more times per day”) on average they 
consumed each food item of a standard portion size. Major soy foods, i.e., tofu and soy milk, 
have been simultaneously included on the FFQs since 1998 in the NHS and 1999 in the NHS II. 
An overall measure of diet quality was calculated by using the Alternate Healthy Eating Index 
(AHEI) score excluding the soy food items, i.e., tofu and soy milk 
(18)
. In calculating AHEI score, 
we assigned individual score to each of the food group as a priory based on their beneficial effect 
to health, and summed up all of the scores.   
Laboratory measurements 
In the current study, we used electrospray ionization liquid chromatography mass spectrometry 
to measure isoflavonoids in urine samples, which has been validated except for the use of an 
orbitrap mass spectrometer 
(6; 7)
. Urinary creatinine levels were measured using a Roche-Cobas 
MiraPlus clinical chemistry autoanalyzer (Roche Diagnostics). The average intra-assay 
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coefficient of variation was 4.1% for daidzein, 7.6% for genistein, 8.2% for DHDE, 10.1% for 
DHGE, 8.1% for DMA, and 5.6% for creatinine. We calculated creatinine-adjusted 
concentrations (nmol/g creatinine) of isoflavonoids by dividing the isoflavonoid levels (nmol/L) 
by creatinine levels (g/L). In a pilot study that evaluated within-person stability of the 
isoflavonoids, intra-class correlation coefficients (ICCs), of two urine samples from 58 NHSII 
participants collected 1-2 years apart were 0.05 for daidzein, 0.14 for genistein, 0.16 for DHDE, 
0.14 for DHGE, and 0.20 for DMA. 
Statistical methods 
We calculated Spearman correlation coefficients between urine excretion of isoflavone 
metabolites with soy foods, i.e., tofu and soy milk, estimated from FFQ. We adjusted for total 
energy intake (kcal/day), BMI (kg/m
2
), physical activity (MET-hr/week), age (years), smoking 
(never, past, current), and first morning urine (yes or no). This analysis was conducted among 
controls to facilitate comparison between cohorts.  
We categorized the isoflavones biomarkers into tertiles. We used conditional logistic regression 
stratified by matching factors to model the association between isoflavone metabolites and risk 
of T2D in the main analysis 
(29)
. We additionally adjusted for hypertension at baseline (yes or no), 
hypercholesterolemia at baseline (yes or no), body mass index (kg/m
2
), smoking (nonsmoker, 
past smoker, current smoker), AHEI score, physical activity (METs-hr/week), total energy intake 
(kcal/day), menopausal status (premenopausal or postmenopausal) (NHS only), and hormone 
replacement therapy (yes or no) (NHS only). P values for linear trend were calculated by 
examining an ordinal score based on the median value in each tertile of isoflavones biomarker 
levels in the multivariate models.  
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Given that menopausal status and postmenopausal hormone therapy were not matching factors in 
NHS, we conducted stratified analyses by menopausal status and postmenopausal hormone 
therapy (yes vs. no) using unconditional logistic regression to maximize statistical power. P 
values for interactions were evaluated using likelihood ratio test, comparing the multivariate 
model with and without interaction terms of dichotomized isoflavones and potential effect 
modifiers in conditional logistic regression. Joint associations of the urinary biomarkers and 
potential effect modifiers were estimated using conditional logistic regression. All P values were 
two-sided. Data were analyzed with the Statistical Analysis Systems software package, version 
9.3 (SAS Institute, Inc., Cary, North Carolina). 
 
RESULTS 
Baseline characteristics of study participants are shown in Table 1. Compared with controls, 
T2D cases consumed a less healthful diet, engaged in less physical activity, had a higher BMI, 
and were more likely to have a history of hypertension and hypercholesterolemia. The baseline 
characteristics according to urine isoflavone excretion are shown in Supplemental Table 1. 
Higher urinary isoflavone excretion was correlated with a healthier dietary pattern, and higher 
levels of physical activity.  
Moderate to strong correlations among urinary isoflavone metabolites were observed (correlation 
coefficient: 0.26 - 0.79), with the strongest correlation observed between daidzein and genistein 
(Supplemetal table 2). Weak yet significant correlations were found between soy foods 
estimated from FFQ and urinary isoflavone excretion among controls.   
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Urinary excretion of daidzein and genistein, which are the main components of isoflavones, was 
associated with a lower risk of T2D (Table 2). For daidzein, compared with the lowest group, 
the odds ratios (ORs) of T2D were 0.78 (0.60, 1.02) in the second tertile and 0.71 (0.55, 0.93) in 
the highest tertile (P for trend = 0.03); for genistein, compared with the lowest group, the ORs of 
T2D were 0.70 (0.53, 0.93) in the second tertile and 0.74 (0.56, 0.97) in the highest tertile (P for 
trend = 0.15). DMA, DHDE, and DHGE, which are the metabolites of daidzein and genistein, 
were non-significantly associated with lower risk of T2D. Comparing the extreme tertiles, the 
odds ratios of T2D was 0.92 (95% CI: 0.70, 1.21) for DMA, 0.80 (95% CI: 0.60, 1.06) for 
DHDE, and 0.82 (95%: 0.62, 1.08) for DHGE, respectively.  
Stratified analyses by menopausal status and hormone use were conducted. Significant 
interaction by postmenopausal hormone use was found for daidzein (P for interaction = 0.001) 
(Table 3). Comparing extreme tertiles of the urinary daidzein, the ORs of T2D was 0.81 (95% 
CI: 0.54, 1.21; P for trend = 0.41) for premenopausal women, 0.76 (95% CI: 0.52, 1.11; P for 
trend = 0.19) for postmenopausal women with hormone use, and 0.58 (95% CI: 0.34, 0.97; P for 
trend = 0.06) for postmenopausal women without hormone use. Consistently, in joint association 
analysis the inverse association between urinary daidzein and risk of T2D appeared to be 
stronger in the postmenopausal women without hormone use (Figure 1). No significant 
interactions between other metabolites and risk of T2D by menopausal status and hormone use 
were found. Further stratified analyses were conducted by age, BMI, and aHEI, and the inverse 
association appeared to be more apparent among women with BMI less than 30 (P for interaction 
= 0.03) (Supplemental table 3).  
DISCUSSION 
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In the combined cohorts of U.S. women, the main components of urinary isoflavones, daidzein 
and genistein, were associated with a lower risk of T2D. Further analyses suggested that inverse 
association between daidzein and risk of T2D appeared to be stronger among postmenopausal 
women who did not take hormone therapy at sample collection. These associations were 
independent of established diabetes risk factors, such as BMI, physical activity, and overall diet 
quality.  
         Isoflavones are able to bind to the estrogen receptors (ER), especially ER-β, with 103-104 
less potency than estradiol 
(25)
. These compounds can exert either estrogenic or anti-estrogenic 
action depending on the level of estradiol in the circulation. When endogenous estrogen levels 
are low, isoflavones primarily exert estrogen-like effects 
(19)
. Our observation that a stronger 
inverse association between isoflavones, especially daidzein, and risk of T2D was noted among 
postmenopausal women without current hormone use is in line with the notion that isoflavones 
exert estrogen-like effects on blood glucose when circulating estrogen levels are low. In addition, 
this inverse association was also consistent with results from short-term clinical trials. 
Supplementation of isoflavones did not significantly lower fasting glucose or insulin levels in a 
comprehensive meta-analysis of randomized clinical trials 
(12)
. Although the non-significant 
results of those trials might be due to short term duration and might not represent the anti-
diabetic potential of long-term isoflavone intake, however, in another meta-analysis that focused 
on perimenopausal and postmenopausal non-Asian women who did not take hormone 
replacement therapy, isoflavone supplementation significantly lowered fasting insulin and 
HOMA-IR levels 
(30)
. Meanwhile, a stronger inverse association between urinary daidzein and 
risk of T2D was observed among non-obese participants. The reason might be that blood 
circulating estrogen might be lower in non-obese women comparing to obese women, as adipose 
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tissue is the main source of circulating estrogens for postmenopausal women without hormone 
use 
(13)
.  
        Besides binding to ER, isoflavones may also bind to and activate nuclear receptors which 
regulate lipid and glucose metabolism, including liver X binding receptor (LXR), sterol regulated 
element binding protein (SREBP), peroxisome-proliferator activated receptors α (PPARα), and 
PPARγ (20; 11; 21). Isoflavones may also increase the phosphorylation of AMP-activated protein 
kinase (AMPK) and acetyl-CoA carboxylase to improve glucose uptake and fatty acid oxidation 
4
. Animal studies have also shown that isoflavones may improve hyperglycemia, glucose 
tolerance, and circulating insulin concentrations 
(2)
.  
        Several cohort studies have been conducted to examine the association between intakes of 
soy foods and isoflavones estimated using FFQs and risk of T2D 
(24
 
37; 26; 22; 40)
. For example, in a 
Japanese population, higher intakes of isoflavones were not associated with diabetes risk in the 
total study population, but an inverse association was found among overweight women 
(26)
. In the 
Singapore Chinese Health Study, intakes of total isoflavones were not associated with T2D risk, 
probably because many soy foods were sweetened in Singapore 
(24)
. In the EPIC-InterAct Study, 
total isoflavone intake was not associated with T2D risk among men and women in eight 
European countries 
(40)
. In addition, two other studies assessed soy food consumption with risk of 
T2D. An inverse association was found in a Chinese cohort 
(37)
, while a positive association 
found in the Multiethnic Cohort in Hawaii 
(22)
. Differences in processing and cooking methods of 
soy food might be an explanation of these inconsistent associations. Moreover, measurement 
errors of FFQ assessments may be of a particular concern, especially among Western populations 
who consume much less soy foods than Asians. To our knowledge, no previous prospective 
studies have examined isoflavone biomarkers in relation to T2D risk. In cross-sectional studies 
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on the association between urinary isoflavones and blood glucose concentration, no associations 
were found 
(27; 34)
. The lack of association might be due to the reverse causation bias that the 
diabetes participants might tend to increase consumption of plant-based diet containing soy foods. 
        Our study had several strengths, including large sample size, long follow-up duration, and 
use of urinary biomarkers to represent the internal dose of isoflavones and account for the inter-
individual variations in bioavailability. Our study also has several limitations. First, the 
isoflavones were measured in spot urine samples, and the frequency of soy food consumption in 
our population was very low. Thus, we obtained low ICCs, which suggested that urinary 
biomarkers might not well represent long-term excretion of isoflavones.. However, in general, 
non-differential misclassification of the exposure biases the results towards null. Moreover, only 
moderate correlation was found between soy foods assessed by FFQ and urinary isoflavones, 
showing that urinary isoflavones might not well represent daily soy food consumption. The 
reason might be due to the measurement errors in both spot urine and FFQ. Second, although we 
adjusted for an array of established and potential risk factors of T2D, we could not exclude the 
possibility that unmeasured confounding or residual confounding, such as a healthy lifestyle, 
might still partially explain the association between isoflavones and risk of T2D. Last, we cannot 
exclude the possibility that chance may play a role in the inverse association only found between 
daidzein and risk of T2D. 
        In conclusion, we observed inverse associations between urinary excretion of daidzein and 
genistein and risk of T2D in U.S. women. In addition, the inverse association for daidzein 
appeared to be stronger among postmenopausal women who did not use hormone replacement 
therapy. Although these findings are in line with evidence from animal experiments and clinical 
trials demonstrating benefits of isoflavone intake on insulin resistance, further studies are 
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warranted to replicate the current findings, preferably using multiple-day 24-hr urine samples to 
achieve more stable estimates of isoflavone marker excretion. 
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Table 1. The age-adjusted baseline characteristics according to diabetes cases and controls in the combined cohort 
 Case Control 
Characteristics* (N=1111) (N=1111) 
Age at urine collection (year) 53.4 53.4 
Body mass index (kg/m
2
) 32.0 25.9 
Physical Activity (MET-hr/week) 16.4 19.5 
Current smoker (%) 11 7 
Hypertension (%) 38 19 
Hypercholesterolemia (%) 55 35 
Family history of diabetes (%) 37 21 
First morning urine (%)‡ 88 88 
Postmenopausal (%)‡ 83 83 
Postmenopausal hormone use  
(% of postmenopausal women) ‡ 43 43 
White (%)‡ 96 97 
Urinary metabolites (quartile range)  
(nmol/g creatinine) # 
  
Daidzein 311 (112, 956) 343 (123, 1013) 
Genistein 122 (48, 424) 128 (48, 419) 
Desmethylangolensin  29 (9, 116) 36 (12, 135) 
Dihydrodaidzein 34 (6, 217) 42 (9, 288) 
Dihydrogenistein 25 (10, 72) 27 (12, 78) 
Diet   
Total energy (kcal/day) 1865 1775 
Alcohol (g/d) 0.3 0.4 
Coffee (cup/day) 1.0 1.2 
Soft drinks (serving/day) 1.2 0.9 
Tofu consumers (%) 10 12 
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Soy milk consumers (%) 4 7 
Fruits (serving/day) 2.0 2.0 
Vegetables (serving/day) 3.5 3.3 
Red meat (serving/day) 1.5 1.3 
Fish (serving/day) 0.2 0.2 
Hot dog (serving/day) 0.1 0.1 
Alternate Healthy Eating Index score 49 52 
 
*All of the variables were age-adjusted, except the urinary metabolites of isoflavones. Values of continuous variables were median. 
Percentages were based on non-missing data.  
‡Matching factors; menopausal status and hormone replacement therapy were matching factors for NHSII only. 
#Values were median (interquartile range). 
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Table 2. Odds ratio (95% CI) of type 2 diabetes by tertiles of urinary isoflavones (nmol/g creatinine) in the combined cohort 
 
Tertiles of urinary markers 
P for 
trend 
 
1 (lowest) 2 3 (highest)  
          Daidzein   
Median 
(Range) 
77 
(0, 171) 
326 
(171, 665) 
1,529 
(665, 196,860) 
 
Case/control 386/354 369/372 356/385  
  Model 1 1.00 0.88 (0.72, 1.07) 0.85 (0.70, 1.04) 0.18 
  Model 2 1.00 0.78 (0.60, 1.02) 0.71 (0.55, 0.93) 0.03 
  Genistein   
Median 
(Range) 
33 
(0, 65) 
125  
(65, 269) 
729 
(270, 375,579) 
 
Case/control 376/364 370/371 365/376  
  Model 1 1.00 0.94 (0.76, 1.15) 0.92 (0.74, 1.13) 0.50 
  Model 2 1.00 0.70 (0.53, 0.93) 0.74 (0.56, 0.97) 0.15 
  Desmethylangolensin (DMA)  
Median 
(Range) 
6 
(0, 16) 
33 
(16, 78) 
225 
(78, 160,620) 
 
Case/control 393/347 365/376 353/388  
  Model 1 1.00 0.82 (0.68, 1.01) 0.77 (0.63, 0.94) 0.039 
  Model 2 1.00 1.00 (0.77, 1.31) 0.92 (0.70, 1.21) 0.74 
  Dihydrodaidzein (DHDE)   
Median 
(Range) 
2 
(0, 14) 
38 
(14, 126) 
568 
(126, 61,237) 
 
Case/control 392/348 366/375 353/388  
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  Model 1 1.00 0.90 (0.73, 1.10) 0.78 (0.63, 0.97) 0.043 
  Model 2 1.00 0.94 (0.72, 1.23) 0.80 (0.60, 1.06) 0.16 
  Dihydrogenistein (DHGE)  
Median 
(Range) 
7 
(0, 15) 
26 
(15, 49) 
150 
(49, 64,372) 
 
Case/control 389/351 357/384 365/376  
  Model 1 1.00 0.84 (0.68, 1.02) 0.89 (0.72, 1.09) 0.55 
  Model 2 1.00 0.73 (0.56, 0.96) 0.82 (0.62, 1.08) 0.45 
 
Model 1: Conditional logistic model stratified by matching factors including age at urine sample collection, month of sample 
collection, first morning urine (yes or no), and race (white or other races) in both cohorts. Menopausal status (premenopausal or 
postmenopausal), and hormone replacement therapy (yes or no) were additionally matched for in NHS II. 
Model 2: Conditional logistic model additionally adjusted for family history of diabetes (yes or no), hypertension at baseline (yes or 
no), hypercholesterolemia at baseline (yes or no), body mass index (kg/m
2
), smoking (nonsmoker, past smoker, current smoker), 
alternative healthy eating index, physical activity (MET-hr/week), total energy intake (kcal/day), menopausal status (premenopausal 
or postmenopausal), and hormone replacement therapy (yes or no).  
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Table 3. Stratified analysis of the association between urine isoflavones biomarkers and risk of type 2 diabetes by menopausal status 
and postmenopausal hormone use in the combined cohort 
 
 
Number of 
participants T1 T2 T3 
 
P for 
interaction*  
Daidzein 
    
 
Premenopausal 975 1.00 0.85 (0.58, 1.24) 0.81 (0.54, 1.21)  
Postmenopausal with HRT 821 1.00 0.86 (0.59, 1.25) 0.76 (0.52, 1.11)  
Postmenopausal without HRT 426 1.00 0.70 (0.41, 1.19) 0.58 (0.34, 0.97) 0.001 
Genistein 
    
 
Premenopausal 975 1.00 0.96 (0.66, 1.41) 1.03 (0.70, 1.52)  
Postmenopausal with HRT 821 1.00 0.73 (0.50, 1.07) 0.75 (0.52, 1.10)  
Postmenopausal without HRT 426 1.00 0.58 (0.34, 1.00) 0.51 (0.30, 0.86) 0.36 
DMA 
    
 
Premenopausal 975 1.00 1.19 (0.80, 1.77) 1.27 (0.86, 1.87)  
Postmenopausal with HRT 821 1.00 1.06 (0.73, 1.53) 0.74 (0.51, 1.09)  
Postmenopausal without HRT 426 1.00 0.79 (0.47, 1.34) 0.77 (0.45, 1.33) 0.21 
DHDE 
    
 
Premenopausal 975 1.00 1.22 (0.82, 1.80) 1.22 (0.82, 1.82)  
Postmenopausal with HRT 821 1.00 0.99 (0.68, 1.43) 0.65 (0.44, 0.96)  
Postmenopausal without HRT 426 1.00 0.75 (0.44, 1.28) 0.63 (0.37, 1.05) 0.82 
DHGE 
    
 
Premenopausal 975 1.00 0.70 (0.48, 1.03) 1.03 (0.70, 1.51)  
Postmenopausal with HRT 821 1.00 0.84 (0.57, 1.23) 0.66 (0.45, 0.96)  
Postmenopausal without HRT 426 1.00 0.80 (0.47, 1.36) 0.71 (0.42, 1.22) 0.90 
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HRT: hormone replacement therapy 
Given that menopausal status and HRT were not matching factors in NHS, unconditional logistic models were used for the stratified 
analysis, and multivariate models adjusted for age at urine sample collection, month of sample collection, fasting status (≥ 8 h or not), 
first morning urine (yes or no), race (white or other races), family history of diabetes (yes or no), hypertension at baseline (yes or no), 
hypercholesterolemia at baseline (yes or no), body mass index (continuous), smoking (nonsmoker, past smoker, current smoker), 
alternative healthy eating index (continuous), physical activity (continuous), total energy intake (continuous). 
 
* Likelihood ratio test comparing the conditional logistic models with and without interaction term was used; the urine isoflavones 
were dichotomized, and the premenopausal and postmenopausal with HRT were combined into one group. 
 
 
 
 
 
 
 
 
 
 
 
186 
 
 
 
 
                      1a. Daidzein                                                           1b. Genestein                                               1c. DMA 
 
 
                        1d. DHDE                                                                 1e. DHGE 
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Figure 1. The joint association of urinary isoflavones biomarkers and postmenopausal status and hormone use with risk of type 2 
diabetes.  
Conditional logistic models adjusted for hypertension at baseline (yes or no), hypercholesterolemia at baseline (yes or no), body mass 
index (kg/m
2
), smoking (nonsmoker, past smoker, current smoker), alternative healthy eating index, physical activity (MET-hr/week), 
and total energy intake (kcal/day). 
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Supplemental Table 1. The age-adjusted baseline characteristics according to urinary total isoflavones in the controls of the combined 
cohort 
Characteristics *  T1 T2  T3  
Number 361 371 379 
Urinary metabolites  
(nmol/g creatinine) 
   
Daidzein 102 424 4766 
Genistein 49  184 5188 
DHDE 17 101 2686 
DHGE 20 46 987 
DMA 22  72 1589 
Diet       
Total energy (kcal/day) 1743 1817 1755 
Alcohol (g/d) 0.4 0.3 0.3 
Coffee (cup/day) 1.2 1.2 1.2 
Soft drinks (serving/day) 1.0 1.0 0.8 
Tofu consumers (%) 10 13 17 
Soy milk consumers (%) 6 5 11 
Fruits (serving/day) 2.0 2.0 2.0 
Vegetables (serving/day) 3.2 3.3 3.4 
Red meat (serving/day) 1.3 1.4 1.2 
Fish (serving/day) 0.2 0.2 0.2 
Hotdog (serving/day) 0.1 0.1 0.1 
Alternate Healthy Eating 
Index score 
52 50 52 
Age at urine sample 53 54 54 
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collection (year) 
Hypertension (%) 16 17 21 
Hypercholesterolemia (%) 33 29 36 
Family history of diabetes 
(%) 
22 22 18 
First morning urine (%) 85 88 90 
Postmenopausal (%) 81 82 80 
Postmenopausal hormone 
use among postmenopausal 
women (%) 
41 41 40 
Current smoker (%) 7 9 7 
White (%) 98 96 97 
Body mass index (kg/m
2
) 26 26 26 
Physical Activity (MET-
hr/week) 
22 18 19 
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Supplemental table 2. Spearman correlation coefficient† between urine isoflavone biomarkers and soy food products assessed by FFQ 
among controls in the combined cohort 
 
Daidzein Genistein DMA DHDE DHGE 
Daidzein 1.00     
Genistein 0.79* 1.00    
DMA 0.60* 0.39* 1.00   
DHDE 0.61* 0.56* 0.60* 1.00  
DHGE 0.43* 0.55* 0.26* 0.58* 1.00 
Soy milk (FFQ) 0.10* 0.14* 0.11* 0.10* 0.11* 
Tofu (FFQ) 0.15* 0.16* 0.11* 0.13* 0.11* 
Total soy food 0.15* 0.18* 0.12* 0.14* 0.13* 
Isoflavones calculated 
from foods 0.09* 0.11* 0.12* 0.11* 0.12* 
  
*P<0.05 
†Spearman correlation coefficient adjusted for total energy intake (kcal/day), BMI (kg/m2), physical activity (MET-hr/week), age 
(years), and smoking (never, past, current). 
Soy foods were the average amount of consumption estimated from FFQs in 1998 and 2002 for NHS, and in 1995 and 1999 for NHS2. 
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Supplemental Table 3. Stratified analysis of the association between urine isoflavones biomarkers and risk of type 2 diabetes by age, 
BMI, and AHEI 
 
N T1 T2 T3 P for interaction* 
Urinary daidzein   
Age   
Age > 60 y 691 1.00 0.68 (0.46, 1.02) 0.65 (0.44, 0.97) 
 Age ≤ 60 y 1531 1.00 0.92 (0.69, 1.24) 0.80 (0.59, 1.08) 0.07 
BMI 
BMI < 30 kg/m
2
 1406 1.00 0.84 (0.64, 1.11) 0.63 (0.47, 0.84)  
BMI ≥ 30 kg/m2 816 1.00 0.87 (0.58, 1.31) 1.05 (0.69, 1.58) 0.03 
aHEI      
aHEI < 52  1233 1.00 0.76 (0.55, 1.05) 0.58 (0.42, 0.81)  
aHEI ≥  52 989 1.00 0.93 (0.65, 1.31) 0.98 (0.70, 1.39) 0.48 
Urinary genistein      
Age      
Age > 60 y 691 1.00 0.70 (0.46, 1.04) 0.75 (0.50, 1.11)  
Age ≤ 60 y 1531 1.00 0.82 (0.61, 1.10) 0.82 (0.61, 1.11) 0.80 
BMI      
BMI < 30 kg/m
2
 1406 1.00 0.74 (0.56, 0.98) 0.71 (0.54, 0.95)  
BMI ≥ 30 kg/m2 816 1.00 1.00 (0.67, 1.51) 0.96 (0.64, 1.45) 0.16 
aHEI      
aHEI < 52  1233 1.00 0.70 (0.51, 0.96) 0.63 (0.45, 0.87)  
aHEI ≥ 52 989 1.00 0.89 (0.62, 1.28) 1.04 (0.74, 1.47) 0.35 
 
AHEI: alternative healthy eating index. AHEI ranged from 0 to 100, with a higher score indicating a healthier diet.  
HRT: hormone replacement therapy 
Unconditional logistic models were used for the stratified analysis, and multivariate models adjusted for age at urine sample collection, 
month of sample collection, fasting status (≥ 8 h or not), first morning urine (yes or no), race (white or other races), family history of 
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diabetes (yes or no), hypertension at baseline (yes or no), hypercholesterolemia at baseline (yes or no), body mass index (continuous), 
smoking (nonsmoker, past smoker, current smoker), alternative healthy eating index (continuous), physical activity (continuous), total 
energy intake (continuous). 
 
* Likelihood ratio test comparing the conditional logistic models with and without interaction term was used; the urine isoflavones 
were dichotomized. 
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II CONCLUSION 
Preventing obesity related chronic disease through promotion of a healthy diet is a public 
health priority globally. The work presented here shows that higher consumption of 
coffee and soy food may be beneficial to several health outcomes, especially type 2 
diabetes and CVD.  
        In Chapter 1, I found a nonlinear relationship of coffee consumption with CVD risk: 
moderate coffee consumption was associated with lower risk of CVD, with the lowest 
CVD risk at 3 to 5 cups per day, and heavy coffee consumption was not associated with 
risk of CVD. In Chapter 2, similar to the findings in Chapter 1, I found a non-linear 
association of coffee consumption with total mortality in the whole population. When 
restricting to never smokers, coffee consumption was associated with lower risk of total 
mortality, and mortality due to CVD, neurological diseases, and suicide. The study 
provides strong evidence that the non-linear association of coffee with total mortality 
might be due to the confounding of smoking. 
        In Chapters 3 and 4, I found that consumption of isoflavones was associated with 
lower risk of type 2 diabetes in three large cohorts. Consistently, I further showed that 
higher concentrations of urinary isoflavones were associated with lower risk of type 2 
diabetes. 
       Taken together, the findings of the four projects suggest that coffee and soy food can 
be incorporated into a healthy dietary pattern. However, randomized clinical trials are 
warranted to further examine the causal effects of coffee and soy food consumption on 
various health outcomes and explore biological mechanisms. 
